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  2Abstract 
 
RNA interference (RNAi) is a highly conserved post-transcriptional gene 
silencing process triggered by double-stranded RNA (dsRNA) in eukaryotic 
cells. Elucidation of the RNAi regulatory pathway and its components has led 
to the identification of endogenous dsRNA molecules, termed microRNAs 
(miRNAs), which are transcribed as a single hairpin molecule prior to their 
maturation into a cytoplasmic dsRNA. The efficient gene silencing achieved 
by these short hairpin RNA (shRNA) molecules and the cumulative 
understanding of the RNAi pathway has prompted the development of hairpin 
expression vectors capable of mediating stable gene silencing in vitro and in 
vivo. The aim of this thesis is to evaluate the efficacy of viral vector-mediated 
RNAi in the retina using recombinant adeno-associated viruses (AAV) and 
lentiviruses that contain silencing hairpin cassettes to target four genes in 
murine photoreceptors and the retinal pigment epithelium (RPE). 
 
A detailed assessment of the utility and extend of RNAi in the retina using 
different viral vectors and hairpin designs is presented in this thesis.   
Lentiviral and AAV vectors were firstly used to silence GFP in vitro and in 
vivo as a proof of concept for vector mediated RNAi in the retina. 
Subsequently, we used lentivirally-mediated RNAi to study disease 
processes in the retina concentrating on tight junction (TJ) modulators ZO-1 
and ZONAB and their role in RPE homeostasis, cell-cycle progression and 
epithelial-mesenchymal transition (EMT). Here we demonstrated how TJ 
misregulation can lead to RPE loss, proliferation or dedifferentiation; 
processes involved in pathological conditions such as atrophic age-related 
macular degeneration (AMD) and proliferative vitroretinopathy (PVR). 
 
Whilst lentivirally-mediated RNAi was used to elucidate aspects of retinal 
function and disease, AAV-mediated RNAi was used to probe the therapeutic 
potential of shRNAs by silencing Peripherin-2 ( Prph2), the second most 
abundant retinal protein, using a miRNA-based hairpin. AAV2/8 particles 
  3were used to target endogenous Prph2 and evasion of silencing was 
demonstrated using an engineered Prph2 cDNA that could be used in a 
suppression and replacement approach for the treatment of dominant retinal 
disorders. 
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  111 Introduction 
 
 
1.1 Aims  of  study 
 
 
RNA interference (RNAi) is a powerful technique for the downregulation of 
endogenous expression that is mediated by short double-stranded RNA 
molecules. Since its discovery about a decade ago, RNAi has proved to be 
an invaluable tool for characterising gene function and has been used in vivo 
to ablate specific mRNAs in various tissues. In this study, the utility of vector-
mediated RNAi in the eye is assessed. The eye is a good candidate for 
genetic intervention because of its confined environment and accessibility 
and here we employed RNAi to test the potency of genetic silencing in 
different parts of the retina using different viral vectors.  
 
Initially, we tested the technology in different parts of the retina using either 
AAV or lentiviral vectors to downregulate a reporter gene in vivo (see 
Chapter 3). Subsequently, lentiviruses were used to silence the tight-junction 
genes ZO-1 and ZONAB in the RPE to study disease processes and the 
importance of RPE cell-cycle regulation in retinal homeostasis. The role of 
the ZO-1/ZONAB pathway in epithelial-mesenchymal transition also 
highlighted the connection between RPE cell-cycle deregulation and gliotic 
retinal scarring in proliferative vitroretinopathy (see Chapter 4). Finally, we 
assessed the potential of RNAi for treating dominantly inherited retinal 
disorders. To date, there are no gene-based therapies for dominant 
retinopathies mainly because dominant disorders are more complex to treat 
than recessive ones due to the nature of the genetic mutation. Here, AAV2/8 
vectors were used to silence Peripherin-2, one of the most highly expressed 
genes in the retina mutations in which are mainly involved in dominant 
retinopathies, indicating the potential of AAV2/8 vectors expressing RNAi 
cassettes for the treatment of dominant retinopathies (see Chapter 5). 
  12 
In brief, the aim of this study is to further assess the potential of viral-
mediated RNAi in the eye for the elucidation of disease mechanisms and for 
the treatment of dominant retinal disorders using the two most commonly 
used ocular gene therapy vectors, AAV and lentiviruses, to mediate efficient 
genetic silencing in photoreceptors and retinal pigment epithelium, 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  131.2 The  eye 
 
 
The eye is regarded as one of the most highly specialised organs in biology; 
an attribute based both on its structure and function. It is part of the central 
nervous system (CNS) and is in effect an extension of the brain. During 
embryogenesis, the first morphological manifestation of the eye structure is 
marked by the appearance of the optic pit, resulting from the invagination of 
the diencephalon. The optic pit gives rise to the early optic cup in which the 
neural retina and the RPE are formed from developmentally distinct regions. 
Meanwhile, inductive signals between the forming eye cup and the surface 
ectoderm initiate an invagination of the latter into what will form the lens 
vesicle and the cornea. At a later stage, the iris and ciliary body develop from 
the point where neural retina and RPE meet in the developing eye cup. At 
this time, the RPE is thin and is in contact with the extraocular mesenchyme. 
The ventral and dorsal areas of the optic stalk fuse into the choroidal fissure, 
which acts as the channel through which blood vessels pass and neuronal 
axons exit. From this point onwards, the neuroretina progressively thickens 
as cells proliferate and differentiate to give rise to different retinal cell types. 
The point at which the RPE associates with the neuroretina is a vital one for 
the future viability of photoreceptors as from that moment onwards the retina 
is isolated and relies on the RPE for its maintenance (see section 1.2.1.3 and 
Chapter 4 for RPE structure and its role in retinal homeostasis). A good 
review on early eye development is provided by Chow & Lang, 2001 [1]. 
 
 
There is a vast morphological variety of eye structures in the animal kingdom. 
However, physical laws and natural selection have restricted the general 
optic design of the eye into eight main types [2]. The mammalian eye lies in 
the chambered-refractive type where light is focused onto specialised nerve 
receptors. It is divided into three layers: the outer layer consists of the 
fibrocollagenous sclera and the transparent cornea that enables light to enter 
the eye; the middle vascular layer is called uvea and consists of the choroid, 
  14the ciliary body and the iris that provide support and nutrients; the inner layer 
includes the neuroretina and the RPE where the visual cycle takes place. At 
the posterior side of the cornea lies the lens which acts as the refractive 
medium that focuses incoming light onto the retina. For a schematic overview 
of the human eye see Figure 1.1. 
  
 
 
Figure 1.1: Anatomy of the eye. A schematic cross-section view of the human eye. The 
murine eye has a significantly larger lens that occupies the majority of the vitreous space 
and lacks a central cone-rich macula or fovea. AC; anterior chamber. (Forrester J.V., The 
Eye: Basic Sciences in Practice, 2002) 
 
 
The retina is the innermost layer of the eye. It is divided into the neuroretina, 
which is the photosensitive tissue that includes the photoreceptor cells, and 
the RPE. 
 
 
 
 
  151.2.1        The retina 
 
The organisation of the mammalian retina is indicative of its highly 
specialised function of phototransduction. The murine retina consists of 
approximately 55 distinct cell types [3] and it is structurally divided into ten 
different layers (Figure 1.2).  
 
 
 
Figure 1.2: Structure of the murine retina.  Schematic diagram of the retinal layers and 
corresponding light micrograph of a semithin section. RPE; retinal pigment epithelium. OS; 
(photoreceptor) outer segments; IS; (photoreceptor) inner segments. OLM; outer limiting 
membrane consisting of intercellular junctions. ONL; outer nuclear layer consisting of 
photoreceptor cell nuclei. OPL; outer plexiform layer consisting of synaptic connections 
between photoreceptor cells and nerve cells. INL; inner nuclear layer consisting of the nuclei 
of nerve and support cells. IPL; inner plexiform layer which is build up of synapses. GC; 
ganglion cell layer. ILM; inner limiting membrane which forms the border between the retina 
and the vitreous. (Adapted from West et al., 2009) [4] 
 
 
 
  161.2.1.1     The neuroretina 
 
In the neuroretina, there are three principal neuronal cells that relay impulses 
generated by light: photoreceptors, bipolar cells and ganglion cells. The 
activity of these cells is modulated by other neuronal cell types including 
horizontal cells and amacrine cells. Up to 11 different types of bipolar cells 
exist and they are primarily responsible for transmitting signals from 
photoreceptors to ganglion cells. In the primate central retina (fovea 
centralis), the ratio of cones to bipolar cells to ganglion cells can be as high 
as 1:1:1, while in the peripheral retina one bipolar cell can receive stimuli 
from up to 50-100 rods. In the latter situation, multiple bipolar cell dendrites 
reach out to various photoreceptors, while only a single axon synapses with 
ganglion and amacrine cells. This process is called signal summation. Their 
axonal input can be initiated through GABAergic or ionotropic glutamate 
receptors. 
 
Horizontal cells exist as two main types and cross-connect numerous 
photoreceptor cells. They are thought to be part of a feedback system that 
modulates contrast in vision. Horizontal axons inhibit excited photoreceptors 
as well as neighbouring ones, adding to the sharpness of the initial signal. 
They constitute 5 % of the inner retina neurons and are situated mainly at the 
borders of outer plexiform layer (OPL) and outer nuclear layer (ONL). 
 
The amacrine cell, although not considered to be one of the principal retinal 
neurons, is the most diverse and one of the most abundant. There are up to 
twenty-nine distinct types of amacrine cells and they outnumber horizontal, 
ganglion or Müller cells. They contribute to most of the ganglion cell 
synapses and their broad range of function is reflected in the variety of 
signalling mechanisms they use, including dopaminergic, cholinergic and 
GABAergic signalling along with paracrine regulated modulation through gap 
junctions. Although the function of each type of amacrine cell is not fully 
elucidated, they play an essential role in creating and shaping the retina’s 
final physiological output. They are situated along the inner nuclear layer 
(INL). 
  17 
Müller cells provide the scaffolding around which the retinal architecture is 
built. They are a retinal glial cell and maintain retinal homeostasis by 
neurotrophic factor secretion, support of retinal blood vessels and 
scavenging of signalling endproducts. Although they do not take part in the 
visual transduction pathway directly, the constant supply of cytokines and 
modulation of inner retinal vascular permeability renders them indispensable 
for the structure and function of the retina as a whole. It has also been 
suggested that these cells are an additional source of 11-cis retinal for cone 
cells [5]. A complex network of adherens junctions at the foot processes of 
Müller cells forms the inner limiting membrane (ILM) that separates the 
neuroretina from the vitreous. A similar junctional network between Müller 
cell end processes and the photoreceptor inner segments forms the outer 
limiting membrane (OLM) that provides structural support to the ONL.  
 
Retinal ganglion cells (RGC) exist as up to ten distinct types according to 
their branching level and their dendritic arbour width. There is a difference in 
size with the smaller cells referred to as midget – a classification also seen in 
bipolar cells – as well as summing and non-summing responsive cell types. 
Ganglion cell dendrites receive impulses from bipolar cells and amacrine 
cells which they subsequently pass on through their axons to the visual 
cortex of the brain via the optic nerve. All ganglion cell axons are collected in 
the nerve fibre layer (NF) and are orientated towards the optic disc.  
 
 
1.2.1.2     Photoreceptors 
 
Photoreceptors occupy the innermost layers of the neuroretina with their 
outer segments adjacent to the apical membrane of the RPE, and their cell 
bodies in the ONL. There are two distinct types of photoreceptors: the rods 
and the cones. Their differences lie both in their structure (Figure 1.3) and 
function. Rods are the prominent type of photoreceptors in the mammalian 
retina outnumbering cones by approximately 20-fold [3]. They are 
  18responsible for sensing motion, contrast and brightness through their highly 
sensitive visual pigment, rhodopsin. Cones, on the other hand, are necessary 
for spatial resolution, colour vision and fine detail; their visual pigments are 
the cone opsins. In primates, they exist in three types according to the 
wavelength of light they absorb. L-cones respond to long wavelengths of light 
(red light), M-cones to medium wavelengths (green light) and S-cones 
respond to short wavelengths (blue light) [3] (see Figure 1.4). 
 
 
 
Figure 1.3: Structure of photoreceptor cells. Schematic representation of rod 
and cone photoreceptor cells. The distinct structural features of each cell type 
are annotated as well as the direction of light and electrical impulse they elicit. 
(Adapted from http://www.cis.rit.edu) 
 
 
The opsins are located in the outer segments (OS) of the photoreceptor cells 
where the phototransduction cascade is initiated (see section 1.2.3). The 
outer segments in rods are formed by a dense network of membrane discs, 
whereas in cones they are formed by membrane infolds. The outer segments 
  19provide a tightly-packed scaffold for the phototransduction cascade to take 
place. This increases the surface area per cell, thereby aiding in the potency 
of the visual signal. The main structural components of the outer segments 
are rhodopsin and Peripherin-2 (Prph2) (see section 5.1 for more detailed 
description of outer segments). The inner segments are rich in mitochondria 
and generate the energy for the demanding process of phototransduction. 
The spherules and pedicles form the synapses with horizontal and bipolar 
cells where neurotransmitters pass on the neural impulse generated by the 
photoreceptors. 
 
The distribution of cones varies in the retina. In humans, there is a central 
cone-rich area in the retina, called macula, which contributes most to the 
visual acuity (Figure 1.4). In the centre of the macula is the fovea which 
consists exclusively of cones. There the supporting nerve cells are displaced 
so that light is directed straight onto this area. This structuring is essential for 
the high levels of visual acuity in primates and its understanding is vital for 
the characterisation of disease patterns in humans (see section 1.3). Mice, 
however, lack a central cone-rich region and the two types of cones (M- and 
S- type) are distributed all over the retina. However, the distribution of murine 
M- and S- cones is not equal in the dorsal-ventral orientation. The majority of 
M-cones are distributed in the dorsal hemisphere (M-field) whereas the 
majority of S-cones occupy the ventral hemisphere (S-field) [6,7]. 
 
 
 
 
  20 
Figure 1.4: Rod and cone distribution in the human fovea. (A) Schematic representation 
of the cone mosaic. An area of 1° visual angle is represented. S-cones (blue) comprise 7% 
of the area, whereas the L-cone (red): M-cone (green) ratio is 1.5. The central area of 0.34° 
is S-cone free. (B) Diagram showing the densities of rods and cones along the horizontal 
meridian. (Adapted from http://webvision.med.utah.edu) 
 
 
1.2.2    The retinal pigment epithelium 
 
The RPE lies posterior to the neuroretina. It consists of melanin-containing, 
cuboidal, epithelial cells that form a rigid interconnected cell layer regulated 
by epithelial tight junctions (TJ), gap junctions (GJ) and adherens junctions 
(AJ). Cellular junctions within the RPE are vital for intracellular and 
paracellular signalling. Junctional components such as ZO-1, ZONAB, β-
catenin and their importance in RPE function are discussed in depth in 
Chapter 4. The basal membrane of the RPE lies on the Bruch’s membrane 
and its apical membrane forms microvilli presented towards the inter-
photoreceptor matrix (IPM) and surrounding photoreceptor OS. The RPE 
plays a vital role in forming the blood-retinal barrier (BRB), physically 
assisting the structure of the neuroretina and maintaining photoreceptor cells 
through phagocytosis of their OS debris. In addition, it is involved in the 
turnover of by-products of the visual cycle (see section 1.2.3) as well as the 
production of neurotrophic factors essential for photoreceptor cell viability. 
Furthermore, the melanin layer confers higher visual acuity by inhibiting 
scattering of the light focused on the retina by the lens. Thus, the RPE is an 
essential non-neuronal cell layer directly involved in the retinal integrity and 
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RPE leads to retinal degeneration and loss of vision. 
 
 
1.2.2.1     Blood-retina barrier 
 
The CNS maintains its homeostasis through the stability and function of the 
blood-neural barrier (BNB) that protects the CNS from surrounding blood or 
cerebrospinal fluid. The blood-retina barrier (BRB) is the ocular part of BNB 
and it is composed of the retinal vascular endothelium (inner BRB) and the 
RPE (outer BRB) [8]. The BRB is maintained mainly through tight, adherens 
and gap junctions between the vascular endothelial cells and between the 
pigmented epithelial cells (see section 4.1). Leakage or breakage of the BRB 
is thought to play a role in numerous ocular disorders. Experimental 
autoimmune uveoretinitis (EAU) serves as a model for human posterior 
uveitis where inflammation of the choroid, neovascularisation and BRB 
leakage leads to retinal scarring. In EAU, TJ function is compromised in the 
retinal vascular endothelium (RVE) and RPE leading to leukocyte infiltration. 
Disregulation of TJs not only compromises the BRB but also the polarity of 
the RPE. Oxidative stress, implicated in the pathogenesis of age-related 
macular degeneration (AMD), has also been shown to affect RPE polarity in 
vitro and causes downregulation of major TJ and AJ components like ZO-1, 
occludin and β–catenin [9]. Typical symptoms of diabetic retinopathy such as 
macular oedema and retinal neovascularisation are also associated with BRB 
breakage [10]. A number of molecules have been shown to affect BRB 
stability through their effect on TJs. Vascular endothelial growth factor 
(VEGF), tumour necrosis factor alpha (TNF-α) and interleukin 1 beta (IL1β) 
have been shown to cause BRB dysfunction by destabilising TJ formation [8]. 
Mutations in CLDN19, a claudin family gene and important TJ anchor protein, 
cause renal failure and optic disc misdevelopment [11].  
 
 
  221.2.3       The visual cycle 
 
Vertebrate visual responses are initiated in the photoreceptor OS by a 
photon-activated chemical cascade. This results in the propagation of a 
neuronal signal that crosses the neuroretina and is transferred to the brain for 
processing. The chemical cascade is a complex pathway that involves the 
continuous recycling of its substrates, hence the term visual cycle. Defects in 
any of the many genes encoding components of the visual cycle can result in 
a form of retinal dystrophy (see section 1.3) 
 
Rhodopsin is the light-absorbing photopigment of rods and is located in the 
disc membrane of OS. It consists of a seven-pass transmembrane domain 
protein, opsin, as well as the Vitamin A analogue chromophore, 11-cis retinal. 
Upon light absorption it isomerises to all-trans retinal resulting in a subtle 
change in the conformation of rhodopsin. The conformational change in the 
molecule exposes a binding site on its cytoplasmic domain for a guanosine-
5'-triphosphate (GTP) binding protein (G protein) called transducin. The α-
subunit of transducin molecule then dissociates and activates a 
photoreceptor-specific disc-bound phosphodiesterase (PDE) by interacting 
with its inhibitory γ-subunit. The phase of the R*→G-protein→PDE cascade 
is greatly amplified at each step, with each molecule activating multiples of its 
downstream substrate. In effect, a single photon creates a relatively potent 
signal in comparison to its initial biochemical impact [12] (see Figure 1.5 for a 
summary).  
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Figure 1.5: The phototransduction cascade. Schematic representation of the activation 
cascade. The cascade initiates with a photon (hv) activating rhodopsin (R*) which in turn 
binds a G protein (G) called transducin. The activated α-subunit of transducin (G*α) binds to 
PDE forming a complex activating the γ-subunit of PDE (G*α-E*). The cGMP gated channel 
function is illustrated under high Ca
2+ concentration (top right) and low Ca
2+ concentration 
(bottom right). GC; guanylate cyclase. CM; calmodulin. cG; cGMP. (Adapted from Pugh & 
Lamb, 2000) [12] 
 
The change of intracellular cGMP concentration results in the closure of 
cGMP-gated channels, thus causing hyperpolarisation. The modulation of 
Ca
2+ gated channels is essential for the onset of hyperpolarisation and the 
recovery that follows. At the height of activation, the intracellular Ca
2+ 
concentration is at its lowest due to the closure of the cGMP-gated channels. 
After the visual signal has been generated and propagated, there are two 
remaining steps to complete the visual cycle: recovery of the cation gradient 
in the photoreceptor matrix and regeneration of 11-cis  retinal – hence 
rhodopsin. At low Ca
+2 concentration, a cGMP-channel binding protein called 
calmodulin, dissociates, increasing the affinity of the intracellular channel 
domains to cGMP. That leads to reopening of the Ca
+2 channels. In addition, 
a calmodulin-like calcium-binding protein, called guanylate cyclase activator 
protein (GCAP), is free to associate with the activating domain of retinal 
guanylate cyclase (retGC). At low Ca
+2 concentrations, Ca
2+ dissociates from 
GCAP which is free to binds to its epitope on retGC, activating the 
conversion of GTP to cGMP. This step further increases the reopening Ca
+2 
channel cascade for the final recovery step of intracellular Ca
2+ 
concentration. 
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RPE. At this point Vitamin A from the diet can enter the cycle as well. Once 
within the RPE cell, it is esteryfied by lecithin-retinol acyltransferase (LRAT) 
and the all-trans retinyl ester is converted to 11-cis retinal by the iron-
dependent isomerohydrolase RPE65 and 11-cis-RDH [13].. Finally, 11-cis 
retinal is transported back into the OS to re-enter the visual cycle as part of 
the inactivated rhodopsin [14,15] (Figure 1.6). 
 
 
 
Figure 1.6: The visual pigment cycle. Schematic diagram of the 11-cis retinal cycle in the 
photoreceptor cell and the RPE. Upon light excitation, 11-cis retinal alters its conformation to 
all-trans retinal. After release from opsin, it is reduced to all-trans retinol and is transported to 
the RPE through the inter-photoreceptor matrix (IPM). In the RPE, it undergoes esterification 
by LRAT. A further isomerisation step and hydrolysis of the ester group is carried out by 
RPE65. Finally, the resulting alcohol group is oxidised to the 11-cis retinal aldehyde by 11-
cis RDH and is transported back into the photoreceptor OS to re-enter the visual cascade. 
(Adapted from Pepperberg & Crouch, 2001) [16]  
 
 
 
 
 
 
  251.3 Retinal  disorders 
 
 
Retinal disorders can be categorised into different classes depending on their 
underlying cause. Disease in the retina can be acquired, inherited or 
complex. Acquired retinal disorders cover a broad range of retinal conditions 
caused by exogenous factors such as infection or injury. Complex retinal 
disorders are multifactorial and the factors leading to them are usually both 
genetic and environmental. Inherited retinal disorders, which are covered 
more extensively below, may be caused by a defect in any one of a large 
number of genes. The complexity of pathways involved in retinal function 
adds to the heterogeneity of the disorders arising from mutations in the 
genes involved. Currently, there are no effective treatments for inherited 
retinopathies that affect 1/3000 people worldwide [17]. The last 20 years 
have seen an increase in the genetic analysis of vision; extensive gene 
mapping and cloning has lead to the identification of 197 genes, of which 150 
have been cloned (Retnet Database update: June 2009, http:// 
www.sph.uth.tmc.edu/Retnet) (also see Figure 1.7). In the following sections, 
inherited retinal disorders are separated based on the effect of the underlying 
mutation on retinal function.   
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Figure 1.7: Compiled graph listing of mapped genes. Advances in gene mapping 
technologies during the last decade enabled for increased gene identification in retinal 
disorders (Retina International Scientific Newsletter, http://www.retina-international.org). 
 
 
Retinitis pigmentosa, macular dystrophies and cone-rod dystrophies are 
three of the main disease categories and between them encompass more 
than 80 of the genes that are known to cause recessive, dominant or X-linked 
dystrophies.  Since the focus of this study with regard to inherited retinal 
degeneration is on dominantly inherited conditions, the following section will 
focus mainly on disorders caused by gain of function mutations (see table 1 
for a summary of genes involved in dominant eye disorders; Retnet Database 
update: October 2008, http:// www.sph.uth.tmc.edu/Retnet). 
 
 
 
 
 
 
 
 
 
 
  27Table 1: Genes involved in autosomal dominant retinal dystrophies. A number of gene 
mutations have been shown to cause dominant retinopathies. Different mutations in the 
same genes may alter the inheritance pattern or even the type of disease (diseases in 
brackets). ad; autosomal dominant. ar; autosomal recessive. RP; retinitis pigmentosa. 
CORD; cone-rod dystrophy. LCA; Leber’s congenital amaurosis. MD; macular degeneration 
(Retnet Database up-to-date: June 2009). 
 
GENE 
 
 
DISEASE 
 
FUNCTION 
RHO  adRP 
(also arRP) 
Rod photoreceptor chromophore 
 
RDS  adRP 
(also digenic) 
Photoreceptor structural protein; localises in outer 
segments; associated with ROM-1 
ROM-1  Digenic adRP  Photoreceptor structural protein; localises in outer 
segments; associated with RDS 
NRL  adRP 
(also arRP) 
Transcription factor expressed in retina; regulates 
rod development 
RP1  adRP  Microtubule-associated protein; vital for 
photoreceptors 
CRX  adRP 
(also adCORD) 
Homeobox transcription factor; associated with 
NRL; involved in circadian rhythm regulation 
PRPF-31  
(RP11) 
adRP  Pre-mRNA splicing factor, ubiquitously expressed 
IMPDH1  adRP 
(also adLCA) 
Dehydrogenase essential for de novo guanine 
synthesis 
GUCY2D  adCORD 
(also arLCA) 
Guanylate cyclase; converts GTP to cGMP during 
visual cycle 
RPGR  adCORD  
(also xlRP) 
Stabilising photoreceptor connecting cilium; 
associated with RPGRIP 
ABCA4  adCORD  
(also ar-Stargard) 
ATP-binding transporter; involved in photopigment 
recovery 
ELOVL4  Stargard-like  
dystrophy (dominant) 
Elongase of long fatty-acid molecules; also 
expressed in epidermis 
VMD2  Best dystrophy  RPE chloride channel component; associated with 
paracellular exchange 
AIPL1  adCORD 
 
Molecular chaperone, involved in protein folding 
TIMP3  Sorby fundus  
dystrophy 
Proteolytic enzyme inhibitor; involved in extracellular 
matrix turnover 
TJ genes 
(e.g.CLDN19)
MD? 
Uveitis? 
Cell-cell adhesion, cell cycle, paracellular 
permeability and BRB 
 
 
 
 
 
 
 
 
 
  281.3.1    Retinitis pigmentosa (rod-cone dystrophies) 
 
Retinitis pigmentosa (RP) is a broad class of retinal disorders that involves 
progressive degeneration of the photoreceptors. It affects 1 in 4000 people 
worldwide resulting in 1.5 million visually disabled patients [17-19]. Typically, 
degeneration starts at the periphery of the retina and advances towards the 
macula at varying rates depending on the type of the mutation. Night 
blindness is the first sign of impact on the patient’s vision caused by 
degeneration of rod photoreceptors. Decreasing visual fields and tunnel 
vision are the signs of progressing RP that eventually leads to legal or 
complete blindness by middle age. At the later stages of the disease, cones 
are also severely compromised as well as the inner nuclear layer of the retina 
which leads to greatly diminished scotopic (rod induced) and photopic (cone 
induced) vision and RP can therefore be regarded as a rod-cone dystrophy. 
Clinical examinations reveal abnormal fundi with pigmented bone-spicule 
deposits and attenuated retinal vessels in the mid-periphery [19,20]. 
 
The inheritance patterns of RP are autosomal recessive (arRP), autosomal 
dominant (adRP), X-linked (xlRP) and digenic. In general terms, the rate of 
progression is thought to be faster in xlRP, followed by arRP, while adRP 
shows the slowest progression in retinal degeneration [21]. In xlRP, the only 
copy of the gene is mutated in male patients leading to the fastest rate of 
degeneration. In arRP cases, fast degeneration occurs due to complete lack 
of function due to mutations in both autosomal copies of the gene with 
Leber’s congenital amaurosis (LCA) cases showing the fastest rate of 
degeneration than any other retinal dystrophies. In adRP, a dominantly 
inherited mutation in one of the two gene copies leads to either 
haploinsufficiency or a gain-of-function that is toxic to the affected cell. RP 
can also be classified as syndromic, where non-ocular tissues are also 
affected and more commonly non-syndromic, where only ocular tissues are 
affected. Usher’s syndrome is the most frequent form of syndromic RP in 
which RP symptoms are usually associated with hearing impairment [19]. 
The first RP causing mutation was reported in 1990 [22]. It resulted in a 
single amino-acid change in rhodopsin. Since then, around 100 different 
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all forms of adRP [23]. To date, mutations in twelve different genes have 
been shown to cause adRP. These genes include rhodopsin (RHO), neural 
retina leucine zipper transcription factor (NRL) [24], RP1 [25], cone-rod otx-
like homeobox (CRX), peripherin-2 (RDS) and retinal outer segment 
membrane protein-1 (ROM-1) (see Chapter 4), ubiquitously expressed pre-
mRNA splicing factors PRPF-31 [26], HPRP3 and PRPC8 [20],   and the 
inosine monophosphate dehydrogenase 1 gene (IMPDH1) which is 
expressed in the retina, lung, thymus and brain [27]. Many of the screened 
adRP causing mutations in NRL, RP1, CRX, RDS and IMPDH1 are missense 
mutations that alter a single amino acid in the protein polypeptide. Amino-
acid changes often result in gain-of-function mutations as they affect the 
folding of the protein leading to toxic saturation in the cell, or by affecting the 
rate of function of the protein when they occur in catalytic domains. Exon 
deletions or insertions, as in the case of PRPF-31, can cause adRP mainly 
due to the haploinsufficiency that rises from loss of function rather than a 
gain-of-function effect. 
 
 
1.3.2    Cone-rod dystrophies 
 
Cone-rod dystrophies (CORDs) are another group of pigmentary 
retinopathies with a collective frequency of 1/40,000 [28]. Fundus 
examination reveals pigmented deposits that are mainly localised in the 
macular region of the patient. The reason why CORDs are diagnostically 
separated from RP is the order of events during retinal degeneration. In 
contrast to RP, in CORDs cones are primarily affected with rod involvement 
occurring as the disease progresses. Consequently, visual loss follows the 
opposite sequence of events to that in RP; visual acuity and sensitivity of the 
central visual field are initially compromised reflecting the loss of cones, 
followed by night blindness as rods begin to degenerate. In general, retinal 
degeneration is more severe in CORDs than in RP.  
 
  30To date, around twelve genes have been identified that can cause non-
syndromic CORD and a number of these genes is also involved in other 
retinopathies [29]. Missense gain-of-function mutations in CRX usually cause 
autosomal dominant CORD (adCORD) [28,30]. More severe frameshift 
mutations that abolish the function of CRX result in LCA. Most GUCY2D 
mutations cause adCORD and are comprised of missense gain-of-function 
mutations in exon 13 of the gene that affects the dimerisation of the proteins. 
However, similarly with CRX, some mutations in GUCY2D that lead to loss of 
function cause autosomal recessive LCA. Missense mutations don’t always 
cause gain-of-function mutations in dominantly-inherited disease. For 
example, ABCA4 truncating mutations are associated with adCORDs due to 
their deleterious effect that results in haploinsufficiency in contrast with amino 
acid changes that lead to a milder phenotype and are associated with 
Stargardt disease. Genes usually associated with RP (e.g. Peripherin-2 and 
RPGR) or LCA (AIPL1 and RPGRIP1) can also cause adCORDS although 
the underlying mechanisms of the mutations have not been elucidated yet. 
 
 
1.3.3    Macular degeneration (cone dystrophies) 
 
Macular dystrophies are a broad group of retinal diseases characterised by 
loss of central vision and degeneration of the macular region [31]. Inherited 
maculopathies are mostly inherited dominantly and, to date, mutations in 
seven genes have been implicated (Retnet Database update: June 2009, 
http:// www.sph.uth.tmc.edu/Retnet).  
 
Autosomal dominant Stargardt-like macular dystrophy is an early-onset 
maculopathy that appears after 20 years of age [32]. Vision loss due to 
geographical RPE atrophy and the presence of yellow macular flecks are the 
main clinical features. Pallor of the optic nerve can usually distinguish the 
disease from other dominant maculopathies. Mutations in the gene elongase 
of very long chain fatty acids-4 ( ELOVL4) have been linked to affected 
pedigrees. The underlying mutations have been often found to be exonic 
deletions that cause a frame-shift leading to dominant disease. ELOVL4 is 
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metabolism. ELOVL4 malfunctions due to missense gain-of-function 
mutations lead to lipofuscin accumulation in the subretinal space as well as 
epidermal barrier malformation as it has been observed in a recent animal 
model with an ELOVL4 knock-in mutation [33].  
   
Best macular degeneration (VMD2) is a juvenile-onset dominantly inherited 
maculopathy characterised by a yellow subretinal macular lesion due to 
lipofuscin accumulation in the RPE. Atrophy of the RPE, especially in the 
fovea, leads to loss of vision. Peri-macular retinal involvement can also occur 
but the progression of the disease is slow with most patients maintaining 
reading vision past the fifth decade of life. The gene product of VMD2, 
bestrophin, is an RPE chloride channel component and it is localised at the 
basolateral membrane [34]. Mutational analysis of VMD2 has indicated that 
the putative second transmembrane domain of the protein is of major 
importance and even single amino acid changes are enough to trigger 
dominant Best’s disease. In vitro analysis has shown that its malfunction 
affects paracellular exchange and leads to debris and lipofuscin 
accumulation between the RPE and Bruch’s membrane [35]. 
 
Sorsby fundus dystrophy (SFD) is a late-onset dominant macular dystrophy 
that appears after 30 years of age and is characterised by the macular 
accumulation of white-yellow drusen, sub-retinal haemorrhage and CNV. The 
gene implicated in SFD is the tissue inhibitor of metalloproteinase-3 (TIMP3) 
that is expressed in endothelial cells of the choriocapillaries and its protein 
localises in Bruch’s membrane [36]. Metalloproteinases are proteolytic 
enzymes that regulate the turnover of the extracellular matrix and their 
deregulation can result in abnormal deposits between RPE and Bruch’s 
membrane. Single point-mutations in TIMP3 have been associated with SFD 
when they cause amino-acid changes. Proteolytic enzymes are highly 
dependent on their tertiary structure and mutations in key residues that affect 
bond formation can abolish the function of the enzyme. A malfunctioning 
TIMP3 can lead to subsequent thickening of the Bruch’s membrane that has 
been also thought to hamper vitamin A absorption by the neuroretina. The 
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also accounts for the occurrence in CNV [37].  
 
It is evident that the nature of retinal disease is not only dependent on the 
affected gene, but mostly on the type of mutation. As described above, the 
genetic causes for each type of disorder are not always distinct with many 
genes involved in more than one type of dystrophy. A deletion leading to a 
frame-shift or a key amino acid change that causes a gain-of-function, rather 
a loss-of-function in the affected protein, often alters the phenotype of the 
disorder (dominant vs. recessive) and hence the therapeutic strategies 
required for its treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  331.4  Therapies for retinal disorders 
 
 
Although to date there have been no effective treatments for retinal 
degenerations, advances in our understanding of the pathophysiology of 
these disorders and the advances in gene and stem cell therapy technologies 
increases the prospects for at least some of these disorders. In the next 
section a brief account of the development of pharmacological and cell-based 
therapies will be given, before reviewing the progress in gene therapy, 
particularly with regard to treating dominant retinopathies. 
 
 
1.4.1    Pharmacological and cell-based treatments 
 
A number of studies have examined whether vitamin A supplementation 
might confer protection against retinal degeneration. Initial findings of a 
clinical trial suggested that vitamin A intake combined with docosahexaenoic 
acid, reduced loss of function over a period of two years in RP patients but a 
follow up of the patient cohort indicated that the effect was not significant 
after that period [38,39]. It has also been suggested that calcium channel 
blockers, antioxidants and neurotrophic factors might also be used to slow 
retinal degeneration following studies using mouse models. However, the 
amelioration is always transient and repeated administration is required [40-
49]. To date, the administration of pharmacological agents as a sole 
therapeutic strategy for the treatment of retinal dystrophies has proved 
largely ineffective in delaying visual loss. In humans, allo-transplantation of 
RPE cells has had a long history but has produced relatively poor results and 
autologous (from the host) transplantation techniques are currently being 
investigated. In AMD patients, RPE from an unaffected area of the 
midperiphery can be transplanted into the macula, in a process called RPE 
translocation [50]. Cell suspensions or patches of RPE and choroid are 
isolated and inserted into the central retina after submacular surgery. Long-
term follow up of four patients after undergoing RPE choroidal translocation 
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submacular space but the gain in visual function had been transient and 
short-lived [51,51]. Since the developed retina might lack the environmental 
cues to drive the lineage of an unspecified stem or progenitor cell, 
transplantation of post-mitotic precursors may prove promising. A 
breakthrough in photoreceptor cell transplantation was recently reported by 
MacLaren and colleagues using retinal precursor cells from the post-natal 
murine retina. Although previous studies failed to show effective integration 
of photoreceptors [52-54], this study described an optimal ontogenic stage at 
which donor cells were more likely to integrate into the host retina. They used 
a transgenic model that expressed GFP under a Nrl promoter. Nrl is an early 
rod-specific marker and therefore GFP expression is localised in cells that 
have entered the rod lineage. By assessing the levels of GFP-positive cell 
integration, they demonstrated that the early postnatal period is optimal for 
harvesting rod precursor cells for transplantation [55]. After subretinal 
delivery into the rhodopsin knockout mouse, increased levels of 
photoreceptor integration (i.e. thousands of integrated cells) were observed 
in conjunction with an improvement in visual function [55]. 
 
To date, the most promising study involving stem cell differentiation has been 
carried out by Osakada and colleagues using conditional pre-differentiation of 
mouse, human and monkey embryonic stem cells [56]. The investigators 
were able to successfully differentiate the cells into mature photoreceptor and 
RPE cells but their integrative potential into a host retina was not 
investigated. Stem cells might have a promising future for certain types of 
neuronal transplants and corneal engraftments but until there are 
improvements in the efficiency of differentiation and integration, it is unlikely 
they will provide an effective treatment for retinal degeneration. 
 
 
 
 
  351.4.2    Gene therapy 
 
Genetic engineering, molecular virology and understanding the genetic basis 
of disease paved the way for the development of gene delivery vectors to 
treat the underlying causes – and not just the symptoms – of genetic 
disorders. Briefly, a therapeutic transgene is placed under the regulation of a 
constitutive, tissue specific or conditional promoter and is delivered in vivo or 
ex vivo to the affected tissue using viral and sometimes non-viral vectors. 
There are three main issues to be addressed when developing gene therapy 
approaches for treating genetic defects:  
 
1.  Efficient gene delivery to the appropriate target cells. Specificity can 
be obtained through the use of specific vectors, promoters and routes 
of administration. 
2.  Appropriate levels of transgene expression.  
3. Avoidance of host immune responses to either vector or transgene 
product. 
 
Gene therapy vectors for the treatment of X-linked chronic granulomatous 
disease (X-CGD) [57], Parkinson’s disease [58] and cystic fibrosis [59] are 
advancing into the clinic. To date, the most successful gene therapy 
applications in the clinic focus on treating forms of severe combine 
immunodeficiency (SCID). X-linked SCID (xlSCID) and adenosine 
deaminase-deficient SCID (ADA-SCID) are characterised by abnormal 
leukocyte development and patients usually do not live past adulthood. 
Because of their severely compromised immune system, patients of xlSCID 
have to live in a protective sterile “bubble” to minimise infection.  Using 
gamma retroviruses, Alan Fischer and Adrian Thrasher demonstrated the 
first ever successful gene therapy treatment of patients. Two boys with 
xlSCID were effectively cured from the disease after ex vivo gene delivery in 
haematopoietic stem cells that were subsequently engrafted to their bone 
marrow [60-62]. Since then, more successful ex vivo gene therapy trials for 
ADA-SCID [63] and xlSCID [64] have been carried out in a number of young 
patients but with post-operative side effects in some xlSCID patients [65]. 
  36Insertional mutagenesis is currently hindering patient treatments due to 
incidents of T cell acute lymphoblastic leukaemia caused by “semi-random” 
integration of the proviral cassette into transcriptionally active areas of the 
genome. Ongoing studies in self-inactivating vectors and site-specific viral 
integration in conjunction with the use of ubiquitously-acting chromatin 
opening elements (UCOE) might aid in the development of a safe gene 
therapy strategy using integrative viral vectors [66,67]. 
 
The eye as a target for gene therapy provides the advantage of accessibility 
and immune privilege. Both administration of vector as well as the follow up 
of the phenotypic effect can be carried out with relatively minimal surgical 
intervention. In addition, the BRB acts to inhibit the release of exogenously 
delivered agents into the systemic circulation reducing the levels of active or 
passive immune responses. Gene therapy approaches have been successful 
in treating monogenic recessive disorders in various animal models of retinal 
disease and recently the first clinical trials to treat a recessive retinal 
dystrophy were initiated. Corrective gene replacement of RPE65 is currently 
in phase I/II in Leber’s congenital amaurosis patients after viral vector safety 
was confirmed in canine models of the disease [68,69]. Early data indicate 
that there are no adverse effects caused by vector administration while some 
significant amelioration in central visual acuity was reported for a number of 
patients [70-74].  
 
The different virus vector types and their potential use for ocular gene 
therapy is presented in depth in section 1.4.2.2.  
 
 
1.4.2.1     Non-viral vectors for gene delivery to the eye 
 
Injection of naked plasmid DNA does not result in cellular uptake because 
cells will not actively take up naked nucleic acids in their vicinity. Therefore, 
cationic liposomes that bind DNA, forming an enclosed protective vesicle, 
have been used to transduce cells both in vitro and in vivo. The most 
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DNA nanoparticle encapsulation. Polyethylene glycol (PEG)-substituted 
lysine peptides encapsulate a single DNA molecule per vesicle and have 
been shown to transfect murine photoreceptors after subretinal delivery [75]. 
Persistence of expression ranges from a few days to a few months 
depending on promoter and plasmid construction. 
 
The overall negative charge of DNA molecules is advantageous not only for 
DNA encapsulation techniques but also for plasmid electroporation in the 
retina. Naked nucleic acids can be injected intravitreally or subretinally 
followed by a series of electrical pulses – ranging from 30 V to 100 V 
depending on age and species – that cause the DNA to migrate through the 
cellular membrane. The direction of the current is applied in such way that 
the DNA moves into the desirable adjacent cell layer (i.e. polarity is inverted 
between intravitreal and subretinal DNA delivery). Transgene expression that 
persists for 50 days in transfected photoreceptor cells has been 
demonstrated in both rat and mice after subretinal injection and 
electroporation in P0 pups [76]. The main drawbacks of retinal DNA 
electroporation are the relatively low efficiency for transfecting high numbers 
of photoreceptors and the inability of the DNA to enter other tissues apart 
from the RPE in adult mice.  
 
The majority of non-viral delivery methods are mostly inefficient in providing 
stable and high transgene expression in the eye or other tissues [77-79], 
hence the focus of gene delivery studies is currently on viral vectors. Since 
non-viral gene therapy vectors have the advantage of delivering very large 
DNA molecules, further optimisation with regard to expression levels and 
persistence may enable gene therapy applications that are not feasible using 
viral vectors. 
 
 
 
  381.4.2.2    Viral vectors for gene delivery to the eye 
 
Viral vector technology has been optimised for efficient transduction and 
expression in various tissues. Viral technology confers an advantage with 
regard to gene delivery to cells in comparison to non-viral techniques due to 
the innate ability of virions to infect a cell and deliver their genome into the 
host’s nucleus.  
 
Upon viral vector construction, part of the viral genome is removed to allow 
space for the transgene expression cassette and to prevent replication of the 
vector. The latter aspect of vector design is essential for the safety of the 
vector and to diminish any host immune responses. Since the virus has lost 
its ability to replicate, production of the recombinant virus particles requires 
“packaging cell lines” that contain trans-acting viral genes needed for vector 
replication and packaging.  
 
Depending on the type of virus used, the transgene cassette is introduced  
episomally into the host nucleus or is integrated mainly into the host’s 
euchromatin – the transcriptionally active chromosomal regions. Integration 
of the transgene in the host genome enables the expression in the daughter 
cells of actively dividing, transduced cells. Episomal delivery in the same 
population would not provide a therapeutic long-term effect as the transgene 
would be lost after cell division. In contrast, episomal gene delivery in post-
mitotic cells can lead to equal long-term expression levels in comparison to 
integrative delivery. 
 
Viral gene therapy in the eye has come a long way during the last 20 years 
with a variety of vectors being developed that efficiently transduce most 
ocular tissues. The majority of the developed retina consists of post-mitotic 
(arrested at G0 of the cell cycle) neuronal cells and non-neuronal glia, 
endothelial and epithelial cells, like the RPE. The overall efficiency of viral 
vector transduction in the eye has been demonstrated by the therapeutic 
effect of virally delivered transgenes into animal models of monogenic retinal 
degeneration.  
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The two most potent expression vectors used in the eye are based on AAV 
and lentiviruses. Their characteristics as well as their progress and prospects 
in treating ocular disorders are described later in detail. HSV and adenovirus-
based vector technology, some of which preceded and aided to the 
construction of the latest AAV and lentiviral vectors, is briefly introduced. 
 
 
1.4.2.2.1     Herpes simplex virus-based vectors 
 
Herpes simplex virus (HSV) is a neurotropic virus with a single stranded DNA 
genome and a broad host cell range. Although they can package large 
inserts, the main drawback of HSV in ocular gene transfer is its inability to 
transduce photoreceptors [80]. In the eye, when HSV vectors are delivered 
intravitreally they allow for rapid but transient expression in the murine RPE. 
Reporter gene expression has been observed just one day after delivery but 
declined after two days reaching undetectable levels at six weeks [81]. In 
another study, intravitreal delivery of HSV vectors carrying an expression 
cassette for FGF2 failed to preserve visual function in a rat model with light-
induced damage two weeks after treatment [82]. The reason for the lack of 
persistence of expression after HSV vector administration lies on the 
immunogenicity of the HSV virion. It has been suggested that upon cell entry 
and within three hours, a rapid immune response is raised against the HSV 
particles mediated by IL-6 and NFkB [83]. Another reason for lack of 
persistence could be viral latency were the inserted provirus lies “dormant” in 
the transduced cells. The high immunogenicity, inability to infect 
photoreceptors and lack of vector persistence render HSV vectors 
inadequate for gene replacement therapy approaches. However, if a less 
immunogenic HSV vector is developed it could be delivered to the anterior of 
the eye to treat acute conditions where fast and robust – but not persistent – 
expression of a therapeutic transgene/neurotrophin is needed.  
 
 
  401.4.2.2.2     Adenoviral vectors 
 
As with HSV-based vectors, adenoviral (Ad) vectors can accommodate large 
transgenic inserts ranging from 8 kb to 38 kb, but their immunoreactivity has 
raised concerns over the years. The need for safe Ad vectors was made 
clear in 1998 when a patient suffering from ornithine transcarbmalayse (OTC) 
deficiency died within 96 h from massive systemic immune responses after 
receiving a systemic dose of Ad vector [84]. 
 
The reason why Ad vectors are not widely used in retinal gene transfer is, 
apart from their immunogenicity, due to their inability to transduce 
photoreceptor cells [85]. After subretinal injection Ad vectors transduce the 
RPE whereas after intravitreal injection they transduce Müller cells [86]. Ad-
mediated delivery of transgenes in the retina has failed to date to 
demonstrate persistent expression of transgenes in photoreceptors. 
Transgene delivery to the rd mouse, that carries a mutation in the β-PDE 
gene, has been attempted using either first or third generation adenoviral 
vectors [87,88]. In both studies, no evidence of photoreceptor transduction 
was presented. The short-term amelioration in the retinal morphology of the 
rd mouse might be explained by intercellular trafficking of β-PDE from the 
RPE to the photoreceptors [89]. The first Ad-based ocular clinical trial was 
carried out in patients with CNV caused by advanced AMD, using a second 
generation Ad vector expressing PEDF but after 3 months no significant 
stabilisation or improvement of CNV lesions were detected [90].  
 
Recently it was shown that by modifying a domain on the Ad vector’s capsid, 
it is possible to increase the vector’s tropism to transduce photoreceptors 
after subretinal delivery [91]. Although this study demonstrated the highest 
levels of reporter gene expression in photoreceptors following Ad-mediated 
delivery, the levels of expression are not comparable to those obtained after 
transduction of photoreceptors using adeno-associated viral vectors. 
 
 
  411.4.2.2.3     Adeno-associated viral vectors 
 
Adeno-associated viruses (AAV) belong to the family of parvoviruses, which 
are among the smallest, simplest eukaryotic viruses.  Essentially, they fall 
into two groups, defective viruses that are dependent on helper virus for 
replication and autonomous, replication-competent viruses. AAVs are helper-
dependent single-stranded DNA viruses that are not associated with any 
human disease and therefore are considered to be one of the most promising 
vectors for gene delivery in the retina. The wtAAV genome is 4.6 kb long 
flanked by inverted terminal repeats (ITRs) that drive viral replication. The 
genome is composed of two multi-cistronic genes, rep and cap.  Rep is 
involved in the site-specific integration of AAV during latency that occurs via 
non-homologous recombination in chromosome 19 (AAVS1), as well as in 
viral replication and packaging [92]. Cap expresses three proteins (VP 1, 2 
and 3) that form the 20 nm icosahedral viral capsid. AAV exist in different 
serotypes that differ in their cell surface receptors, heparin sulphate and sialic 
acids, which results in different cell tropism of viruses. Therefore, it is 
possible to use different serotypes to target specific cells in vivo. Chimeric 
virions can be produced by using the regulatory element rep of one serotype 
(usually from AAV2) in conjunction with the capsid element cap from another 
serotype (e.g. AAV5; the resulting chimeric virus is termed AAV2/5). In effect, 
recombinant AAV particles are produced that are capable of trasducing 
different retinal layers depending on the capsid pseudotyping and route of 
administration [93]. Following subretinal injection, serotype 1 transduced the 
RPE and has an onset of expression after 3 days, whereas serotypes 5 and 
8 target both RPE and photoreceptors initiating expression after 2 weeks. 
Serotype 2 transduces RPE and photoreceptors when delivered subretinally 
but it is capable of transducing the ganglion cells when delivered intravitreally 
with onset of expression at 4 weeks after delivery. Approximately fifteen 
serotypes have been isolated from different species and six of them have 
been isolated from humans [94]. Depending on the serotype, between 10
8-
10
9 infectious viral particles can lead to transduction of approximately 50 % 
of the murine photoreceptors after subretinal delivery. 
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kb inserts to be cloned between them. In vitro vector production requires the 
presence of rep and cap products in trans together with a helper Ad or HSV 
virus or a plasmid that provides Ad or HSV functions (see Figure 1.8). The 
need for high-titre, pure AAV preparations of different serotypes has led to 
the development of various purification techniques. Heparin [95], mucin [96] 
and ion-exchange chromatography binding matrices [97,98] provide up to 
10
13 particles per ml of rAAV virions with 99 % purity. In order to reduce the 
time needed for the onset of transgene expression, self-complementary AAV 
(scAAV) vectors have been developed. scAAV carries a double-stranded 
genome and mutated ITRs to evade the rate-limiting step of second-strand 
synthesis after transduction. Although the size of the insert is reduced to 2.4 
kb, scAAV vectors mediate earlier and stronger expression than their single-
stranded counterparts of the same serotype [99,100]. 
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Figure 1.8: AAV genome and vector components. (A) Schematic diagram of the wtAAV 
genome and the rAAV expression cassette. ORF; open reading frame. The promoter can be 
an RNA polymerase III or II, ubiquitous or tissue specific, constitutive or conditional 
depending on the nature of the ORF: long cDNA transgene (pol II) or short RNA transcript 
(pol III). (B) Schematic diagram of rAAV production. The rAAV plasmid and a plasmid 
carrying the rep and cap genes are co-transfected into 293T or BHK cells followed by 
infection with a helper virus (HSV or Ad). rAAV is harvested 72 h and purified using the 
appropriate binding matrix according to its serotype. 
 
 
rAAV vectors have provided the platform for numerous successful gene 
replacement therapies in ocular gene therapy. Investigators demonstrated 
the potential of AAV to transduce retinal tissues [101,102] mediating efficient 
expression of therapeutic genes [103]. Since then, rAAV2/2, 2/5 and 2/8 have 
been used to rescue mice models of monogenic ocular disorders with 
mutations in rds [103], rpe65 [104], RPGRIP [105], AIPL1 [106], Gnat2 
(achromatopsia) [107] and Rs1h (retinoschisin) [108]. In addition, AAV-
mediated delivery of neurotrophic factors (Fgf2 [44], Cntf [49], Gdnf [42]) has 
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the neurotrophic factor alone or in conjunction with a replacement cassette. 
Although the majority of studies has been carried out in mice or rats, 
expression in canine [69,109] and primate [110,111] models has also 
demonstrated the ability of rAAV vectors to efficiently transduce various 
tissues in larger animals. 
 
The lack of human pathogenicity together with their broad tropism has placed 
rAAV vectors at the front of pre-clinical gene therapy research. However, 
recently a few studies have raised concerns about rAAV vector safety 
following systemic, hepatic or intramuscular delivery. Yuasa and colleagues 
demonstrated transgene-specific immunotoxicity in the canine skeletal 
muscles after rAAV2/2 delivery of the micro-dystrophin gene [112]. They 
concluded that the immunogenicity was associated with the transgene and 
the poor transduction efficiency (i.e. muscular absorption) of the vector, 
rather than a specific AAV-targeted immune response. Although the absence 
of the rep cistron is thought to abolish specific integration in the AAVS1 site 
with 5 % of vector randomly integrating into the host genome [92], Donsante 
and colleagues reported rAAV2/2-mediated insertional mutagenesis in mice 
following systemic delivery [113]. Hepatocellular carcinomas were found to 
be caused by upregulation of genes adjacent to the integration locus. 
However, other research groups have failed to replicate the study by 
Donsante et al. or to show integration after rAAV administration concluding 
that rAAVs mainly persist as an episome. Recently, Pien et al. have 
demonstrated that hepatic toxicity can be mediated by the capsid of the AAV 
and not the transgene. In their study, AAV2/2 capsids were found to sensitise 
hepatocytes for cytotoxic T-cell mediated destruction [114]. Another issue 
with regard to intracellular AAV particles has been raised by Stieger and 
colleagues. They reported that AAV virions persist in the retinae of dogs and 
primates six years after subretinal injection [115]. Although no immune 
responses were raised against the persisting virions possibly due to the 
immune privilege of the eye, the authors suggested that future clinical trials 
should address the issue of intracellular virion clearance. 
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phase I clinical trials have been initiated using rAAV2/2 vectors for the 
treatment of Parkinson’s disease [58] and LCA (Rpe65) [70,72,116]. In the 
LCA studies, patients were subretinally injected with approximately 10
8 
rAAV2/2 particles diluted in either 100μl or 1000μl. So far, no immune 
responses have been raised in the patients while some of the patients have 
shown visual improvement. The CNS is a good target for AAV-mediated 
gene delivery and establishment of a safe clinical protocol will pave the way 
for further gene therapy clinical trials in other organs. Future trials may also 
employ rAAV2/8 vectors which are being increasingly used in gene therapy 
research. Although the clinical safety of serotype 8 viruses will need to be 
assessed pre-clinically after reports of trans-synaptic transmission to the 
visual cortex following subretinal delivery in dogs [117], they are a favourite 
candidate for the treatment of early-onset retinal disorders due to their ability 
to mediate rapid and high levels of transgene expression [99]. 
 
 
1.4.2.2.4     Lentiviral vectors 
 
Lentiviruses are a sub-category of retroviruses, RNA-based virions that carry 
a diploid single-stranded RNA genome. Retroviruses are generally highly 
pathogenic, infect dividing cells and integrate their genome into their host’s. 
Lentiviruses are also capable of infecting cells at the post-mitotic G0 phase of 
the cell cycle, providing an advantage for the development of a gene delivery 
vector. Lentiviruses have a 9-10 kb genome flanked by long terminal repeats 
(LTRs) that are essential for integration and the initiation of gene expression 
[118,119]. Feline immunodeficiency virus (FIV), equine infectious anaemia 
virus (EIAV) and the human immunodeficiency virus type I (HIV-1) are 
various lentivirus family members used in vector construction, with the latter 
being the most widely used in research. In lentiviral vectors most of the 
genome is deleted leaving space for expression cassettes up to 9 kb in size 
to be incorporated. In the latest 3
rd generation HIV-based vectors, most of the 
lentiviral genes are deleted and some are delivered in trans during vector 
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for the capsid, polymerase/integrase and envelope components, respectively. 
The remaining genes of the lentiviral genome (like vpu,  vif,  vpr and tat) 
encode for “accessory proteins” that enhance proviral expression and are 
mostly removed. The cis-acting packaging element, ψ, remains present in the 
vector plasmid to enable recombinant viral particle formation. The 3’-LTR is 
partially deleted to ensure it does not elicit any promoter activity of 
downstream genes but retaining the sequence required for reverse 
transcription and integration of the proviral DNA. Vectors with the 3’-LTR 
deletion reduce the risk for ectopic host gene activation as well as the risk of 
vector mobilisation in the host and are called self-inactivating (SIN) vectors. 
Capsid pseudotyping is essential in order to induce the desired cell tropism of 
the vector and it is achieved by cloning the gag gene from the genome of 
another virus. Vesicular-stomatitis virus G-protein (VSV-G) pseudotyping is 
the most widely used in HIV-based lentiviruses as it confers a broad host-cell 
range. 
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Figure 1.9: HIV-1 genome and lentiviral vector constructs. Schematic diagram of the 
wtHIV-1 genome, the lentiviral vector plasmid (LNT.promoter.ORF) and the helper plasmids 
with the viral polymerase (pCMVR8.91) and envelope (PMD.G) genes. The Woodchuck 
hepatitis virus post-transcriptional element (WPRE) is often used in pol II expression 
cassettes to increase gene expression. The three plasmids are co-transfected into 293T 
cells and the virus is purified after 48 h through ultracentrifugation. cPPT; central polypurine 
tract. RRE; rev-responsive element. 3’ΔLTR; partially-deleted 3’ LTR. CMV; cytomegalovirus 
promoter. 
 
 
Following subretinal injection, VSV-G pseudotyped HIV-based lentiviruses 
specifically transduce the RPE in mice [122] and dogs [123]. Inneficient 
photoreceptor and INL transduction has been seen at the injection site or 
after subretinal delivery in mice neonates [124]. Depending on the gene, 
therapeutic levels of transgene expression in the RPE are achieved after 
subretinal delivery of at least 10
5 viral particles. Lentivirus-mediated gene 
therapy has been successfully applied in the RCS rat [125,126], and the 
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-/- mouse [123,126] to rescue the retinal degenerations caused by lack 
of expression of the RPE-specific Mertk and Rpe65 genes, respectively.  
 
The retina contains mainly non-dividing neurons and transgene expression is 
not diluted by cell proliferation. The integrative ability of retroviruses makes 
lentiviral vectors a promising vehicle for efficient transduction of dividing cells 
in other tissues. Episomal transgene expression is diluted in an actively 
dividing population since the episome is not transferred to the daughter cells 
after cell division. However, lentiviral-mediated integration is non-specific and 
occurs at random in euchromatic regions. The risk of insertional mutagenesis 
was demonstrated in a retroviral-based clinical trial for the treatment of X-
SCID, where activation of a downstream host oncogene resulted in 
leukaemic neoplasia [65]. Although the occurrence of insertional 
mutagenesis is not high [61], there is a need for an optimised non-integrating 
vector that transduces dividing cells.  
 
Non-integrating lentiviral vectors have been designed carrying a mutation in 
the pol gene that prevents integration of the provirus. The vectors retain their 
tropism and expression levels but persist episomally [127]. Such vectors are 
useful for transduction of mitotic tissues were the risk for insertional 
mutagenesis is high even though integrase-deficient lentiviral vectors have 
also been shown to efficiently transduce post-mitotic cells in the retina and 
brain [126]. However, these vectors do not address the problem of transgene 
dilution across mitotic daughter cells and recent studies on vector technology 
concentrate on the generation of a site-specific or tightly-regulated lentivirus. 
The chicken β-globin insulator element has been used to “shield” the 
integrated cassette from position-effect variegation, or ectopic downstream 
activation [128]. Similarly, Zhang and colleagues demonstrated that a vector 
encompassing a ubiquitously-acting chromatin opening element (UCOE) 
offers stable transgene expression without ectopic activation [67]. UCOEs 
consist of methylation-free CpG islands and drive the expression of the 
downstream gene without activating adjacent genes or being silenced by 
site-specific factors. Even though the post-mitotic environment of the retina 
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regulation often hampers lentiviral transduction [129] and maintaining the 
activity of the transgene cassette is as essential as the abolishment of 
insertional mutagenesis.  
 
Development of the next generation of lentiviral vectors aims to combine 
tightly regulated promoters with site-specific scaffold regions for specific 
locus integration, overcoming the current safety issues raised in the clinic. 
 
 
1.4.3    Approaches for treating gain of function mutations 
 
Gene replacement therapy approaches have been used successfully for 
treating animal models of recessive monogenic retinal disorders where there 
is a deficiency in a functional gene product. In some dominant disorders, 
however, the mutated gene product may have a toxic impact on the cell, as a 
result interfering adversely with its normal cellular pathway. Therefore, 
supplementing the cell with a normal copy of the gene would not necessarily 
reduce the negative effect of the mutation. Ablating the mutated gene’s 
expression is essential for the treatment of gain of function dominantly 
inherited disorders and if haploinsufficiency results after the silencing of the 
mutation, it can be treated with a replacement gene therapy approach. The 
term “suppresion and replacement” was coined by Jane Farrar and Peter 
Humphreys (Trinity College, Dublin) to describe this concept and its 
application is described later (see section 1.5.3) [130]. To date, three main 
approaches for the ablation of a toxic gene product have been devised: 
antisense nucleotides, ribozyme technology and RNA interference. 
 
Antisense RNAs are ssRNA molecules that can range in size up to a few 
hundred base pairs and they hybridise with the target mRNA. The aim of 
antisense technology is to cause host-induced mRNA degradation. The 
antisense nucleotides either alter the secondary structure of the mRNA in a 
way that hinders translation, or form an RNA double helix that elicits RNase-
  50specific degradation. The drawback with delivering antisense RNA molecules 
is their instability. RNA has a high turnover in the cell and the effect from a 
single administration is transient. Stabilising the molecule and increasing its 
persistence has been achieved by modifying the phosphate bonds in the 
RNA backbone [131]. Sugar modifications, like oxetane or deoxyribose, can 
be introduced in the nucleosides of the backbone. In this way, the molecule 
persists in the cell for longer hence providing extended target silencing. 
Antisense oligodeoxynucleotides (ADN) 20 base pairs (bp) long have been 
used to target VEGF production in laser-induced CNV lesions in primates 
[132]. Intravitreal delivery of ADN reduced neovascularisation in treated eyes 
three days after the CNV lesion. Similarly, antisense nucleotides have been 
used to silence TNF-α in mice with HSV-induced retinitis resulting in reduced 
inflammation after one and four days following subconjuctival injection [133]. 
The fast degradation of naked RNA in retinal cells abolishes any therapeutic 
effect after a few days rendering them inefficient for long-term treatments. 
However, a transient targeting may be promising for the treatment of an 
acute condition but not for the treatment of a genetic defect. 
 
Ribozymes are small RNA molecules that catalyse the cleavage of a targeted 
mRNA and are derived from viruses, lower eukaryotes and bacteria [134]. 
Although some, such as the Group I intron ribozymes, can cleave the 
phosphate backbone of the RNA and reattach it at a different point, others 
cleave the RNA molecule without re-ligating the broken ends and hence 
leading to silencing of the transcript. Hammerhead ribozymes are 30 bp long 
and are the smallest ribozyme molecules long enough for their intramolecular 
secondary structure to provide the epitope for mRNA binding. An advantage 
that ribozymes present over ADNs is the fact that they can be transcribed as 
hairpin molecules providing a stable supply in the affected tissue overcoming 
the issue of rapid RNA degradation. Expression cassettes encoding 
ribozymes can be delivered with various vectors providing silencing of a 
mutation and can be highly specific as to target a point-mutation in an allele-
specific manner. Ribozymes have been shown to specifically target 
mutations  in vitro when delivered synthetically [135] or virally [136]. The 
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on a rat model for dominant RP expressing the P23H rhodopsin mutation 
where a partial rescue of the model was demonstrated for up to 3 months 
after AAV-mediated delivery [137]. The P23H rats have a murine rhodopsin 
transgene with an amino-acid changing mutation leading to loss of 50 % of 
the photoreceptors within three months of age [138]. In a different study, 
AAV2/2-mediated delivery of a hammerhead ribozyme targeting the P23H 
mutation reduced ONL degeneration for eight months and partially improved 
the ERG response for three months after treatment [139]. Rats were treated 
at either P15 or P45 and were followed for eight months. In another study, 
the same model was treated with an AAV2/5 vector expressing a rhodopsin-
targeting ribozyme cassette. A 46 % reduction in expression of the P23H 
allele  in vivo after three months was demonstrated [140]. In all efforts to 
rescue the P23H rat, the amelioration of the phenotype was transient and a 
functional rescue did not exceed three months after treatment. In addition, 
treatment for dominantly inherited disorders in the early postnatal period 
would not be possible in patients due to ethical concerns rendering 
ribozymes inefficient to reverse or halt the progression of the dominant 
phenotype. Apart from the P23H rat model were an optimal ribozyme 
clievage site was engineered in the P23H mutant murine allele to increase 
efficiency, ribozyme technology has not shown to deliver stable silencing in 
vivo.  
 
During the last decade a novel technique emerged on the field of gene 
silencing whose efficiency surpasses the knockdown achieved with 
ribozymes [136]. RNA interference is probably the most efficient way to 
silence the expression of a gene and is rapidly advancing into the clinic. 
Below the main principles, vector design and therapeutic applications of RNA 
interference are discussed.  
 
 
 
  521.5 RNA  interference 
 
 
RNA interference (RNAi) is the term given to post-transcriptional gene 
silencing induced by double-stranded RNA (dsRNA) in eukaryotic cells. In 
1998, Fire and colleagues demonstrated that the introduction of dsRNA 
molecules into the nematode, C. elegans, leads to specific silencing of a fully 
complementary mRNA [141]. Furthermore, the extent of mRNA silencing was 
far more potent than that achieved after the introduction of single-stranded 
RNA (ssRNA) molecules. In their landmark publication, they also reported 
that the interference between dsRNA and mRNA was not stochiometric and 
that a small quantity of dsRNA molecules within the cell could provide almost 
total mRNA knockdown indicating a catalytic pathway. Further studies 
revealed that RNAi utilises an endogenous highly conserved trans-kingdom 
pathway, developed as a defence mechanism by eukaryotes against 
transposons and viral infections. Whereas in lower organisms the dsRNA 
molecules can vary in size, in mammalian cells long dsRNA molecules trigger 
a toxic, non-specific global knockdown that leads to cell death. Short-
interfering RNA (siRNA) molecules 19-21 bp long have been found to 
specifically silence the complementary mRNA in mammalian cells by 
becoming incorporated into a large multicomponent RNA-protein complex 
called the RNA induced silencing complex (RISC) [142,143]. The siRNA 
guides the RISC to the complementary mRNA which is then catalytically 
cleaved. The specific size requirements of siRNAs (19-21 bp) together with 
the low tolerance for size deviations was clarified with the discovery of Dicer, 
an RNase III endonuclease that cleaves long dsRNA molecules into siRNAs 
[144,145]. 
 
The potential therapeutic implications of harnessing this natural defence 
mechanism are apparent and studies on the two main components of RNAi, 
RISC and Dicer, led to the elucidation of the catalytic cleavage mechanism 
as well as to the analysis of siRNA design down to every nucleotide of the 
molecule. However, the discovery of endogenous cellular short RNA 
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dsRNA introduction, suggested the existence of other yet unknown 
pathways. Since then, a whole “panoply” of small noncoding RNA (ncRNA) 
molecules has been found to control gene silencing and chromatin structure 
indicating that they might constitute the most important group of regulatory 
molecules in the cell. The discovery of microRNAs (miRNAs) has led to a 
better understanding of the endogenous pathways that in turn have aided the 
design of more potent therapeutic siRNAs. For this reason, miRNAs will be 
discussed first before addressing their impact on siRNA technology. 
 
 
1.5.1    MicroRNAs (miRNAs) 
 
Of the total transcriptional output of the cell, 97 % is ncRNA. Transfer RNA 
(tRNA), ribosomal RNA (rRNA), untranslated regions (UTRs), introns and 
transposable elements make up the majority of the previously known 
ncRNAs. With the emergence of RNAi, a new group of highly conserved 
small ncRNAs, called small temporal RNA or microRNA (miRNA) molecules, 
was found to be involved in gene regulation. miRNAs are 20-22 nucleotides 
(nt) long ssRNA molecules formed after nuclear and cytoplasmic processing 
of longer transcripts [146-148]. Lagos-Quintana and colleagues first observed 
miRNA function in C. elegans by studying miRNAs lin-4 and let-7 [149]. 
Expression of miRNAs was found to be variable during embryogenesis 
suggesting a regulatory role in differentiation and tissue development. 
Further studies in Drosophila and human tissue confirmed the existence of 
miRNAs as temporal gene expression regulators that cause the translational 
repression of their complementary mRNA. To date, at least 800 miRNAs 
have been found in the human genome [146,150]. 
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Figure 1.10: The miRNA biogenesis pathway. (A) Schematic representation of miRNA 
transcription (pri-miRNA), nuclear processing (pre-miRNA) and cytoplasmic maturation 
(miRNA duplex) steps. On the left side of the diagram, the steps where exogenously 
delivered molecules enter the pathway are annotated (see section 1.5.2). Exp5; Exportin 5. 
Ago2; Argonaute 2 (not the only one; indicative of the whole family). RISC; RNA-induced 
silencing complex. (Adapted from Cullen, 2005) [146] (B) Secondary structure of the human 
pre-miR-30, one of the most studied miRNA molecules. *; G-U wobble nucleotide bonding 
(Adapted from Boden et al., 2004) [151] 
 
 
MicroRNAs are transcribed from RNA pol II promoters in clusters that are 
several kb long. Each miRNA sequence contains a palindrome whose 
secondary structure is a non-perfect hairpin. The initial primary miRNA (pri-
miRNA) transcript is processed in the nucleus by an RNase III enzyme called 
Drosha. Drosha catalyses the excision of miRNA hairpins from the primary 
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cleaving ~22 nt away from the hairpin loop. The ~70 nt long pre-miRNA 
hairpin bears a 2 nt 3’ overhang after Drosha cleavage that acts as a 
recognition site for its interaction with Exportin-5 [152] (Figure 1.10). 
Exportin-5 is a nuclear export factor that mediates the transfer of the pre-
miRNA to the cytoplasm where a second RNase III enzyme, namely Dicer, 
catalyses the final step in the formation of a mature miRNA duplex. Dicer 
recognises the 2 nt 3’ overhang of the pre-miRNA and cleaves ~22 nt away 
from the last base excising the terminal loop and leaving another 2 nt 3’ 
overhang [144,153,154]. The strand with the least thermodynamically stable 
5’ end incorporates an effector complex called miRNA ribonucleoprotein 
(miRNP) complex that includes RISC [155]. miRNPs consist of a number of 
miRNAs and RNA binding proteins mainly from within the Argonaute (Ago) 
family. Recent studies on Ago proteins reveal that they are key factors in 
many different RNA silencing pathways through the interactions of their PAZ 
(Piwi Argonaute and Zwille) and PIWI domains with RNA molecules [156]. 
PAZ is a 130 amino acids (aa)  domain that recognises the 3’ overhang of the 
miRNA strand whereas the PIWI domain (300 aa) forms the core of the 
protein than guides mRNA alignment to the miRNPs [156,157]. Through PIWI 
induced coupling of the miRNA strand and the 3’ UTR of the target mRNA, 
translational repression occurs. Although PIWI domains have been shown to 
have endonuclease capacity, in the miRNA silencing pathway the mRNA is 
not degraded upon recognition. Instead, the miRNA strand forms a non-
perfect duplex at the 3’ UTR hindering translation. This is the main 
characteristic of the miRNA pathway: translational repression as opposed to 
mRNA degradation (in siRNA pathway) or chromatin rearrangements (in 
piRNA pathway). 
 
The targeting of an mRNA by its corresponding miRNA depends on the free 
energy value of the miRNA:mRNA duplex. More specifically, the first 6-8 nt of 
the miRNA’s 5’ end are used as a “seed region” for mRNA coupling 
[146,158]. In addition, non-perfect complementarity between miRNA and 
mRNA creates nucleotide wobbles that can have an additional effect apart 
from influencing total free energy values. Guanine:Uracil (G:U) wobbles in 
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“seed region” whereas other mismatches are more tolerated [158]. Further 
upstream of the miRNA biogenesis pathway, the pri-miRNA hairpin loop has 
been shown to affect its nuclear processing. Polymorphisms within the loop 
sequence have an impact on Drosha processing and therefore on 
cytoplasmic miRNA concentration [159]. The existence of sequence 
polymorphisms with functional effects indicates the dynamic role of the 
miRNA pathway in development as well as in disease. Expression levels of 
miRNAs have been shown to be altered in cancer and indeed in retinal 
degenerations [148,160-163]. This finding presents a new therapeutic 
platform for the treatment of certain diseases. For example, in cases of 
miRNA overexpression, stable synthetic “anti-miR” molecules can be 
introduced to the cell to reduce the concentration of an endogenous active 
miRNA. Antagomirs are 2’-O-Methyl modified RNA molecules that bind the 
active miRNA strand preventing its incorporation into miRNPs, hence 
influencing mRNA translation [160,164].  
 
The expression levels of pri-miRNAs and their target mRNAs, the number of 
targeting miRNAs per mRNA as well as the variable processing of each 
miRNA depending on tissue and developmental timing, indicates that 
miRNAs provide a finely tuned mechanism for the regulation of gene 
expression. 
 
 
1.5.1.1     Piwi-interacting RNAs (piRNAs) 
 
Apart from miRNAs another ncRNA group called Piwi-interacting RNAs 
(piRNAs), or repeat-associated siRNAs (rasiRNAs), has recently beem 
discovered. 
 
piRNAs are slightly longer than miRNAs and siRNAs ranging between 26-
31nt [165]. They are associated with chromatin rearrangements during 
gamete formation and their presence has been confirmed in nematodes 
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transcribed from long ssRNA transcripts and gene clusters of piRNAs have 
been found in Drosophila [166] as well as mouse [168,170] and rat [169] 
testes. The main structural difference to miRNAs or siRNAs is not the gene 
clustering but the absence of antisense piRNA strands or hairpin formation 
within the multicistronic piRNA transcript [165]. However, the process and the 
components that mediate the excision and generation of an active piRNA as 
well as the pathway through which they trigger epigenetic modifications are 
not known yet. RNA involvement in genomic rearrangements has been 
previously reported in Tetrahymena through what was thought to be an 
RNAi-dependent pathway [171]. Yao and colleagues demonstrated that 
genome-wide DNA rearrangements that persist in the progeny of protozoa 
can be induced by introducing dsRNA. The targeted region was not merely 
translationally repressed but excised from the genome. Germline DNA 
rearrangements alter chromatin structure through histone modifications to 
silence parasitic repetitive elements like transposons. The pathway through 
which piRNAs trigger DNA rearrangements is not fully understood but 
Argonaute-based complexes (similar to miRNPs and RISC) have been found 
to be involved. 
 
The Argonaute family can be divided into the Ago and Piwi subfamilies based 
on aa sequence variations. In general, the Ago subfamily is ubiquitously 
expressed and associated with the miRNA and siRNA pathways. The Piwi 
subfamily is restricted to the germline and stem cells where it is associated 
with genomic rearrangement pathways [168]. It seems possible that, apart 
from Argonaute based RISC complexes, piRNAs also interact with as yet 
unknown enzymatic methyltransferases or acetylases that induce histone 
modifications based on an RNA-based template.  
 
Further studies on the catalytic function of piRNAs may in the future enable 
the construction of novel siRNA molecules that when provided in the host cell 
together with Piwi components, could mediate not only RNA silencing but 
also specific genomic DNA rearrangements. 
 
  581.5.2    Short-interfering RNAs (siRNAs) 
 
1.5.2.1     Mechanism and components of siRNAs 
 
The presence of dsRNA in the cytoplasm triggers its degradation by Dicer 
into ~22 nt siRNAs. The main difference between the miRNA and siRNA 
pathway is the pattern of cleavage by Dicer and the recruitment of an RNA-
binding helicase, RDE-4, in the siRNA pathway [172]. In the miRNA pathway 
Dicer cleaves the pre-miRNA molecule on the basis of the Drosha-generated 
hairpin. In the siRNA pathway, Dicer can degrade a long dsRNA into 
consecutive ~22 nt siRNAs [143,145]. After Dicer maturation, the majority of 
miRNAs and siRNAs are virtually identical in size (~22 nt) and structure (3’ 2 
nt overhangs). They both incorporate into a large ribonucleoprotein complex 
that acts as the effector molecule for transcriptional repression. RISC is a 
large 500 kDa complex that mediates siRNA: mRNA association through 
Ago-2 [143]. Prior to mRNA silencing, RISC degrades the sense (passenger) 
strand and retains the antisense (guide) strand as a template for mRNA 
recognition. Of all the Argonaute family members, Ago-2 demonstrates 
splicer activity that can lead to the cleavage of the complementary mRNA 
[156]. Furthermore, Ago-2 mediated mRNA cleavage occurs when the level 
of complementarity between mRNA and siRNA is very high. In contrast to the 
miRNA pathway, non-perfect mRNA:siRNA duplexes do not lead to 
transcriptional repression but instead greatly reduce the degradation of the 
non-perfect transcript. The fact that the majority of Ago proteins (Ago 1,3,4) 
do not demonstrate splicer activity might suggest that most of the 
transcriptional repression is brought about via the miRNA and not the siRNA 
pathway [156]. However, understanding the basis of the siRNA pathway’s 
high stringency can aid to develop a highly efficient targeting therapeutic 
molecule. 
 
 
 
  591.5.2.2     Design of siRNAs and stringency of silencing 
 
RNAi pathways rely on certain key steps in the maturation of the targeting 
molecule and its target coupling. These steps involve nuclear Drosha 
processing and Exportin-5 trafficking as well as cytoplasmic Dicer maturation 
and RISC activation via strand selection and target recognition. The main 
optimisation points for efficient RNAi design are summarised below (also see 
Table 2). 
 
Each mature siRNA duplex consists of two strands: the passenger and guide 
strands. The RISC cannot distinguish between the two strands for 
incorporation, therefore each strand has equal chances of RISC binding 
given they have equal thermodynamic stability. Various studies have shown 
that the strand with the least thermostable 5’- end is more likely to enter 
RISC [173-176]. In fact, high adenine/uracil (A/U) content in the 5’-end of the 
guide strand as opposed to high G/C content in the 5’-end of the passenger 
strand can drive antisense strand RISC incorporation as well as eliminate 
sense strand incorporation. G:U wobble mutations have also been recruited 
to aid in strand selection [177]. 
 
Once the guide strand is incorporated in the active RISC, the knockdown 
efficiency depends on mRNA complementarity and the catalytic function of 
Ago-2. Although the exact catalytic epitopes of Ago-2 and their function 
relative to siRNA:mRNA coupling have not been elucidated, there are certain 
sequence biases that increase the silencing efficiency of an siRNA. Optimal 
GC content has been estimated at 36 – 52 % and the siRNA guide strand 
should be devoid of strong internal secondary structures like hairpins caused 
by palindromes [173,175]. These two characteristics ensure for efficient 
strand separation aided by RISC’s helicase activity and correct guide strand 
placement in the PAZ and PIWI domains of Ago. Furthermore, the presence 
(or absence) of certain nucleotides in certain positions seems to increase 
silencing efficiency: U at position 11, A at position 1 and position 16 of the 
guide strand are preferable for siRNA function [175,178,179]. The absence of 
G/C at position 7 is also favourable. In addition, position 10 and position 16 of 
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activity of Ago-2 [180]. The catalytic role of these central nucleotides is 
stringent enough to distinguish between point mutations when purine:purine 
mismatches occur at these positions [180]. In this way, it is possible to 
silence an allele with a point mutation while the wild-type allele remains 
unaffected [181,182]. Alternatively, supplementation with a gene carrying a 
wobble mutation at the point of target is also possible [183].  
 
Apart from ensuring efficient knockdown of the targeted mRNA, siRNA 
design should also concentrate in minimising off-target silencing. The 5’-end 
of the guide strand, and especially positions 2-8, is the “seed region” and is 
associated with siRNA target recognition [173]. On the other hand, the 3’ end 
of the guide strand and especially the central nucleotides (positions 10-16) 
are involved in the catalytic function of the siRNA. Off-targeting has been 
associated with “seed region” complementarity between siRNA and 3’ UTRs 
[184,185]. These observations are taken into account in algorithm-based 
siRNA designing software for target prediction in order to narrow down the 
selection criteria for any given gene target. 
 
Finally, other design strategies concentrate on the flanking sequences of the 
active siRNA in order to enhance nuclear Drosha and cytoplasmic Dicer 
processing prior to RISC incorporation. Synthetic hairpins, 29 nt in size rather 
than the standard 19-21 nt, have been shown to act as a more efficient 
substrate for Dicer because of their similarity to the natural miRNA hairpins 
[186]. These “miRNA mimetics” have been further optimised by incorporating 
flanking sequences of pre-miRNAs or pri-miRNAs to facilitate Drosha as well 
as Dicer processing [187-189]. However, the pre- and pri-miRNA templates 
are too large to be delivered synthetically and since their presence is 
required in the nucleus, they are provided in expression cassettes driven 
from RNA pol III promoters. 
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siRNA design are listed together with their underlying molecular rationales. Their 
accumulation has been progressive and recent sequence prediction software may use some 
or all of them. Note that these criteria increase the probability of efficient siRNA design and 
do not guarantee it. Likewise, sequences derived without the previously mentioned criteria in 
mind might be successful in a specific cellular context. SNP; single nucleotide polymorphism. 
DESIGN CRITERION  RATIONALE  REFERENCES 
5’ reduced thermostability 
Increasing the chance for RISC 
incorporation 
[173-176] 
36 – 52 % GC content 
Although RISC has helicase 
activity, a high siRNA GC content 
might delay incorporation 
[173,175] 
Absence of strong siRNA 
secondary structure 
Palindromes lead to hairpin 
formation that hinders Ago 
binding and mRNA recognition 
[175,178] 
High A/U frequency at 5’ 
U at pos. 11 
A at pos. 1 & 16 
Not G/C at pos. 7 
SNP targeting at pos. 16 
Certain positions within the 
siRNA are more crucial than 
others. Probably because of Ago-
2 epitope association 
[175-178,180-
183]  
Avoid “seed region” 
complementarity with 3’ 
UTR of non-target mRNAs 
3 or more consecutive nucleotide 
matches should be avoided as 
3’UTRs are more prone to off-
targeting 
[173,184,185] 
Use pre- and pri-miRNA 
hairpins as templates 
Natural design enhances Drosha 
and Dicer processing 
[186-189] 
Avoid immunostimulatory 
sequences in the siRNA 
Certain sequences 5-9 nt in size 
may activate Toll-like receptors 
[178] 
 
 
 
 
  621.5.2.3     Alternative design of hairpins 
 
The majority of hairpin-based RNAi studies employ a standard design 
rationale for the construction of an expression cassette that drives the 
transcription of sense and antisense strands separated by a loop sequence. 
The shRNA hairpin produced by the cassette is not processed in the nucleus 
after transcription but instead is transported to the cytoplasm where the loop 
sequence is cleaved by Dicer. The only variable part of the expression 
cassette apart from the target area is the loop sequence as it can vary 
between three and twelve nucleotides. The variations in the size of the loop 
have arisen from different studies that concentrated on the loop sequence as 
a means of increasing the silencing potential of the shRNA molecule [190-
192]. 
 
In an effort to further improve shRNA processing, various groups have 
examined the endogenous regulatory miRNA pathway and its components 
(see section 1.5.1). As the endogenous miRNA pathway was being 
deciphered and key enzymes in the miRNA pathway were identified, it was 
apparent that the initial transcript of a miRNA undergoes three main stages of 
maturation to reach the cytoplasmic siRNA duplex state. Sequence analysis 
of initial (pri-miRNA) and intermediate (pre-miRNA) states indicated that 
apart from an extended loop sequence, the miRNA molecules contained 5’ 
and 3’-unspecific sequences that although did not contribute to the target 
area  per se, they did influence nuclear processing and cytoplasmic end 
concentration [152,159]. The term “miRNA mimetics” is used to describe the 
mimicking of naturally occurring flanking sequences when designing an 
shRNA expression cassette. The aim is to use the nuclear machinery to 
process the hairpin molecule more efficiently, increasing its cytoplasmic 
concentration and thus its potency [193]. In addition, miRNA-based hairpins 
have also been shown to reduce non-specific toxicity in host cells. The same 
target areas incorporated into standard shRNAs induced toxicity caused by 
high hairpin concentration [194]. miRNA-based design should improve the 
silencing capacity of any hairpin; something which could prove useful in 
applications where the choice of target area is limited. For example, in 
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targeted and the most efficient candidate is used for the construction of a 
hairpin cassette. However, in the case of point mutation targeting there is 
minimal flexibility in siRNA selection. Similarly, when targeting a highly 
expressed gene, the most efficient siRNA candidate may still not be efficient 
enough to achieve total silencing. 
 
With the advancement of tissue miRNA profiling, a number of highly 
expressed miRNAs have been identified in most tissues and range from 
universal miRNAs (house-keeping regulators) to tissue-specific miRNAs 
(tissue-specific regulators). The structure of these miRNAs can be mimicked 
in hairpin design and increase the levels of gene knockdown. miR-30 is one 
molecule which has been used in miR-based hairpin design [151,195,196]. 
As in all miRNAs, miR-30 contains 3’ and 5’ flanking sequences as well as an 
extended loop sequence (Figure 1.10). In addition, mismatches decrease the 
energy stability of the molecule at various positions. This feature has already 
been used in standard siRNA design as a means of increasing the ratio of 
antisense-sense strand Dicer incorporation.  
 
 
1.5.2.4     Evading silence using the degeneracy of the genetic code 
 
The degeneracy of the genetic code is a powerful asset for DNA transcription 
as it “shields” the cell from the accumulation of random mutations over time. 
In effect, 61 codons correspond to 20 amino acids resulting in each amino 
acid being incorporated into a polypeptide by a range of codons (from a 
minimum of one codon, only in the case of tryptophan and methionine, to a 
maximum of six codons in the case of arginine, leucine and serine). With 
regard to RNAi design, when selecting target sequences randomly, the 
chances that the target area is situated in the ORF of the gene are higher as 
it often exceeds the 3’ or 5’-UTRs in size. The stringency with which siRNA 
molecules function renders the degeneracy of the genetic code a powerful 
tool to evade silencing for “suppression and replacement” approaches. 
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altering the 3’ and 5’-UTRs in the replacement construct could lead to similar 
levels of silencing [130]. When targeting within the ORF, by manipulating the 
third nucleotide of the codons in the target area it is possible to produce an 
altered transgene that is not silenced by the mismatched siRNA, while at the 
same time it encodes the same polypeptide as the siRNA’s target. One 
precaution that needs to be taken into consideration prior to inserting the 
codon-altering mutations, is the relative abundances of their respective 
tRNAs. In each species, the tRNAs carrying the amino acids for each 
corresponding codon do not exist in equal cytoplasmic concentrations [197]. 
The reason for this is that certain codons are far more common than others 
and equimolar cellular tRNA concentrations hamper mRNA translation. When 
considering codon exchanges within a polypeptide, the codon with the lowest 
relative abundance (i.e. the rarest) in the original cDNA should first be 
identified. Since the rarest codon is the rate limiting factor during mRNA 
translation, the substituted codons in the area of interest should not have 
lower relative abundances. Slower production of the polypeptide might be 
deleterious especially when high transgene expression levels are needed. 
 
 
1.5.2.5     Hairpin expression cassettes and viral vectors 
 
Synthetic siRNA administration provides a transient knockdown of the target 
mRNA as its cytoplasmic turnover is very fast. Expression cassettes that 
transcribe a hairpin RNA can be more persistent than synthetic siRNA 
transfection and the incorporation of a hairpin cassette into a viral vector can 
prolong the short hairpin RNA (shRNA) expression even further depending 
on the nature of the virus and the transduced tissue. 
 
Plasmid shRNA expression requires an RNA pol III promoter such as U6 or 
H1 to drive the transcription of the sense and antisense strand which are 
separated by a oligonucleotide loop sequence that enables hairpin formation. 
Brummelkamp and colleagues have demonstrated that plasmid-based 
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knockdown of p53 and CDH1 [198]. In addition, they performed a loop size 
analysis indicating that a 9 nt long loop provides better knockdown than 
hairpins with 5 or 7 nt. The loop size can vary from 3 nt to large miRNA 
based ones and it should allow for efficient hairpin formation [190]. RNA pol 
III promoters can also be enhanced for increased or selective expression. A 
CMV enhancer has been shown to increase shRNA expression from the U6 
promoter in 293T cells and has been used to target an allele-specific SOD1 
mRNA point mutation [192]. Doxycyclin and tetracycline H1 inducible 
promoters have been successfully used in human colorectal cancer cells to 
target β–catenin [199] and DNMT1 [200] expression, respectively. Silencing 
of these genes was greater than 2-fold and resulted in growth arrest of the 
cancer cell line. 
 
A main advantage of RNAi expression cassettes is their relatively small size 
(~500 bp) that enables their cloning in viral vectors often in bicistronic 
configuration together with a reporter gene expression cassette. Lentiviruses 
expressing shRNA cassettes have been used to effectively target luciferase 
[201] and the K-RAS oncogene [202] in human cells. The efficient virally-
induced silencing of K-RAS was also demonstrated in vivo in athymic mice 
by preventing tumour progression [202]. When miRNA-based design is 
employed together with lentiviral expression, the silencing of the target gene 
can be even more potent and stable. Lentiviral transduction of 293T cells with 
a miRNA-based cassette targeting the HIV-specific tat gene resulted in 80 % 
reduction of the p24 antigen titration value [151]. The potency of lentiviral 
miRNA-based hairpin expression was further demonstrated by Shin and 
colleagues on mouse embryonic fibroblasts and macrophages. At an MOI of 
1, efficient and stable tetracycline-regulated silencing of G protein subunits 
was observed in both cell lines [203]. In addition, multicistronic miRNA 
cassettes were efficiently transcribed from one promoter leading to equal 
levels of silencing for two different G protein subunits. AAV-based hairpin 
expression has also proved to be effective in vitro and in vivo for the targeting 
of cancer or neural cell specific expression [204-206].  
  661.5.2.6     Hairpin toxicity and off-targeting 
 
Although the efficiency of siRNAs or shRNA expression cassettes has been 
widely demonstrated in various studies, any non-specific off-targeting or toxic 
effect that these molecules might have is not always assessed. In 
mammalian cells, the presence of dsRNA might activate cellular defence 
mechanisms through the interferon response pathway resulting in non-
specific RNA degradation. A few studies employed microarray profiling or 
interferon stimulated gene (ISG) expression analysis to answer the question 
of siRNA non-specificity. Efficient knockdown of chromatin regulating MORFL 
genes in human lung fibroblasts increased the expression of 2’5’-
oligoadenylate synthetase (OAS1), a classic interferon target gene, by 50-
fold [207]. Although the effect might depend on the nature of the targeted 
gene, the cell line or indeed immunostimulatory sequences in the siRNA 
[208], the authors of the study point out that many cancerous cell lines, which 
are often used in RNAi experiments, have a defective interferon response 
and hence an immunostimulatory effect may not be observed. In human 
glioblastoma cells, laminin siRNA transfection resulted in multiple ISG 
overexpression through a pathway independent from PKR, a dsRNA-
dependent protein kinase, and RNase L, the main dsRNA interferon triggers 
[209]. It has been speculated that toll-like receptor 3 (TLR3) activation may 
be the cause of siRNA immunoreactivity but this has not been confirmed 
[210]. TLR3 is a cell surface double-stranded viral RNA sensor that protects 
the cell from viral infections. Naked siRNAs are able to activate the 
extracellular part of TLR3 causing non-specific mRNA degradation and 
eventually leading to cell death. This process is initiated by TLR3 and 
propagated through the interferon response system for the protection of the 
host. Kleinman et al. also demonstrated that the minimum siRNA length 
required for TLR3 activation was 21 nt of conventional design [210]. Smaller 
siRNAs did not activate the receptor. Although the authors clearly 
demonstrated TLR3 activation by naked RNA, they did not test 
corresponding shRNAs or siRNAs delivered using transfection reagents. 
Although U6 and H1 are the most popular promoters used to drive RNAi 
expression, other RNA pol III promoters can be used for shRNA transcription. 
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interferon response due to a GGG triphosphate addition at the beginning of 
the hairpin [211]. It is, however, possible to prevent the immune response by 
using an additional two 3’ adenosine residues at the end of the hairpin that 
abolishes coupling with the GGG at the 5’-end allowing RNAse T1 to cleave 
them.  
 
Apart from initiating an interferon response, it has been suggested that off-
targeting may result in siRNAs acting as miRNAs on non-perfect 
complementary mRNAs [212]. RISC incorporation does not determine 
whether the short RNAs progress down the siRNA or miRNA pathway, 
instead it is the complementarity with the target mRNA that determines this. 
However, the exact process by which RISC distinguishes between miRNA 
and siRNA guide strands, is not yet known. Jackson and colleagues carried 
out an extensive microarray analysis on off-targeting after siRNA transfection 
targeting MAPK14 and IGF1R in HeLa cells. A number of mRNAs with a 
minimum complementarity of 11 consecutive nucleotides to the siRNA were 
also downregulated [213]. However, all the nucleotide identities were located 
towards the 5’ end of the guide strand indicating binding of the siRNA “seed 
region” to the 3’UTR of the off-targets. This study further highlights the 
importance of safe siRNA design and the need for updated sequence 
predicting software.  
 
A recent study suggested that RNAi toxicity may be due in large part to the 
levels of shRNA/miRNA expression rather than their silencing effect on gene 
expression. Grimm and colleagues used AAV2/8 vectors to drive miRNA-
based cassettes targeting 49 different areas within 6 mRNA targets [214]. 
Systemic delivery of the viruses in mice resulted in dose-dependent liver 
injury (36 viruses) and/or death (23 viruses). The saturation of the 
endogenous miRNA pathway that resulted in the downregulation of liver-
specific miRNAs was found to be the reason of toxicity. Exportin-5, in 
particular, is the key protein that chaperones pre-miRNAs to the cytoplasm 
and was mostly affected. Supplementation with an Exportin-5 transgene 
restored endogenous miRNA processing indicating toxicity was caused by a 
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potent vector (AAV2/8) and expression cassette (miRNA-based), an optimal 
dosage is essential to minimise toxicity and at the same time maintain the 
desired silencing. Therefore, safe design as well as appropriate choice of 
vector and hairpin template are the main prerequisites to ensure successful 
application of this technology. 
 
 
1.5.3    Applications of RNAi 
 
RNAi-mediated knockdown has been successfully applied in vitro and in vivo 
using various delivery methods. Oncogenes [215-218], HIV-1 regulatory 
elements [151,219,220] and triplet-repeat expansion mutations [221-224] 
have been silenced in various animal models. In the eye, viral-mediated 
RNAi has been used to efficiently silence photoreceptor-specific genes in 
mouse models of dominant RP. 
 
Inhibition of an angiogenic factor in the retina to combat neovascularisation 
has been the first effort to efficiently treat an ocular condition using RNAi 
[178,225,226].  VEGF has been silenced using synthetic [227,228] or viral 
hairpin cassettes [229] resulting in reduced neovascularisation in a mouse 
model for CNV. The first clinical trial using a synthetic siRNA downregulating 
VEGF expression to treat AMD patients is currently in progress and is 
expected to enter phase II soon. Administration of siRNA via intravitreal 
injection requires minimal surgery and is the favoured route of administration 
for repeated siRNA delivery in the eye. The advantage of using synthetic 
siRNAs to target VEGF over shRNA expression cassettes relies on the fact 
that shRNA delivery to the retina is still being optimised in terms of choice of 
vector and regulation of expression. Intravitreal injections are routinely 
performed and even though repeated administration of siRNAs is required, 
their short period of action eliminates many possible side-effects of prolonged 
expression. Since angiogenesis is part of healthy retinal development, 
constitutive downregulation of angiogenic factors like VEGF might not be 
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neovascularisation where permanent silencing would not be favourable since 
VEGF is an important component of vascular regulation. Although the 
majority of anti-angiogenic studies concentrate on VEGF, other molecules 
involved in the neovascularisation pathway, like HIF-1, have recently 
attracted attention as they act upstream of VEGF in the angiogenesis 
pathway [230]. 
 
Another area of interest is the silencing of major photoreceptor genes. Palfi 
and colleagues used a plasmid based shRNA expression cassette to silence 
~80 % of Prph2 mRNA in retinal explants and transfected COS-7 cells [231]. 
They also demonstrated replacement of PRPH2 through the expression of an 
alternate Prph2 cDNA with 8 point mutations within the siRNA target area. 
Subsequent silencing of other photoreceptor genes (rho silenced by 50 %, 
pde silenced by 20 %) that had no homology to the targeted area of Prph2 
were attributed to secondary effect after Prph2 depletion rather than off-
targeting [231]. Although this explanation is quite possible, partial 
complementarity with these genes’ 3’UTR should also be investigated. 
 
RNAi-mediated knockdown of rhodopsin has been studied more extensively 
as Rho mutations account for the majority of adRP mutations. Cashman and 
colleagues used human embryonic retinoblasts to demonstrate Rho 
knockdown after plasmid transfection with an shRNA cassette. Robust 
silencing of ~95 % of Rho expression was observed in the transfected cells 
[232] although it is not clear how expression levels in embryonic retinoblasts 
compare with that in adult photoreceptors. The hairpin used in this study 
silenced both wild-type Rho mRNA and Rho mRNA carrying the P23H 
mutation while a Rho cDNA mutated within the target area of the hairpin 
using the degeneracy of the code was left unaffected. In vivo,  Rho 
knockdown has been attempted using subretinally injected AAV2/5 vectors 
by two different research groups. Gorbatyuk and colleagues showed wild-
type Rho knockdown in rho
+/- mice resulting in 40 % reduction of scotopic 
ERG values and a reduction in ONL thickness (53 – 86 %) 2 months after 
injection [233]. Although the feasibility of in vivo Rho knockdown was clearly 
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expressing a Rho mRNA carrying the P23H mutation using an allele-specific 
shRNA cassette [234]. Despite mRNA and protein level depletion three 
weeks after in vivo delivery there was no morphological amelioration in the 
treated eyes after four months possibly because of non-specific knockdown 
of Rho mRNAs. The authors suggested that the in vivo level of silencing was 
not high enough and the construction of a more robust shRNA cassette for 
the treatment of dominant Rho mutations would be required. O’Reilly and 
colleagues recently published the most promising study on Rho mutation-
independent silencing for the treatment of the P23H dominant mutation [235]. 
They constructed a number of shRNAs that targeted Rho at different regions 
achieving ~90 % silencing in retinal explants. Rho cDNAs mutated at the 
target area of the shRNA remained unaffected in vitro and in retinal explants. 
Morphological amelioration was observed in 2 month-old transgenic mice 
carrying the P23H mutated allele on a rho+/- background after subretinal 
injection at P10 of an AAV2/5 expressing Rho shRNA and replacement 
cDNA. The thickness of the ONL in treated eyes was ~33 % thicker than the 
control eGFP injected eyes [235]. Electrophysiological responses were not 
included in the study although it would be interesting to compare the 
morphological rescue with a possible amelioration in visual responses. 
However, the efficiency of in vivo “suppression and replacement” in 
mammalian photoreceptors has been demonstrated in this study and its 
follow up successfully targeting the Pro357Ser Rho mutation in mice [236]. In 
that study, the efficient downregulation of the Pro357Ser mutation was 
coupled with a doubling of the ERG amplitudes in comparison to control eyes 
ten weeks after subretinal delivery, demonstrating that AAV-mediated RNAi 
can reduce the rate of retinal degeneration and lead to functional 
amelioration in models of adRP. 
 
 
The emergence of RNAi and the discovery of a broad range of novel ncRNAs 
have shaped the field of molecular therapeutics during the past decade. In 
the future, RNAi technology employing vectors with regulated targeting 
hairpin and gene supplementation cassettes may lead to clinical applications 
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which up to now has not been possible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  722 Materials and Methods 
 
 
2.1  Hairpin RNA design 
 
 
Upon designing a short-interfering RNA various factors must be considered 
in order to maximise the silencing potential of the molecule. For a detailed 
analysis on sequence, size and intramolecular dynamics, see Chapter 1.4.2. 
The target sequences of the egfp and peripherin-2 genes were obtained from 
one of the numerous sequence prediction websites available in the internet 
(www.dharmacon.com).  
The target sequences for ZO-1 and ZONAB were kindly provided by Karl 
Mater, IOO. 
The hairpins where designed so as to contain the sense and anti-sense 
stands of the target sequence separated by either a 3nt (ATG) or a 9nt loop 
(TTCAAGAGA) or by the miR-30 human micro RNA loop. The miR-30 full 
sequence is 5’ – GCGACUGUAAACAUCCGUCACUGGAAG 
CUGUGAAGCCACAGAUGGGCUUUCAGUCGGAUGUUUGCAGCUGC – 
3’. The sequence in bold indicates the natural miR-30 sequence and was 
substituted by the target sequence of interest (see Table 1). The sequence in 
italics indicates the stem loop. 
 
 
 
 
 
 
 
 
 
 
  732.2 Cloning 
 
2.2.1 DNA electrophoresis 
 
After restriction digests or PCR reactions, DNA fragments were separated on 
a 1-2 % (w/v) agarose gel, according to the size of the DNA fragment, using 
1x TBE buffer. Ethidium bromide (1 µl of 10 mg/ml concentration per 50 ml of 
gel) was added to visualise nucleic acid bands. Samples were loaded onto 
the gel using gel-loading buffer (6x; 0.25 % (w/v) bromophenol blue in water 
and a 1 kb DNA ladder (Bioline Ltd., UK) was run at the same time to provide 
a size marker. The voltage was set between 50-90 V considering the 
separation time of fragments of the expected size. The gels were 
photographed on an ultraviolet transilluminator.  
 
Ethidium bromide concentration was reduced to a 1:100 dilution when 
attempting difficult clonings in order to reduce DNA chelation that hinders 
ligation. 
 
2.2.2 DNA extraction from agarose gels 
 
The required DNA fragments were excised from the agarose gel and the 
DNA was extracted using QIAquick
TM Gel Extraction Kit (QIAGEN Ltd., UK) 
following the manufacturer’s instructions. The concentration of the eluted 
DNA was measured by photospectroscopy using a NanoDrop
® ND-1000 
Spectrophotometer (LabTech Int., UK). 
 
2.2.3 Cloning ligations 
 
The ligation of gel purified DNA fragments was carried out at 25°C for 3 hr or 
at 16°C overnight. T4 DNA ligase (New England Biolabs Ltd. UK), the 
supplied buffer, the vector backbone and the insert of interest were added in 
accordance with the manufacturer’s instructions at a final volume of 20µl. To 
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transformed in E.Coli bacteria. DNA was isolated from the bacterial cultures 
using GenElute
TM Plasmid Miniprep Kit (Sigma, UK) and analysed by the 
appropriate restriction enzyme digests and subsequent gel electrophoresis. 
Bacterial cultures of positive clones (680 µl) were mixed with glycerol (180 µl) 
(Sigma, UK) and kept in -80°C for long-term storage. All cloning end-products 
were subsequently sent for sequencing at MWG Biotech, UK together with 
appropriate primers in order to obtain sequencing reading from both DNA 
strands. The insert together with part of the backbone was thoroughly 
sequenced for all cloned plasmids presented in this study. 
 
2.2.4 Transformation and recovery of plasmids 
 
DH5α
TM competent cells (Invitrogen Ltd., UK) were defrosted on ice. After the 
bacterial suspension had thawed on ice, the ligation solution was added and 
the transformation mix was incubated on ice for 15-30 min. Samples were 
then heat-shock treated for 90 sec at 42°C in a water bath, quickly 
transferred for 15 min on ice, and 500 µl LB (Luria Bertani, Merck Ltd, UK) 
medium was added. All plasmids used included the ampicillin or kanamycin 
resistance gene as a selection marker for successfully transformed colonies. 
To ensure efficient expression of the resistance gene, transformed bacteria 
were incubated for 1 hr at 37°C before they were spread on selective LB 
agar plates. LB agar plates were prepared containing 20 g Bacteriological 
agar (Oxoid Ltd., UK) per litre of water, 15 g/l yeast extract (Oxoid Ltd., UK), 
10g/l NaCl (Sigma, UK), 10g/l peptone from casein and 100 µg/ml ampicillin 
or 50 µg/ml kanamycin (1000x; Sigma, UK). Plates were incubated overnight 
at 37°C to allow resistant bacteria to grow. 
 
Bacterial colonies were inoculated into 5 ml of LB medium containing 100 
µg/ml ampicillin or 50 µg/ml kanamycin (1000x; Sigma, UK) the following day 
and were incubated at 37°C overnight to allow for growth. For small scale 
preparations, plasmids were recovered using GenElute
TM Plasmid Miniprep 
Kit (Sigma, UK). For large scale preparation 50 µl of the 5 ml culture were 
  75used to inoculate 500-1000 ml LB medium and bacteria were grown as 
described above. DNA was then recovered using QIAGEN
® Plasmid Mega 
Kit (QIAGEN Ltd., UK). For transformation and preparation of highly 
recombinogenic plasmids, all the incubations were carried out at room 
temperature for 30 hrs. 
 
  
2.2.5 Basic RNAi expression vector (mu6pro) 
 
The target sequences for RNAi on the genes of interest where converted into 
DNA hairpin oligonucleotides (see Table 1) in order to be cloned into the 
mU6pro expression plasmid. The oligonucleotides were designed so that the 
sense and antisense strands of the target area are separated by a 3 or 9 nt 
loop sequence (ATG or TTCAAGAGA), and after primer annealing the 
restriction site overhangs of BbsI and XbaI form at the 5’ and 3’ end of the 
fragment, respectively. In this way, the hairpin sequence can be cloned 
exactly downstream of the U6 promoter. For the miR-30 based hairpins, the 
same nucleotide overhangs were used when incorporating the target 
sequence into the microRNA template.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  76Table 2: Hairpin RNA design. The two strands of the hairpin sequences for each gene are 
displayed in 5’ to 3’ orientation. The sense and guide strand of the hairpin target area (bold) 
are separated by the loop sequence and flanked by the sequences of the restriction 
enzymes BbsI and XbaI. Hairpins with the sh prefix have the standard 3 or 9 nt loop design. 
The miR prefix indicates miR-30 based design. miRshCON and shCON target area is a 
control non-targeting sequence. 
NAME  
(TARGET 
GENE) 
HAIRPIN SEQUENCE (OF EACH DNA STRAND) 
TTTGGTTCATCTGCACCACCGGCAAGTTTCAAGAGA 
GCTTGCCGGTGGTGCAGATGAACTTTT 
shGFP (egfp) 
CTAGAAAAGTTCATCTGCACCACCGGCAAGCTCTCTTGAA 
ACTTGCCGGTGGTGCAGATGAAC 
TTTGGCGAGTTCATCTGCACCACCGGCAAGTCTGTGAAGCCACAGATGGG 
GCTTGCCGGTGGTGCAGATGAACCTGCTTTT  miRGFP 
(egfp)  CTAGAAAAGCAGGTTCATCTGCACCACCGGCAAGCCCCATCTGTGGCTTCACAG 
ACTTGCCGGTGGTGCAGATGAACTCGC 
TTTGTCGACATGCTCCAGATTGAATGTCAATCTGGAGCATGTCGATTTT 
shRDS4 (rds) 
CTAGAAAATCGACATGCTCCAGATTGACATCAATCTGGAGCATGTCGA 
TTTGATAATTCTGAGAGCCACTTATGAAGTGGCTCTCAGAATTATTTTT 
shRDS5 (rds) 
CTAGAAAAATAATTCTGAGAGCCACTTCATAAGTGGCTCTCAGAATTAT 
TTTGCTACAGCTATGACCATCATATGCTGATGGTCATAGCTGTAGTTTT 
shRDS6 (rds) 
CTAGAAAACTACAGCTATGACCATCATCATCTGATGGTCATAGCTGTAG 
TTTGGCGACTACAGCTATGACCATCATCTGTGAAGCCACAGATGGG 
CTGATGGTCATAGCTGTAGCTGCTTTT 
miRDS6 (rds) 
CTAGAAAAGCAGCTACAGCTATGACCATCAGCCCATCTGTGGCTTCACAG 
ATGATGGTCATAGCTGTAGTCGC 
TTTGAAGATAGTTTGGCAGCAAGAGATGCTCTTGCTGCCAAACTATCTTTTTT  shZO-1  
(ZO-1)  CTAGAAAAAAGATAGTTTGGCAGCAAGAGCATCTCTTGCTGCCAAACTATCTT 
TTTGAACTTACCGCCCAAGGTACCGATGCGGTACCTTGGGCGGTAAGTTTTTT  shZONAB 
(ZONAB)  CTAGAAAAAACTTACCGCCCAAGGTACCGCATCGGTACCTTGGGCGGTAAGTT 
TTTGGATCGGACACTCCTCATAAATGTTATGAGGAGTGTCCGATCTTTT 
shCON 
CTAGAAAAGATCGGACACTCCTCATAACATTTATGAGGAGTGTCCGATC 
TTTGGCGAGATCGGACACTCCTCATAACTGTGAAGCCACAGATGGG 
TTATGAGGAGTGTCCGATCCTGCTTTT 
miRCON 
CTAGAAAAGCAGGATCGGACACTCCTCATAACCCATCTGTGGCTTCACAG 
TTATGAGGAGTGTCCGATCTCGC 
  772.2.6 Peripherin-2 site-directed mutagenesis PCR 
 
Prph-2 cDNA was amplified from our pre-existing pD10.Rho.Rds plasmid 
using 2 sets of primers. The two step PCR was used to introduce 3 
nucleotide changes in the Prph-2 cDNA targeted by our shRDS6 and 
miRDS6 hairpins (pos: 906-927). The primers used were:  
P1 – CACCGCACTCGGTAAGCATGGCG – (5’ outer forward),  
P2 – TCAGCCAGCCTCTGG – (3’ outer reverse),  
P3 – TATAGTTACGACCATCAGACTGAGGAGCTCAAC – (middle forward),  
P4 – AGTCTGATGGTCGTAACTATAGTGCGCCGAGTTG – (middle 
reverse). 
Nucleotides in bold indicate point mutations. PCR reactions were performed 
in a total volume of 30 µl, 0.2 mM dNTPs (Promega, UK), 3 µl of buffer, 30 
pM of each primer and 1 U of Expand High Fidelity PCR System polymerase 
(Roche, UK) were with 100-200 ng of plasmid template DNA or 50-100 ng of 
PCR product. Initially, primers P1&P3 and P2&P4 were used in pairs on the 
plasmid template to generate two halves of the mutated Prph-2 cDNA. The 
two PCR products were then mixed together and P1&P2 were used to 
generate the full length cDNA. The final amplified fragment (mutRDS) was 
then sequenced also using outer primers P1 and P2 to confirm point mutation 
incorporation (MWG Biotech, UK). 
 
CYCLING CONDITIONS: 
 
Initial denaturation    3 min at 95°C 
Denaturation     1 min at 95°C 
40 cycles  Annealing      30 sec at 51°C 
Extension      1 min at 72°C 
Final extension    10 min at 72° 
 
 
 
  782.3 Tissue  Culture 
 
2.3.1 Cell lines and culture of cells 
 
Baby hamster kidney (BHK) cells were grown in BHK-21 medium 
supplemented with 10 % heat inactivated foetal bovine serum (FBS), 100 
U/ml penicillin and 0.1 mg/ml streptomycin, 5 % tryptose phosphate broth, 2 
mM L-glutamine and 0.25 mg/ml geneticin G418. 293T cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10 % FBS, 
100 U/ml penicillin and 0.1 mg/ml streptomycin. Madin-Darby canine kidney 
(MDCK) cells were cultured in a 1:1 mixture of DMEM and Ham’s F-12 
nutrient medium supplemented with 10 % FBS, 100 U/ml penicillin and 0.1 
mg/ml streptomycin. ARPE-19 cells were grown in a 1:1 mixture of DMEM 
and Ham’s F-12 nutrient medium supplemented with 10 % FBS, 100 U/ml 
penicillin, 0.1 mg/ml streptomycin and 56 mM sodium bicarbonate. HeLa cells 
were grown in DMEM. 10 % FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin 
and 0.25 mg/ml geneticin G418 and were added to the medium (all reagents 
were purchased from Invitrogen Ltd., UK). Cells were grown in a Sanyo CO2 
incubator at 37°C with 5 % CO2. 
 
 
2.3.2 Passaging of cell cultures 
 
Confluent cell cultures were split usually 1:2 or 1:7 to maintain healthy 
colonies. The old medium was removed and cells were washed twice with 1x 
PBS (10 phosphate buffered saline tablets (Oxoid Ltd., UK) dissolved in 1 l 
sterile dH2O) before trypsin-EDTA (Invitrogen Ltd., UK) was added until all 
cells were covered. Plates were then incubated for approximately 10 min at 
37°C to allow cells to dissociate. The process was stopped by adding FCS 
containing growth medium before the cells being split into new plates in the 
appropriate ratio.  
 
  792.3.3 Cell line long-term storage 
 
For long-term storage cells were trypsinised and pelleted by centrifugation. 
Approximately 5 x 10
6 cells/ml were resuspended in 1 ml growth medium with 
20 % FCS and 10 % dimethylsulfoxide (DMSO; Invitrogen Ltd., UK). The 
cryovials were pre-cooled on ice and once the cells were aliquoted they were 
kept overnight at -80°C in a storage container with isopropanol. The following 
day the frozen cultures were transferred to liquid nitrogen.  
 
Frozen cells can be re-cultured by thawing the cryovials in a water bath at 
37°C. Cells were then pelleted by centrifugation and the DMSO containing 
medium was removed. The process was repeated washing the cells with 1x 
PBS before resuspending them in the appropriate medium. 
 
 
2.3.4 Infections 
 
Cells were split the day before at appropriate concentrations and at low 
confluency. The multiplicity of infection (MOI) was calculated using the 
number of cells plated and the titre of the virus in transducing units per ml. 
The virus suspension was mixed with the medium and added onto the cells. 
Microscope imaging of reporter gene expression was carried out after 24hr 
when using a lentiviral vector. For fluorescent microscopy and nucleic acid or 
protein extraction, the cells were left for 4 to 7 days. For FACS sorting, 
pellets were recovered through centrifugation at 2000 xg for 5 min and 
resuspended in 400 µl PBS with 4 % PfA. The cells were kept on ice and 
sorted using an Epics XL flow cytometer (Beckman Coulter, UK). 
 
 
2.3.5 Transfections 
 
Similarly to the conditions prior to infection, the cells were split the day before 
at appropriate concentrations and at 60 to 70 % confluency. A total amount of 
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® (Invitrogen Ltd., UK) with 2 
µl Lipofectin reagent (Invitrogen Ltd., UK) and incubated at room temperature 
for 20 min. The cells were washed with 1x PBS after removal of the growth 
medium and the transfection medium (DNA–Lipofectin) was added onto the 
cells. After 4 hr incubation at 37°C, the transfection medium were removed 
and replaced with normal growth medum. The following day the cells were 
visualised under a fluorescent microscope to assay the transfection efficiency 
based on reporter gene expression. At 72 hr after transfection, the cells were 
trypsinised and pellets were recovered through centrifugation at 2000 xg for 5 
min prior to their resuspension in 400 µl PBS with 4 % PfA. The cells were 
kept on ice and sorted using an Epics XL flow cytometer (Beckman Coulter, 
UK). 
 
 
2.3.6 Generation of peripherin-2 and egfp expressing stable 
cell lines 
 
293T cells were seeded in a 24 well-plate the day before. LNT.SFFV.RDS or 
LNT.SFFV.EGFP was added at limiting MOI in each well and the cells were 
left to grow for 6 days splitting them once in between. The cells were then 
seeded in a 96 well-plate at limiting dilutions and left to grow colonies. For 
the  peripherin-2  expressing cells, pellets were recovered through 
centrifugation at 2000 xg for 5 min and resuspended in 2x Laemni buffer. The 
protein was prepared for western blotting and the cell clone with the highest 
peripherin-2 expression and viability was selected and propagated. For the 
egfp expressing cells, pellets were recovered similarly and resuspended in 
200µl PBS with 5 % BSA. The cells were kept on ice and sorted using a 
Beckman Coulter Epics Altra cell sorter with Expo32 software (Beckman 
Coulter, UK). The single-cell clone with the highest egfp expression was 
selected, using UV microscopy, and propagated. 
 
 
  812.3.7 Cell immunofluorescent staining 
 
For immunofluorescence staining, MDCK or ARPE-19 cells were grown on 
glass coverslips and after infection were fixed with methanol at –20°C or with 
PfA at room temperature. The samples were then rehydrated with PBS, 
permeabilised with Triton X-100 (1 %) and blocked for 1hr with 0.5 % BSA 
solution. The 1° antibody was then added at the appropriate concentration 
and incubated for 1hr at room temperature. The cells were washed with PBS 
and the 2° antibody was added for 50 min at room temperature. After rinsing 
with 1x PBS, the samples were analysed using fluorescent microscopy. 
 
 
2.3.8 3-D cultures 
 
MDCK cell cysts were grown in 3-D collagen gels. Briefly, MDCK cells were 
trypsinised, diluted 1:3 with serum-containing medium to inactivate trypsin, 
spun, and then resuspended to a single cell suspension and counted. Cells 
(20,000 in 5 µl) were mixed with 100 µl collagen-Matrigel master mix that was 
prepared by neutralizing 60 µl of ice-cold solution containing 1 mg/ml calf 
skin type I collagen (Sigma, UK) with 10 µl 10x DMEM, 2 µl HEPES 1 M (pH 
7.4), and 2 to 3 µl of 2 M NaOH that was then mixed with 10 µl of 100 % fetal 
bovine serum and 16 µl of Matrigel (growth factor reduced; BD Biosciences, 
UK). The cell-collagen-Matrigel mix was plated in a well of a 48-well dish 
containing a coverslip that had been covered with 100 µl of the collagen-
Matrigel master mix for 1 hr at 37°C. The plated mixture was then allowed to 
form a solidified gel at 37°C prior to the addition of culture medium. The 
medium was replaced every 2 days, and the cysts were allowed to develop 
over 5 to 6 days. For fluorescence labelling, cells were fixed with 3 % PfA for 
20 min at room temperature and were then washed twice with PBS. Then, 
the cells were blocked and permeabilised for 30 min at room temperature 
with 2 % BSA, 1 % Triton X-100, and 25 mM Tris in PBS, followed by 
incubation overnight at 4°C with a goat anti-beta-catenin antibody. After three 
washes with 2 % BSA, 1 % Triton, 25 mM Tris in PBS, the samples were 
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isothiocyanate (FITC)-phalloidin and Hoechst 33528. After three washes with 
PBS, cells were mounted with Mowiol. For quantification of the different 
structures, low-magnification pictures from the actin stainings were taken. 
Ten pictures of each cell line and condition were quantified from two 
experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  832.4  Adeno-associated viral vectors 
 
2.4.1 RNAi Constructs 
 
The RNAi hairpin cassettes (U6 promoter + hairpins) were cloned into a 
pD10.CBA.RFP backbone using the AscI and BstZ17I restriction sites in the 
pD10.CBA.RFP plasmid and AscI and SnaBI to excise them from the donor 
mU6pro plasmid. The pD10.CBA.RFP plasmid also drives expression of rfp 
through a CBA promoter. The resulting plasmids were verified by sequencing 
(MWG Biotech, UK) and AAV virus particles were made for each hairpin 
vector. 
 
 
2.4.2 Production and purification of rAAV2/2 
 
Production of recombinant AAV2/2 (rAAV2/2) was carried out by co-
transfection of two plasmids in the presence of a helper virus in BHK cells as 
previously described [95]. BHK cells were seeded into 150 mm plates at a 
concentration of 10
6 cells/plate. The plates were incubated overnight so that 
they reach 70 % confluency the following day. The cells were transfected 
with the aforementioned pD10 constructs that contained the RNAi and RFP 
expression cassettes flanked by AAV-based ITRs and the helper plasmid 
pHAV7.3 that contains the viral rep and cap genes. The two plasmids were 
mixed in a 1:1 weight ratio (60 µg total/plate) in 6 ml Opti-MEM
®/plate. In a 
separate tube, 240 µg of a β-integrin-targeting peptide used to improve the 
binding of the DNA [(K16)GACRRETAWACG)], was mixed with 45 µl of 
Lipofectin reagent (Invitrogen Ltd., UK). The two tubes were mixed and 
incubated at room temperature for 1 hr in order for the DNA to bind the 
Lipofectin-peptide complex. The medium was removed from the plates and 
the cells were washed with Opti-MEM
® prior to the addition of the transfection 
solution. The plates were then incubated at 37°C for 4 hr. After incubation, 
the transfection solution was replaced by normal growth medium containing a 
helper PS1 HSV helper virus at an MOI (multiplicity of infection = average 
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37°C for a further 36 hr, to allow the completion of the lytic cycle and were 
subsequently scraped and centrifuged before being resuspended in serum-
free medium. The viral particles were released from the harvested cells by 3 
freeze-thaw cycles at -80°C and 37°C. Vigorous vortexing for 5 min in 
between ensured adequate cell lysis. Treatment with 50 U of benzonase 
(Sigma, UK) to eliminate any plasmid DNA was followed by centrifugation 
and retention of the supernatant. The supernatant was further treated with 
0.5 % deoxycholic acid and filtered through 5 µm and 0.8 µm syringe filters 
before proceeding with the rAAV particle concentration. The cell lysate was 
bound on a heparin-agarose column (Sigma, UK) that had been equilibrated 
with 10 ml PBS-MK. After the loading of the virus, the column was washed 
with 10 ml PBS-MK + 0.1 M NaCl and the rAAV particles were eluted in 6 ml 
PBS-MK + 0.4 M NaCl (the first two ml were discarded). The eluate was 
concentrated using Centricon 100 columns (Millipore, USA) by centrifugation 
at 5000 xg for 25 min followed by a wash with PBS-MK. The Centricon 
columns were then turned upside down and the concentrated rAAV was spun 
into a collection tube. The average yield of the rAAV2/2 production protocol is 
approximately 100 µl of concentrated virus (10
12 viral particles/ml) per 10 
plates of transfected BHK cells. The virus was then aliquoted and frozen at -
80°C. 
 
 
2.4.3 Production and purification of rAAV2/8 
 
Production of recombinant AAV2/8 (rAAV2/8) was carried out by co-
transfection of three plasmids in 293T cells. In addition to the pD10-based 
plasmids, pAAV8 (that carries the rep and cap genes) and pHGTI (that 
carries helper accessory genes) plasmids were used in a CaCl2-based 
transfection. 293T cells were seeded into 150 mm plates at a concentration 
of 10
6 cells/plate. The plates were incubated overnight so that they reach 70 
% confluency the following day. The transfection medium was prepared using 
the following amounts: 
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pAAV8  → 100  µg 
pHGTI  → 30  µg 
pD10-RNAi  → 100  µg 
CaCl2 2.5M  → 1.25  ml 
dH2O  →  up to 12.5 ml 
 
The same amount in volume (i.e. 12.5 ml) of 2x HBS buffer was added 
dropwise to the plasmid solution followed by 25 ml of full DMEM medium. 
Five ml of the transfection solution was then added to the 293T plates without 
removing the old medium and the cells were incubated for 36 hrs before 
scraping and harvesting in TD buffer. The freeze-thaw cycles, benzonase 
and deoxycholic acid treatments were carried out in the same way as 
performed in the rAAV2/2 production. The lysate was then filtered through a 
0.45 µm syringe filter before proceeding with the exchange chromatography 
purification using an ÄKTA
TMprime FPLC apparatus (Amersham, UK) to bind 
the rAAV2/8 particles on an anionic sephacryl S300 and a POROS 50HQ 
column. The FPLC purification was carried out in Dr Amit Nathwani’s 
laboratory (UCL) with the assistance of Dr Jenny McIntosh. FPLC purification 
is carried out by binding the viral lysate first to the anionic column followed by 
the POROS 50HQ column and eluted using an increasing salt gradient 
(Buffer A and B; see Buffers & solutions). Approximately 15 ml of eluate are 
produced by 10 plates which are subsequently concentrated in Centricon 100 
columns to a final volume of approximately 200 µl. The virus was then 
aliquoted and frozen at -80°C. 
 
 
2.4.4 Genomic titration by dot-blot analysis 
 
One and 5 µl samples from the rAAV preparations were treated with 100 µg 
proteinase K (Promega, UK) in 100 µl 2 x proteinase K buffer and 100 µl 
dH2O. After 1 hr incubation at 37°C, viral DNA was precipitated by adding 
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volumes of 96 % ethanol and left at -80°C for 30 min. DNA was pelleted by 
centrifugation at 5000 xg for 30 min at 4°C. Each DNA pellet was washed 
with 200 µl of 70 % ethanol, air dried and resuspended in 200 µl 0.4 M NaOH 
+ 10 mM EDTA solution. 
 
A dilution series of plasmid DNA (usually the pD10-based plasmid) ranging 
from 10
12 to 10
7 molecules was used to produce a standard ladder. The 
samples were prepared with 0.4 M NaOH + 10 mM EDTA solution in a total 
volume of 200 µl. The rAAV DNA and standard ladder samples were 
denatured at 100°C for 2 min and then cooled for 2 min on ice. The samples 
were then applied onto a pre-wet 0.45 µm Hybond
TM-N+ membrane 
(Amersham, UK) in a Dot-blot apparatus (Bio-Rad, UK). Each well of the 
manifold that would have a sample loaded onto it was pre-washed with 0.2 
ml of dH2O and vacuum dried before sample loading. After the DNA samples 
were bound onto the membrane, 0.2 ml of 0.4 M NaOH and 10 mM EDTA 
was added to each well and was subsequently vacuum dried. The membrane 
was then moistened with dH2O, placed in a hybridisation tube and heated to 
65°C in a hybridisation oven to cross-link the DNA on the membrane. A 
hybridisation bottle was pre-heated in a hybridisation rotisserie oven at 65°C, 
together with Church buffer. The blot membrane was transferred to the pre-
heated bottle between hybridisation mesh and pre-hybridised for 30 min. 
 
Meanwhile the probe DNA (CBA promoter fragment) was excised from the 
plasmid and isolated from an agarose gel. The extracted probe DNA was 
denatured at 95°C for 5 min followed by incubation on ice for 2 min. 
Biotinylation of the probe DNA was carried out using the NeoBlot Phototope 
Kit (New England Biolabs Ltd., UK) according to the manufacturer’s 
instructions. In brief, a reaction with a total volume of 50 µl was performed by 
adding to the probe DNA 5x Labelling mix (containing random octamer 
primers), 10µM dNTP mix (containing a biotinylated dATP) and 1 µl Klenow 
polymerase. The probe was incubated at 37°C for 1 hr followed by the 
addition of 5 µl 0.2 M EDTA, pH 8 to terminate the biotinylation reaction. DNA 
precipitation was carried out by incubating the probe at -20°C for 30 min in 
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centrifugation at 5000 xg for 10 min at 4°C, the DNA pellet was washed with 
70 % ethanol and precipitated again. The final probe DNA pellet was 
resuspended in 20 µl dH2O and stored at -20°C. 
 
Five µl of the probe were added to the pre-hybridised membrane and 
incubated at 65°C overnight to ensure hybridisation to the viral samples and 
the standard ladder. The blot was then washed three times with 50 ml 33 mM 
sodium phosphate buffer, pH 8 for 5 min per wash. Block solution was then 
added onto the blot ensuring that it is covered and it was incubated on a 
shaking platform at room temperature for 1 hr. Streptavidin incubation was 
carried out by diluting the supplied stock 1:1000 in Block solution and 
applying it onto the drained blot at room temperature for 20 min. Two rounds 
of washing in Wash solution I for 5 min were followed by a 5 min room 
temperature incubation with pre-diluted (1:1000 in Block solution) biotin-
conjugated alkaline phosphatase. Two rounds of washing in Wash solution II 
were followed by the addition of the CDP-Star reagent directly onto the blot 
covering the area that with blotted samples. The blot was immediately 
wrapped in cling film and exposed to an X-ray film for a variable amount of 
time (usually 3 min but depends on the strength of the signals). Viral titre 
determination was then possible by comparison between the viral samples 
and the standard ladder. 
 
 
 
 
 
 
 
 
 
 
  882.5 Lentiviral  vectors 
 
2.5.1 RNAi Constructs 
 
The RNAi hairpin cassettes shCON, shGFP, miRGFP, shRDS5, shRDS6, 
shZO-1 and shZONAB were cloned into the pHR’SIN third generation 
lentiviral backbone using AscI and Acc65I restriction sites. The SFFV 
promoter and WPRE were removed before cloning the RNAi cassette in. The 
rest of the backbone sequence is identical to the construct pHR’SIN-cPPT-
CEW as described by Bainbridge et al. [122]. The resulting plasmids were 
verified by sequencing (MWG Biotech, UK) and lentivirus particles were 
made for each hairpin cassette. 
 
 
2.5.2 Peripherin-2 or ZONAB construct 
 
The peripherin-2 or ZONAB cDNA was cloned into the pENTR
® vector and 
the Gateway
® cloning kit was used to make LNT.SFFV.RDS or 
LNT.SFFV.ZONAB, respectively. The mutated peripherin-2 cDNA (dRDS) 
(see 2.2.6) was cloned into the pENTR/D-TOPO
® vector. Likewise, 
LNT.SFFV.dRDS was made using the Gateway
® cloning kit. 
 
 
2.5.3 Production of recombinant lentivirus 
 
For the production of recombinant lentivirus, 293T cells were seeded the day 
before in 175 cm
2 flasks so that the cells are 80-90 % confluent prior to 
transfection (30-40x10
6 cells per flask). The cells were transfected with 60 µg 
of the lentiviral recombinant construct per flask in addition to the lentivirus 
helper constructs pMD.G (21 µg) and the packaging plasmid p8.91 (39 µg) 
using the following protocol. The aforementioned plasmid amounts were 
added to 6 ml Opti-MEM
®. In a separate tube, 1 µl of a 10 mM stock of 
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®. 
DNA and PEI solutions were mixed 1:1 and left at room temperature for 20 
min. The cells were washed in Opti-MEM
® and then 12 ml of the PEI and 
DNA complexes were added to each flask. The cells were incubated at 37°C, 
5 % CO2 for 4 hr. The medium was then replaced with complete DMEM (25 
ml/plate). Twenty-four hours after transfection the medium was removed and 
replaced with fresh medium (15 ml per plate). The virus was harvested the 
following day by centrifugation of the harvested medium at 2500 rpm for 10 
min and then filtered through a 0.45 µm filter. The filtered medium was 
transferred to polyallomer ultra-centrifuge tubes (11.5 ml/tube for TH641 rotor 
or 33 ml/tube for Surespin rotor) and were ultra-centrifuged at 4°C, for 2 hr at 
23,000 rpm (TH641 rotor) or 22,000 rpm (Surespin rotor). The supernatant 
was decanted off and the tubes maintained upside down on tissue paper to 
drain the remaining supernatant. The last drops around the rim were dried 
with paper. Then, 50 µl (TH641 rotor tubes) or 125 µl (Surespin rotor tubes) 
of DMEM without serum were added per tube and pipetted ten times. 
Parafilm was placed over the top and the tubes were left on ice for 1 hr. 
The medium were then pipetted another 10 times to resuspend the virus and 
were transferred to an eppendorf. The average yield of the lentivirus 
production protocol is approximately 500 µl of concentrated virus (10
9 viral 
particles/ml) per 10 plates of transfected 293T cells. The virus was then 
centrifuged for 10 min at 4000 rpm to remove cell debris, aliquoted and 
stored at -80°C. 
 
 
 
 
 
 
 
 
 
 
  902.6 Quantification  of  Expression 
 
 
2.6.1 Total RNA isolation 
 
Cell pellets (10
5 cells), FACS sorted cells (10
4 cells) or whole retinas (quick 
frozen in liquid N2) were resuspended in 500 ml TRI-BD
® reagent (Sigma, 
UK). Vigorous resuspension with a pipette (or a homogeniser) is essential to 
ensure breaking down of the cell wall.  When the solution was homogenous, 
200 µl chloroform were added and the samples were mixed by inversion. 
Straight after, the samples were centrifuged at 5000 xg for 15 min at 4°C. 
The clear top phase (contains RNA) was removed to another tube and the 
organic phases were kept for protein isolation (see 2.6.3). Equal amount of 
isopropanol was added to the clear phase and the samples were frozen for a 
minimum of 2 hr at -80°C. Overnight incubation at -20°C is favourable, 
however, because it increases the amount of RNA precipitation. Then, the 
samples were spun at 5000 xg for 10 min at 4°C. The supernatant was 
carefully decanted without disturbing the pellet. One ml of ethanol was added 
and the RNA pellets were spun at 5000 xg for 5 min at 4°C. The ethanol was 
removed and the samples were left to air dry for 5 min at room temperature. 
Each pellet was resuspended in 20 µl dH2O. Alternatively, the RNeasy Mini 
Kit (QIAGEN Ltd., UK) was used for RNA extraction of cell pellets or laser 
dissected cells (approximately 100 cells dissected using ZEISS PALM 
RoboMover Axiovert 200) according to the manufacturer’s instructions. The 
RNA concentration was measured using a NanoDrop
® ND-1000 
spectrophotometer (LabTech Int., UK). Total RNA was stored in -80°C. 
 
 
2.6.2 Generation of cDNA & Relative quantification 
 
For cDNA generation the QuantiTect
® Reverse Transcription Kit (QIAGEN 
Ltd., UK) was used according to the manufacturer’s instructions. Briefly, the 
RNA samples were thawed on ice and up to 12 µl (or up to 1 µg) were added 
  91to 2 µl of gDNA Wipeout Buffer. The reaction was made up to 14 µl with 
water and incubated at 42°C for 2 min. In a separate tube, 1 µl of 
Quantiscript Reverse Transcriptase, 4 µl of Quantiscript RT Buffer and 1 µl of 
RT Primer mix (containing random octamers and dT nucleotide mix) were 
mixed before adding them to the template RNA. The reaction tube (20 µl final 
volume) was incubated at 42°C for 1 hr to enable reverse transcription, 
followed by a 3 min incubation at 95°C to inactivate the Quantiscript Reverse 
Transcriptase. The efficiency of the reaction provides a 1:1 conversion ratio 
of RNA:cDNA, hence up to 1 µg of cDNA was made per sample. Total cDNA 
was stored in -20°C. 
 
Fifty ng (or 1 µl approximately) of total cDNA from each sample, was loaded 
onto a 96 well-plate with 2x FastStart TaqMan
® Probe Mastermix (ROX) 
(Roche, UK), forward and reverse primers for amplification of gene of interest 
(Final concentration: 900 nM each), appropriate hydrolysis probe that binds 
the amplified area (Final concentration: 250 nM; Roche, UK), ROX reference 
dye (Final concentration: 400 nM; Roche, UK) and dH2O to make the final 
reaction volume up to 50 µl. The amount of cDNA template used in each 
reaction ranged from 5-500 ng with 50 ng being the usual loading amount. 
Quantitative real-time PCR was run on an ABI Prism 7900HT Fast Real-time 
Sequence Detection System (Applied Biosystems, UK) and the 
manufacturer’s software (SDS 2.2.2) was used to obtain Ct values for the 
reactions. The relative expression between comparable samples in relation to 
the expression of the genes of interest was calculated through the formula:  
2
-ΔΔCt
.  
 
 
2.6.3 Total Protein isolation 
 
Cell pellets of 10
5 cells were resuspended vigorously with a pipette in 25 µl of 
PBS and 25 µl of 2x Laemni buffer. The organic phases from chloroform 
treatment (see 2.6.1) were precipitated using 150 µl of 100 % ethanol. The 
samples were mixed by inversion and incubated at room temperature for 3 
  92min. Centrifugation was carried out at 4000 xg for 5 min at 4°C. The 
supernatant was transferred to a new tube and 3 V acetone were added. The 
samples were mixed and incubated at room temperature for 10 min and spun 
at 5000 xg for 10 min at 4°C and the pellet was washed with 70 % ethanol. 
The samples were then spun at 5000 xg for 5 min and the pellet was 
resuspended in 25 µl PBS and 25 µl 2x Laemni buffer. The protein 
concentration was measured using a NanoDrop
® ND-1000 
spectrophotometer (LabTech Int., UK). Total protein samples were stored in -
20°C. 
 
 
2.6.4 Western Blot 
 
Polyacryramide gels were made as two discontinuous gels, a 12 % 
separating and a 4 % stacking gel. Eight µg of each sample were made up to 
15 µl with 1x Laemni buffer and bromophenol blue was added to 0.05 % 
concentration. The samples were boiled for 5 min and loaded on the gel 
together with a pre-stained molecular weight marker (Bio-Rad, UK). The gel 
was run in Running buffer until bromophenol blue run out of the gel (200 V for 
50 min). The glass plates were separated and the stacking gel was removed. 
The separating gel was marked (cut at corner) and equilibrated in Transfer 
buffer for 20 min. Immobilon P membrane (Amersham, UK) was cut at the 
size of the gel and put in methanol for 15 sec. Then it was rinsed in water for 
2 min, and equilibrated in Transfer buffer for 5 min. The transfer formation 
was set up on the appropriate apparatus in the order: anode – Immobilon P – 
Gel – Cathode with 4 pieces of Whatman 3 MM paper in between. It was run 
for 30 min at 10 V. Immediately after transfer, the membrane was washed 
with PBS and immersed in methanol for 10 sec. Then it was dried on filter 
paper and blocked with Blocking solution for 2 hr at 4°C. The membrane was 
washed 3 times with PBS and the 1° antibody was incubated in Hybridisation 
solution at appropriate concentration overnight at 4°C. The following day, the 
membrane was washed 3 times with PBS and the horse-radish peroxidase 
(HRP)–conjugated 2° antibody was incubated in Hybridisation solution for 50 
  93min at room temperature. The membrane was washed 3 final times with PBS 
and put on a plate. ECL reagents (Amersham, UK) were mixed and added 
onto the membrane for 1 min. The western blot was imaged either using a 
UVIchemi Chemiluminometer (UVItec ltd., UK) or by exposing and 
developing of photographic film. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  942.7  In vivo experiments 
 
2.7.1 Animals 
 
Wild-type C57BL/6 or GFP
CBA+/+ transgenic 6-8 week old female mice
 were 
used for this study. All animals were cared for in accordance with the Animal 
Scientific Procedures Act 1986 and procedures were in accordance with the 
ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. 
 
2.7.2 Anaesthesia 
 
For intraocular procedures animals were anaesthetised by intraperitoneal 
injections of Dormitor (1 mg/ml, Pfizer Pharmaceuticals, UK) and ketamine 
(100 mg/ml, Fort Dodge Animal Health, UK) mixed with sterile water in the 
ratio 5:3:42. Young adult mice weighing 200 g received 0.2 ml of the 
anaesthetic solution. After treatment (see 2.7.3), 1 % Chloramphenicol (FDC 
International ltd., UK) was carefully applied topically on the cornea. To 
reverse the anaesthesia 0.2 ml of Antiseden (0.10 mg/ml, Pfizer 
Pharmaceuticals, UK) was injected intraperitoneally and the mice were 
placed into an oxygenated chamber until they regained consciousness. 
 
 
2.7.3 Subretinal injections 
 
Surgery was performed under direct retinoscopy through an operating 
microscope. The pupils were dilated with 1 % Tropicamide (Chauvin 
Pharmaceuticals, UK) topically administered. The eye was protruded by 
gentle pressure on either side of the eye and held in position by holding a 
section of the conjunctiva and extraocular muscle with a pair of forceps. The 
fundus was visualised using a contact lens system consisting of a drop of a 
coupling medium solution on the cornea (Viscotears, Novartis 
  95Pharmaceuticals, UK) and a cover slip. The tip of a 1.5 cm, 34-gauge 
hypodermic needle mounted on a 5 μl Hamilton syringe (Hamilton, 
Switzerland) was guided underneath the cover slip to the sclera of the eye 
and then inserted tangentially through it, causing a self-sealing wound tunnel. 
The needle tip was brought into focus between the retina and the RPE and 
2 μl of virus suspension containing around 10
8-10
9 particles of rAAV or 10
5-
10
6 particles of lentivirus were injected to produce a bullous retinal 
detachment in the superior hemisphere. Where necessary, a second injection 
was performed subsequently to produce a similar detachment in the inferior 
hemisphere. Where appropriate, 0.2 ml of a 100 ng/ml 5-bromo-2-
deoxyuridine solution (BrdU; Sigma, UK) was injected intraperitoneally 
following the subretinal vector administration. 
 
 
2.7.4 Fluorescein angiography 
 
Five minutes after the induction of anaesthesia, 0.2 ml of 2 % fluorescein 
sodium diluted in dH2O was administered by intraperitoneal injection. A Kowa 
Genesis small animal fundus camera equipped with appropriate excitation 
and barrier filters was used to obtain fluorescein angiograms at early (90 s 
after fluorescein injection) and late (7 min) phases of dye transit. At the early 
phase, the retinal vasculature is clearly defined by the intravascular 
fluorescein dye. At the late phase, any extravascular leakage or RPE loss is 
evident as patches of topical hyperfluorescence. Both the superior and 
inferior hemispheres were individually photographed in rapid succession 
(within 15 s). The contralateral eye was then immediately photographed. 
 
 
 
 
 
  962.8 Histological  Analysis 
 
2.8.1 Cryosections 
 
At various time points, treated animals were sacrificed by exposure to carbon 
dioxide and the eyes were retrieved and immediately immersed in a fixation 
solution of 4 % PfA for 2 hr. After fixation the eyes were embedded in O.C.T. 
(R.A. Lamb, E. Sussex, UK) and frozen in isopentane which had been pre-
cooled in liquid nitrogen. Specimens were stored at -20°C and 12 µm thick 
sections were cut using a Bright cryostat. Slides were stored at -20°C. 
 
 
2.8.1.1 Immunohistochemistry 
 
For immunofluorescence, cryosections were air-dried for 10 min and marked 
with a hydrophobic marker pen. They were then blocked for 1 hr with a TBS-
T solution containing 1 % BSA, Triton-X (0.5 %), and 5 % serum of the 
species the 2° antibody was raised in. The 1° antibody was then added at the 
appropriate concentration and left overnight at 4°C. After washing six times 
with TBS-T, sections were incubated with the 2° antibody diluted at the 
appropriate concentration in blocking solution for 2 hr at room temperature. 
The slides were then washed six times with TBS-T. In order to visualise cell 
nuclei, sections were usually counterstained with 1:1000 dilution of 
Hoescht33342 (Sigma, UK) and mounted on mounting medium (DAKO) prior 
to placing a coverslip on top. Analysis was performed from 30 min afterwards 
or preferably the following day using confocal (see 2.8.1.2) or fluorescent 
microscopy before capturing images with a Leica DC 500 digital camera 
mounted on the microscope. Slides were stored at 4°C. 
 
 
 
  972.8.1.2 Confocal  Imaging 
 
Cryosections were analysed using the 3-laser ZEISS LSM 510UV Confocal 
Imager and its software was used to capture images at x40 and x60 
objective, at various thickness layers (Z-stack) of the section. The images of 
the Z-stack were either used individually or as projected composite of each 
other. 
 
 
2.8.2 Fixation of eyes for semithin and ultrathin sections 
 
At various time points, eyes were retrieved from treated animals and 
immediately orientated with a nasal stitch. Then eyes were immersion fixed in 
3 % glutaraldehyde and 1 % PfA buffered to pH 7.4 with 0.07 M sodium 
cacodylate-HCl buffer (Karnovsky’s; 0.2 M (CH3)2AsO2Na.3H2O with 0.2 M 
HCl). After 12 hr the anterior part of the eye was removed by microdissection. 
The posterior segments were then osmicated for 2.5 hr in a 1 % aqueous 
solution of osmium tetroxide, followed by a dehydration series through 
ascending alcohols (50 – 100 %, 10 min per step). After 3 changes of 100 % 
ethanol, specimens were passed through propylene oxide (3x 10 min) and 
left overnight in a 50:50 mixture of propylene oxide and araldite. Following a 
single change to fresh araldite (5 hr with rotation) the specimens were 
embedded in resin and cured for 48 hr at 60°C.  
 
 
2.8.3 Semithin Sections 
 
Semithin sections (0.7 µm) were cut using a Leica ultracut S microtome fitted 
with a diamond knife (Diatome histoknife). Sections were stained with 
toluidine blue stain (25 ml 2 % hydrated sodium borate, 25 ml 100 % ethanol, 
0.5 g toluidine blue, SPI-Chem
TM) and slides were mounted with DPX after 
the sections had dried. Sections were analysed using a Leitz Diaplan 
microscope for observation and imaged with a Leica DC 500 digital camera. 
  982.8.4 Ultrathin sections 
 
Ultrathin sections (70 nm) were cut using a Leica ultracut S microtome fitted 
with a diamond knife for ultrathin sections (Diatome histoknife for ultrathin 
sections). Sections were taken of treated areas of retinae and collected onto 
grids. Sections were stained with uranyl acetate for 10 min and lead citrate 
for 7 min and then washed with dH2O. After the sections had dried they were 
analysed by electron microscopy (JEOL 1010 TEM). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  992.9  Buffers and Solutions 
 
Blocking solution (for Western blot): 1x PBS, 3 % BSA or non-fat dried milk 
solution, 0.5 % Tween 
 
Buffer A (for AAV2/8 purification): 5.65 g Bis-Tris propane, 2.42 g Tris up to 1 
l with dH2O, pH 9; filtered through 0.2 µm 
 
Buffer B (for AAV2/8 purification): Buffer A + 175.32 g NaCl; filtered through 
0.2 µm 
 
Church Buffer: 21 g of NaH2PO4, 48.55 g Na2HPO4, 70 g of SDS, 0.5 M 
EDTA, up to 1 l with dH2O 
 
HBS (2 x): 16 g NaCl, 0.74 g KCl, 0.2 g NaH2PO4H2O, 2 g Dextrose, 10 g 
HEPES, up to 1 l with dH2O, pH 7; filtered through 0.2 µm  
 
Laemni buffer (2 x): 125 mM Tris-HCl pH 6.8, 20 % glycerol, 4 % SDS, 10 % 
2-mercaptoethanol 
 
LB growth medium: 20 g LB extract (Oxoid Ltd., UK) per litre of dH2O 
 
PBS (1 x): 85 g NaCl, 4.3 g KH2PO4, up to 10 l with dH2O, pH 7.2 
 
PBS-MK: 1 x PBS, 2.5 mM KCl, 1 mM MgCl2
 
Proteinase K buffer: 100 mM Tris (pH 7.4), 50 mM EDTA and 0.5 % SDS 
 
Running buffer (for Western blot): 3.3 g Tris, 14.4 g Glycine, 1 g SDS, up to 1 
l with dH2O  
 
Sodium phosphate buffer: 97.1 g Na2HPO4, 43.6 g NaH2PO4, pH 7.2, up to 1 
l with dH2O 
  100 
TBE (50 x): 242 g Tris, 57.1 ml Boric Acid, 18.6 g EDTA, up to 1 l with dH2O 
 
TD Buffer (1 x): 8.2 g NaCl, 0.37 g KCl, 0.12 g K2HPO4, 0.33 g MgCl2, 3 g 
Tris, up to 1 l with dH2O, pH 7.5; filtered through 0.2 µm 
 
Transfer buffer (for Western blot): Running buffer + 20 % methanol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  1013 Virus-mediated RNAi targeting 
in the retina 
 
 
 
3.1     Introduction 
 
 
In order to achieve efficient and persistent knockdown of a gene of interest in 
the retina, an shRNA-expressing cassette must be delivered into the target 
cells. Transduction of certain retinal layers using various viral vectors has 
proven to be very efficient [93,122,237]. Selective transduction of retinal cell 
types can also be achieved by capsid pseudotyping of the recombinant AAV 
vectors used. Tissue specific expression of cassettes in conjunction with 
capsid pseudotyping can further restrict transgene expression in the desired 
cell type. Efficient knockdown depends on successful delivery, efficiency of 
the selected hairpin molecule, as well as on the expression levels of the 
targeted gene.  
 
In this study, the specificity and stringency of RNAi knockdown was analysed 
in vitro by comparing the silencing effect of the selected shRNA molecule on 
two different, but highly homologous, GFP transgenes. We also used a GFP 
transgenic mouse, which constitutively expresses eGFP through a CBA 
promoter, as a model to target endogenous GFP expression using viral-
mediated RNAi. The high expression levels that a CBA promoter provides, 
make this model a useful candidate for RNAi experiments since successful 
downregulation of GFP would indicate the feasibility of silencing highly 
expressed genes in the retina, such as rho or Prph2.  
 
 
 
 
  1023.2     Hairpin expression vectors 
 
 
The targeting sequence for eGFP (siGFP) was kindly provided by Steven 
Howe (Molecular Immunology unit, Institute of child Health, UCL) after its 
efficiency was tested synthetically in vitro by transfection in HeLa cells stably 
expressing  eGFP. A non-targeting control (siCON) sequence was also 
designed to be tested alongside siGFP in our in vitro and in vivo experiments 
(see section 2.2.5; Table 1 for sequences). The siCON target sequence was 
scanned for homology with murine and human genome databases using the 
BLAST alignment algorithm (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and no 
positive hits were returned. However, the siCON molecule was not assessed 
in vitro to investigate whether it incorporates into RISC or whether it elicits 
any innate immune responses via the TLR3 pathway. 
 
 
3.2.1    mU6pro – RNAi expression vector 
 
In order to make an RNAi expression cassette, a DNA-based template of the 
siRNA target area needs to be constructed. The main concept behind these 
short expression cassettes is the transcription of both the sense and 
antisense strands of the siRNA of interest in one transcript through an RNA 
polymerase III promoter, like U6 or H1. Upon transcription of the sense and 
antisense strands separated by an intermediate loop sequence, RNA 
complementarity causes the single-stranded RNA molecule to fold back onto 
itself and form an shRNA (Figure 3.1). After export of the shRNA to the 
cytoplasm, an RNase III enzyme (Dicer; see section 1.4) excises the loop 
sequence that forms the hairpin giving rise to a mature siRNA duplex. 
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Figure 3.1: Diagram of shRNA production. The U6 promoter-based RNAi cassette 
transcribes an shRNA molecule in the nucleus. The hairpin is transported to the cytoplasm 
where it is cleaved by Dicer to produce a mature active siRNA molecule. 
 
 
The mU6pro vector is an RNAi expression vector employing the polymerase 
III U6 promoter to transcribe the shRNA of choice [238]. The DNA sequence 
of the shGFP was cloned downstream of the U6 promoter in the form of 
annealed oligonucleotides. A subsequent enzyme digestion upstream of the 
U6 promoter and downstream of the shRNA sequence (AscI/SnaBI) yielded 
the whole RNAi cassette at a size of around 400 bp (Figure 3.2). This 
digestion was performed to check the integrity of the cloned cassette, as well 
as to retrieve the cassette for further cloning into the AAV and lentiviral vector 
backbones. 
 
 
 
 
  104Figure 3.2: Digestion confirming the cloning of shGFP 
hairpin into the mu6pro plasmid. After ligating the shGFP 
oligonucleotides downstream of the U6 promoter, the whole 
shGFP cassette (~400 bp) was excised for further sub-cloning 
using restriction enzymes AscI that cut upstream of the U6 
promoter and SnaBI that cuts downstream of the shGFP 
hairpin. The 3000 bp band corresponds to the mU6 backbone. 
The Bioline 1 kb ladder was used to determine the size of the 
excised fragments. +clone; positive clone. 
 
 
 
 
 
A positive clone was named mu6.shGFP. The non-targeting control hairpin 
was cloned in a similar way and the resulting plasmid was named 
mu6.shCON. 
 
 
3.2.2    pHR’SIN – lentiviral production vector 
 
After confirming the sequence of each hairpin by sequencing (MWG Biotech, 
UK, see Chapter 2.2.3), the hairpin cassettes were cloned into the pHR’SIN 
lentiviral backbone. The pHR’SIN vector contains the 5’- and 3’- LTR 
sequences from HIV-1 virus together with the central polypurine track (cPPT) 
fragment from the wild type virus. The 3’LTR of the vector is partially deleted 
to hinder viral particle replication in the infected host cell. The 3’ΔLTR and the 
lentiviral production system that is based on a three plasmid co-transfection 
protocol ensure that the recombinant lentiviral particles are replication 
incompetent. The successful cloning of either the shGFP or shCON hairpin 
cassettes into the pHR’SIN backbone was checked by excising the RNAi 
cassettes after cloning using the restriction sites AscI and XbaI (Figure 3.3). 
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Figure 3.3: Digestion confirming the cloning 
of shGFP and shCON cassettes into the 
lentiviral pHR’SIN backbone. Three positive 
clones are depicted. After restriction digest with 
AscI and XbaI, the lentiviral backbone (~9 kb), 
the RNAi cassette (~400 bp) and the 3’ LTR 
(~300 bp) were excised from positive colonies. 
The Bioline 1 kb ladder was used to determine 
the size of the excised fragments. +clone; 
positive clone. 
 
 
 
 
The lentiviral plasmids bearing the RNAi cassette targeting eGFP or the non-
targeting control were named pHR’SIN.shGFP and pHR’SIN.shCON, 
respectively. The integrity of the incorporated RNAi cassettes was checked 
by sequencing (MWG Biotech, UK, see Chapter 2.2.3). 
 
 
3.2.3    pD10 – AAV production vector 
 
The relatively small size of the RNAi cassette (400-500 bp) enables the 
construction of bicistronic vectors in which the RNAi cassette can be placed 
upstream or downstream of an adjacent RNA polymerase II-based 
expression cassette. This option allows the co-expression of a reporter gene 
that will aid in the visualisation and selection of transduced cells. A pre-
existing pD10 vector driving the expression of RFP through a CBA promoter 
(pD10.RFP) was used as the recipient backbone for our RNAi expression 
cassette. However, since the incorporation of the RNAi cassette was not 
feasible with the existing restriction sites within the backbone, a polylinker 
had to be cloned upstream of the CBA-RFP cassette. Five restriction sites 
were cloned into the pD10 backbone and the resulting plasmid was named 
  106pD10.RFP.poly (Figure 3.4). Polylinker integrity was checked by sequencing 
(MWG Biotech, UK, see Chapter 2.2.3). 
 
 
Figure 3.4: Digestion confirming the 
cloning of polylinker in the 
pD10.RFP.poly. Three positive (next to 
ladder) and one negative clone after ligating 
the designed polylinker with the pD10 
backbone. The positive clones exhibited a 
400 bp band excised after restriction digest 
with AscI and SnaBI. The Bioline 1 kb ladder 
was used to determine the size of the excised 
fragments. +clone; positive clone. -clone; 
negative clone. 
 
 
After further restriction digests to confirm the integrity of all the subcloned 
fragments (Figure 3.5), AscI and EcoRV were used to digest the 
pD10.RFP.poly plasmid. Following the ligation of the shGFP expression 
cassette with AscI and SnaBI overhangs into the pD10 backbone, further 
restriction enzyme digestion with AscI and PmeI confirmed its successful 
incorporation and the final rAAV vector plasmid was named 
pD10.RFP.shGFP (Figure 3.6). Similarly, the shCON expression cassette 
was cloned into the pD10 backbone using the same restriction sites and the 
resulting rAAV vector plasmid was named pD10.RFP.shCON. The integrity of 
the incorporated RNAi cassettes was checked by sequencing (MWG Biotech, 
UK, see Chapter 2.2.3). 
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Figure 3.5: pD10 polylinker site integrity. Polylinker incorporation was confirmed by 
digesting the plasmid with each of the five incorporated sites (AscI, BstZI7, BsrGI, EcoRV 
and PmeI). The expected sizes for double digests were 3700 bp and 2600 bp after NotI 
digestion and 6000 bp and 400 bp after SnaBI digestion. The Bioline 1 kb ladder was used to 
determine the size of the excised fragments. 
 
 
 
 
 
Figure 3.6: Restriction digest to confirm the cloning of 
the shGFP cassette into the polylinker of pD10. The 
shGFP cassettes (~400) that had been previously excised 
from mU6.shGFP using AscI and SnaBI restriction 
enzymes was cloned into the pD10.RFP.poly plasmid that 
had been digested with AscI and EcoRV. Upon ligation, 
both blunt restriction sites on either fragments (SnaBI and 
EcoRV) are destroyed. Confirmation of the cloning was 
carried out by digestion of pD10.RFP.shGFP with AscI and 
PmeI which results in a fragment of ~450 bp. The Bioline 1 
kb ladder was used to determine the size of the excised 
fragments. +clone; positive clone. 
 
 
 
 
  1083.3     Lentiviral-mediated GFP silencing 
 
3.3.1    In vitro eGFP silencing and stringency of knockdown 
 
In order to test the eGFP silencing efficiency of LNT.shGFP in vitro, a cell line 
stably expressing eGFP was constructed using a different lentivirus that 
drives the expression of eGFP from an SFFV promoter (LNT.eGFP). Human 
embryonic kidney fibroblasts (293T) were infected at a limiting multiplicity of 
infection (MOI) using a ratio of infectious virus particles to cells <1 (see 
section 2.5.2). The use of limiting MOI makes it likely that the infected cells 
will be transduced by a single viral particle and hence produce eGFP through 
a single transgene cassette. A single eGFP cassette should be capable of 
producing enough eGFP to test the efficiency of the shGFP hairpins. The 
transduced cells were FACS sorted and single eGFP
+ cells were propagated 
to obtain clonal cell populations to ensure that we obtained a cell line that 
would express eGFP homogeneously (293T/eGFP
+). These cells were 
subsequently transduced with LNT.shGFP at increasing MOIs (1, 5, 10 and 
20) and FACS analysed one week after transduction to measure the 
reduction in the mean fluorescence intensity (MFI) caused by the silencing of 
the host eGFP expression cassette by shGFP (Figure 3.7). 
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Figure 3.7: FACS plot overlay of GFP expression. Representative overlay of mean 
fluorescence intensity (MFI) of 293T/GFPP
+ cells after transduction with LNT.shGFP vectors. 
GFP expression was gradually reduced in the transduced cells as MOI values increased. 
 
 
The expression of eGFP in the transduced cells was reduced gradually as 
the number of virus particles increased. Untransduced 293T/eGFP
+ cells 
were used as a control and their mean fluorescence intensity (MFI) exceeded 
that of transduced cells (Figure 3.7; blue line). Increasing the MOI, effectively 
increases the number of shGFP cassettes introduced into the host cells 
leading to a progressively more potent knockdown of eGFP. 293T/eGFP
+ 
cells already express high levels of an exogenous protein and their viability 
levels tend to decrease when transduced with a large number of viral 
particles. This is represented by the reduction in cell numbers for the 
samples transduced with an MOI higher than 5 (Figure 3.7; MOI=5, 10 or 20). 
Whilst figure 3.7 depicts a representative overlay of samples, the reduction in 
  110cell numbers after lentiviral infection at an MOI above 5 was observed in all 
tested samples (n=3). For statistical interpretation see figure 3.8. 
 
The next step of in vitro testing concentrated on the stringency of the 
targeting LNT.shGFP vector. In order to test the stringency of the shGFP 
hairpin, an additional stable cell line expressing humanised recombinant GFP 
(hrGFP) was constructed in a similar way to the previous cell line. The 
resulting cell line was named 293T/hrGFP
+. hrGFP is a green fluorescent 
protein that has been engineered so that it utilises more abundant human 
tRNAs. Even though eGFP and hrGFP are not derived from the same 
species, they have approximately 30 % sequence homology. 
 
Both LNT.shGFP and LNT.shCON were packaged into recombinant vectors 
(see section 2.5.3) and used to transduce the 293T/eGFP
+ and 293T/hrGFP
+ 
cell lines at increasing MOIs. The MFI of each transduced sample was 
analysed by FACS (Figure 3.8). 
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Figure 3.8: Graphical representation of GFP expression in 293T cells after 
transduction with eGFP and control targeting lentiviruses. (A) Reduction of eGFP in 
293T/eGFP
+ cells after transduction with the LNT.shGFP at various MOIs. (B) Transduction 
of the same cell line with LNT.shCON did not result in eGFP reduction. (C, D) GFP 
expression in 293T cells expressing hrGFP was not reduced after transduction of 
LNT.shGFP or LNT.shCON. (E) The specificity of the LNT.shGFP towards eGFP was high 
since there was no reduction in hrGFP levels even though there was partial siGFP:hrGFP 
homology with up to 7 consecutive nucleotides. Bold nucleotides = mismatches. *P<0.001 
(Student’s t-test; n=3, where 3 is the number of infections performed per virus type). 
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+ cells with LNT.shGFP resulted in a decrease in 
MFI (Figure 3.8A) whereas infection with LNT.shCON did not result in any 
significant eGFP knockdown (Figure 3.8B). Neither LNT.shGFP nor 
LNT.shCON resulted in a reduction of the MFI in the 293T/hrGFP
+ cells 
(Figure 3.8C,D). Even though the decrease in MFI in figure 3.8A was highly 
significant (P<0.001) for MOIs=5,10 and 20, the reduction in cell numbers at 
these MOIs should be addressed in the future in order to avoid similar 
increase in cell death when delivering in vivo. Using hrGFP instead of eGFP 
might improve cell viability as hrGFP is much better tolerated by 293T cells. 
 
Although hrGFP is an engineered GFP protein that allows more efficient 
production in human derived cells (note MFI differences between graphs in 
Figure 3.8), it has 30 % homology to the eGFP transgene. Therefore, 
complementarity levels between the hrGFP transcript and the target area of 
shGFP were assessed using BLAST (Figure 3.8E). Even though at the 3’-
end of the target area there were seven consecutive nucleotides that were 
homologous between hrGFP and shGFP, the silencing potential of the 
hairpin was abolished due to the mismatching in the first half of the target 
area. This experiment demonstrates how target:hairpin mismatching does not 
just affect the efficiency of the silencing, but completely abolishes it. 
 
 
3.3.2    Silencing of eGFP in the RPE in vivo 
 
Titre matched preparations of LNT.shGFP and LNT.shCON (10
8 v.p./ ml), 
were injected in the subretinal space of young adult mice expressing eGFP 
throughout the retina. The C57BL/6
GFP+/GFP+animals carry an eGFP 
transgene driven by a CBA promoter. Vectors were injected subretinally and 
the effect of vector-mediated eGFP silencing was assessed two weeks after 
administration. Injected eyes were collected, fixed in paraformaldehyde and 
prepared for cryosectioning through the treated area. GFP expression in the 
RPE was analysed in eyes injected with either LNT.shGFP or LNT.shCON. 
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Figure 3.9: In vivo silencing of eGFP after subretinal injection of LNT.shGFP in GFP 
transgenic mice. Confocal imaging of fixed cryosections indicating red nuclear stain (PI) 
and GFP expression. (A) Eyes injected with LNT.shCON presented homogenous GFP 
expression throughout the retina. (B) LNT.shGFP injected eyes showed a marked decrease 
in RPE-specific GFP expression 14 days p.i. Black arrows indicate the RPE. Size bar; 20 
μm. n=4. 
 
 
In eyes that received LNT.shCON (Figure 3.9A; n=4) there was 
homogeneous  GFP expression throughout the retina driven by the 
constitutive CBA promoter of the integrated eGFP expression cassette. No 
reduction in GFP levels were detected in the RPE within the treated areas. In 
eyes that received LNT.shGFP (Figure 3.9B; n=4) GFP expression was 
retained in all the retinal layers apart from the RPE in the area of retinal 
detachment. Within this area, the RPE was almost devoid of GFP indicating 
that the lentivirally-delivered shGFP expression cassette was silencing 
endogenous GFP expression. Any residual GFP localisation around the cell 
membranes could be accounted for by the remaining levels of endogenous 
expression not silenced by the RNAi cassette as well as GFP molecules that 
had entered the RPE through outer segment phagocytosis. In addition, the 
fact that no other retinal layer showed reduced GFP expression within the 
treated area was consistent with the specificity of the lentiviral vector. The 
robust and RPE-specific silencing of GFP following delivery of LNT.shGFP 
indicated that lentiviral vectors can accommodate RNAi cassettes and 
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endogenous genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  1153.4  AAV-mediated shGFP expression in 
vivo 
 
 
After testing the efficiency of GFP knockdown via lentiviral-mediated delivery 
of shGFP, the efficiency of gene silencing was assessed in the context of an 
AAV vector. Since AAV is the most effective vector for transduction of 
photoreceptor cells, the successful accommodation of RNAi cassettes in 
rAAV vectors is essential for future RNAi applications to silence dominant 
mutations in photoreceptor-specific genes. We chose to test an AAV2/8 
platform because of the particularly efficient transduction of photoreceptors 
using this serotype (see section 1.4.2.2.3).  
 
The targeting plasmids pD10.RFP.shGFP and pD10.RFP.shCON were used 
to make AAV2/8 preparations (see section 2.4.3) and both viral preparations 
were titre matched prior to use. In contrast to lentiviral vectors, AAV2/8 could 
not be tested in vitro in human or murine cell lines as infection of cells in 
culture with this serotype is very inefficient. Whereas low transduction 
efficiency when using AAV2/2 can be overcome with adenoviral super-
infection, in the case of AAV2/8 super-infection does not improve the 
transduction rate. Therefore, the resulting viral preparations, 
AAV8.RFP.shGFP and AAV8.RFP.shCON, were tested in vivo to assess 
GFP knockdown in the photoreceptor cell layer. 
 
Two µl of the titre matched AAV2/8 preparations (5x10
11 v.g./ml), 
AAV8.RFP.shGFP and AAV8.RFP.shCON, were injected in the subretinal 
space of C57BL/6
GFP+/GFP+ young adult mice. Vectors were subretinally 
injected and the effect of AAV-mediated eGFP silencing was assessed five 
weeks after administration. Injected eyes were collected, fixed in 
paraformaldehyde and prepared for cryosectioning through the treated area. 
GFP expression in the photoreceptors was analysed in eyes injected with 
either AAV8.RFP.shGFP or AAV8.RFP.shCON. 
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Figure 3.10: In vivo transduction efficiency after subretinal injection of 
AAV8.RFP.shCON or AAV8.RFP.shGFP in GFP transgenic mice. Confocal imaging of 
fixed cryosections with DAPI nuclear stain (blue) RFP (red) and GFP expression (green). (A) 
Eyes that received AAV8.RFP.shCON (n=3) had homogenous GFP expression throughout 
the retina and within the treated area as indicated by the co-expression of RFP. (B) In 
AAV8.RFP.shGFP (n=4) injected eyes there was poor transduction efficiency of 
photoreceptors that was evident by the relatively low number of cells expressing RFP. Size 
bar; 20 μm. 
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order to visualise the transduced photoreceptors. The control virus 
AAV8.RFP.shCON resulted in high transduction efficiency within the treated 
area with the majority of the ONL transduced (Figure 3.10A; n=3). As 
expected, GFP silencing was not observed in transduced cells after 
transcription of the shCON hairpin. The AAV8.RFP.shGFP virus preparation 
did not efficiently transduce photoreceptor cells (Figure 3.10B; n=4). Even 
though the titre of both vectors was equivalent (5x10
11 v.g./ml), the infectious 
capacity of AAV8.RFP.shGFP appeared to be many times less than that of 
AAV8.RFP.shCON. After thoroughly sectioning all the treated eyes (n=4) it 
was confirmed that the failure to identify treated areas with equivalent 
transduction efficiency was not due to ascertainment bias but instead failure 
to transduce photoreceptors with the same efficiency. 
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Figure 3.11: Fluorescence profile of transduced photoreceptors after in vivo 
subretinal delivery of AAV8.RFP.shGFP. Confocal image of a fixed cryosection showing 
RFP (red) and GFP expression (green) and its fluorescence intensity plot. (A) An area with 
RFP-expressing photoreceptors from an AAV8.RFP.shGFP injected eye was selected and a 
sample area (indicated by red arrow) was selected to analyse the GFP and RFP 
fluorescence patterns of three RFP
+ photoreceptors. (B) The fluorescence analysis indicated 
that although the selected cells expressed RFP at high levels, the GFP intensity did not fall 
below basal levels found in adjacent untransduced photoreceptors (green arrow) and hence 
there was no GFP knockdown taking place within those cells. Either the RNAi cassette was 
not strong enough to silence GFP or its integrity had been compromised during virus 
production. 
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possible to easily visualise GFP downregulation in the few transduced cells 
because of the high expression levels of GFP from adjacent untransduced 
cells. In addition, the number of cells expressing RFP was so low that it 
would not be possible to FACS sort an amount adequate enough to proceed 
to RNA and protein analysis. Therefore, a fluorescence profile was prepared 
for selected RFP
+ cells in order to compare the intracellular levels of GFP 
and RFP (Figure 3.11). Although this technique does not account for all 
transduced cells, as FACS sorting would do, it does give a detailed analysis 
of fluorescence for each analysed cell. An area with transduced 
photoreceptors was selected and the fluorescence measurements were 
taken from an area indicated by a red arrow set to include three adjacent 
transduced cells (Figure 3.11A). The fluorescence profile was generated by 
measuring the relative fluorescence of both GFP and RFP alongside the area 
of the sampling red arrow. The end result is presented as a plot of 
fluorescence over absolute length of the selected area (Figure 3.11B). The 
intracellular green fluorescence measurements could be correlated with the 
three spikes in RFP expression that corresponded to the three transduced 
photoreceptors. Extracellular red fluorescence measurements rapidly 
decreased to background levels as would be expected. The green 
fluorescence profile fluctuated slightly within cells corresponding to higher 
GFP concentration close to the nuclear membrane and lower in the centre of 
the nucleus. However, the overall intracellular GFP profile of transduced cells 
was not reduced below basal levels indicating that no detectable GFP 
knockdown occurred. 
 
The integrity of both pD10.RFP.shCON and pD10.RFP.shGFP was re-tested 
by sequencing the plasmids. Although pD10.RFP.shCON contained both the 
RNAi and RFP expression cassettes intact, an aberrant sequence was 
detected in pD10.RFP.shGFP within the RNAi hairpin, the sense-loop-
antisense motif was mutated to sense-loop-insertion abolishing the function 
of the cassette as no hairpin could be produced. The possible recombination 
most likely occurred prior to the viral production protocol and after the 
bacterial-based production of high amounts of the transfected plasmids that 
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protocol with the original correct clone, the issue was not resolved. It was not 
clear why the shGFP-bearing pD10 vector would be a lot less stable than the 
shCON-bearing pD10. Possible reasons and future precautions are 
discussed below. 
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In theory, incorporation of any transgene cassette in a viral production vector 
should be possible as long as it meets the size requirements for the vector of 
choice. Since the average RNAi expression cassette will not exceed 500 
base pairs in length, it is easily accommodated by any viral vector and viral 
vector-mediated RNAi should be straightforward. Although some studies 
have successfully demonstrated viral vector-mediated knockdown of 
endogenous genes using hairpin expression cassettes [233,235,239], others 
have found it more difficult to match the in vitro efficiency of their hairpin to 
that following in vivo vector-mediated delivery [234]. So far, there has been 
no insight into the reasons why certain sequences do not function 
equivalently in different genetic or cellular contexts and such problems are 
viewed as part of a “hit-and-miss” RNAi design rationale. 
 
In the experiments presented in this chapter, the efficiency of delivering an 
RNAi hairpin into the retina using two different types of viral vectors was 
tested. The target gene was eGFP and we attempted to deliver an shGFP 
hairpin in vivo using lentiviruses and AAV. Incorporation of hairpins into the 
lentiviral backbone did not present any obstacles and the targeting shGFP 
hairpin was successfully delivered both in vitro and in vivo. The integrity of 
RNAi cassettes in the viral preparations is indicated by the successful 
knockdown of eGFP that is dose-dependent based on MOI calculations. 
However, given the increase in cell death in the 293T/eGFP
+ cells after 
infection of the silencing vectors at high MOIs, it would have been more 
appropriate to use hrGFP as a reporter gene in our assays rather than eGFP. 
eGFP is known to have a toxic effect when highly expressed in certain cell 
lines as was the case in this study and demonstrated by reduced numbers of 
sorted 293T/eGFP
+ cells (Figure 3.7). In vivo, the RPE-targeting lentiviruses 
demonstrated almost total knockdown of endogenous eGFP expression 
within the treated area without causing cell toxicity or silencing eGFP in 
adjacent cells (such as the photoreceptors). Even though the reduction in 
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statistical analysis on fluorescence values of sorted cells, it would have also 
been useful to confirm gene suppression in mRNA levels by quantitative 
PCR. Although mRNA silencing can be suggested through the reduction in 
protein levels, it cannot be confirmed. In addition, comparison of mRNA and 
protein levels after suppression would provide a correlation between mRNA 
molecules and protein translation for eGFP; a useful set of data for future 
eGFP silencing experiments. 
 
Incorporating RNAi cassettes in an AAV vector proved to be more 
problematic. The AAV vector backbone – pD10 – is prone to recombination 
due to the ITRs’ palindromic sequences. Although this problem can be 
usually overcome by adjusting the plasmid production protocol (see section 
2.2.4), insertion of additional palindromic sequences (like an RNAi hairpin or 
two identical promoters) can exacerbate the problem of spontaneous 
recombination. In our vectors, the integrity of both the RNAi cassette and the 
RFP reporter gene cassette was essential and they were both checked by 
sequencing after cloning. 
 
The shCON hairpin cassette posed no problems with regard to cloning during 
the generation of pD10.RFP.shCON. The shGFP hairpin cassette proved to 
be very difficult to clone particularly in pD10.RFP.poly. Most attempts to 
clone the hairpin resulted in empty vectors that had failed to incorporate the 
shGFP cassette. After adjusting the bacterial cloning temperature and the 
pre-ligation handling of the plasmid fragments (see section 2.2.4), the shGFP 
was finally incorporated into pD10.RFP.shGFP and a clone with the correct 
sequence was identified. At this point, it should be noted that all plasmids 
were sequenced using primers that confirmed part of the CBA promoter, the 
entire RFP cDNA and the entire RNAi cassette. Apart from confirming the 
integrity of ITRs by restriction digestion, the remaining sequence of the pD10 
backbone was not confirmed. 
 
After in vivo delivery the transduction efficiency of AAV8.RFP.shGFP was 
considerably lower than that of AAV8.RFP.shCON even though the titres of 
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compared to the sequence of RFP to ensure that the low transduction 
efficiency was not a result of RFP knockdown caused by the eGFP-targeting 
hairpin. In addition, no eGFP silencing could be measured in the few 
transduced photoreceptors. After re-sequencing the plasmids we observed 
that although pD10.RFP.shCON was still correct, pD10.RFP.shGFP had an 
aberrant sequence inserted after the loop of the hairpin and into the place of 
the antisense strand. Moreover, the resulting sequences from three separate 
sequencing reactions were different even though they all occurred at the 
loop-antisense junction. This indicated that multiple independent 
recombination events had occurred that abolished the function of the hairpin 
in all cases. The resulting RNAi cassettes lacked the antisense strand as well 
as a valid terminator sequence therefore no functional shRNA could be 
produced. 
 
It is essential for RNAi hairpins to retain their structural integrity in order to 
ensure efficient target silencing. All the components of the sense-loop-
antisense motif are equally essential in any given hairpin as mutations within 
the sense or antisense strand will affect the thermodynamic coupling in the 
mature siRNA. The loop sequence is equally important for the hairpins 
secondary structure and loop mutations may greatly hinder the coupling of 
the sense and antisense strand. Although the junctions between a hairpin’s 
components are known targets for major enzymes of the RNAi pathway like 
Drosha and Dicer, their corresponding DNA templates are not thought to act 
as substrate for DNA-specific recombinases. It is possible that in the case of 
pD10.RFP.shGFP, the adjacent nucleotides in the loop-antisense junction 
formed a highly unstable recipient site which accepted donor insertions from 
at least three different non-specific areas of the pD10 backbone. Even 
though unrecombined clones were constructed, their stability was low and 
further recombination effects could have taken place during any of the steps 
of plasmid and vector production. 
 
Although the integrity of the RNAi cassette was compromised, the RFP 
cassette was present since the probe used to titre the viral vectors was part 
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however, evident that most viral particles did not express the RFP cassette.  
Although we have not been able to determine a specific cause, it is possible 
that the recombined RNAi cassette which was upstream of the RFP cassette, 
affected the function of the CBA promoter by altering the secondary structure 
of the plasmid.  
 
The work described in this chapter analysed the feasibility of lentivirus- and 
AAV-mediated RNAi in vivo. We found that RNAi cassettes can be 
successfully delivered using lentiviruses or AAV but spontaneous 
recombination can hinder the efficiency of AAV incorporation for certain 
hairpins. For this reason sequencing the hairpin at every stage of plasmid 
preparation is essential. Spontaneous recombination might occur because of 
the sequence of the hairpin or because of its interaction with another 
sequence in the viral backbone. Altering the targeting sequence is one option 
as different sequences might be less recombinogenic, as suggested by the 
shCON results (see also Chapter 5). However, further analysis in hairpin 
dynamics and its interactions with viral sequences and/or components of the 
viral machinery might identify specific sequence patterns that could be 
incompatible in a viral context and hence aid in the design of RNA hairpins 
easily accommodated by different viral vectors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  1254 Lentiviral vector-mediated 
RNAi targeting of epithelial 
tight junctions 
 
 
 
4.1     Introduction 
 
 
The aim of the work described in this chapter is to determine the utility of viral 
vector-mediated shRNA delivery for probing retinal function and 
pathophysiology through selective downregulation of target genes. Here, we 
describe the use of lentiviral vectors to manipulate junctional signalling in 
mouse RPE in vivo. Our results demonstrate that lentiviral vectors expressing 
RNA hairpins are capable of regulating junctional proteins in vivo and 
indicate that the ZO-1/ZONAB pathway is important for RPE homeostasis 
and disturbance of this pathway may result in RPE transformation and cause 
disease. 
 
 
4.1.1    Epithelial cellular junctions 
 
The blood-retinal barrier (BRB) is maintained in the retina through endothelial 
cell-cell adhesion in retinal vessels or epithelial cell-cell adhesion of the RPE. 
There are four major types of junctions that regulate cellular adhesion: 
adherens junctions (AJ), desmosomes, gap junctions (GJ) and tight junctions 
(TJ) (see Figure 4.1). In general, junctions consist of 3 types of components: 
transmembrane anchoring proteins that physically implement cellular 
adhesion (e.g. E-cadherin, occludin, claudins); cytoskeletal proteins that 
create an intracellular scaffolding connecting the junctions (e.g. actins, 
vinculin) and finally, nucleus and adhesion complexes (NACos) that regulate 
cell density, gene expression and proliferation (e.g. ZONAB, β-catenin, 
  126CDK4) [240,241]. Mutations in genes encoding junctional components and 
malformation of retinal junctions are implicated in various types of ocular 
disease (see section 1.2.2.1).  
 
 
Figure 4.1: Epithelial cellular junctions. Schematic representation of desmosomes, tight, 
adherens and gap junctions located at the lateral membrane of a polarised epithelial cell. 
Tight and adherens junctions are situated closer to the apical membrane and are connected 
to actin filaments of the cytoskeleton. Desmosomes are interconnected through intermediate 
filaments. Each of the junctions acts as an adhesion point between adjacent epithelial cells. 
(Adapted from Matter & Balda, 2003) [241] 
 
 
The formation of junctions allows epithelial cells to polarise and form 
selective barriers to separate different tissues. Polarisation of epithelial cells 
creates apical, basal and lateral membrane domains. Often, basal and lateral 
domains are referred to as the basolateral membrane. In the RPE, the apical 
membrane forms fine foldings called microvilli that are involved in 
photoreceptor OS phagocytosis, whereas the basal membrane lies on 
Bruch’s membrane anchoring the neuroretina and supporting its structure. 
  127The lateral sides are in contact with adjacent RPE cells forming a uniform 
closely packed monolayer underlying and supporting the neuroretina [242]. 
 
AJs and desmosomes are the main adhesive junctions between epithelial 
cells. AJs are often concentrated close to TJs near the apical membrane 
where they share cytoplasmic interactions with cytoskeletal actin filaments, 
whereas desmosomes are usually distributed all around the basolateral 
membrane sharing connections with the intermediate filaments of the 
cytoskeleton [243]. AJs’ and desmosomes’ anchoring molecules are 
cadherins that interact with each other at their extracellular domains. They 
are known to be involved in tumour suppression and morphoregulation [244]. 
In addition, it has been suggested that E-cadherin is involved in epithelial 
tyrosine-kinase dependent endocytosis through its ubiquitination by a zinc-
finger family protein, Hakai [245,246]. Intracellularly, cadherins are involved 
in the sequestration of catenins (β-catenin or plakoglobin (γ-catenin)) which 
are known to be transcription regulators of proliferative markers. β-catenin 
has been known to regulate several genes involved in cancer like c-myc, 
cyclin D1 and matrix metalloproteases [243].  
 
TJs regulate diffusion of molecules through the paracellular pathway and 
they delineate the apical-basolateral epithelial domains [247]. These two TJ 
characteristics are known as “gate and fence” functions. They circumvent 
each cell at the apical end of the lateral membrane forming a dense network 
that prohibits free compound exchange in the apical-basal orientation. They 
are composed of three types of transmembrane proteins: occludin, claudins 
and junction adhesion molecules (JAMs) [243,247]. They all mediate cell-cell 
adhesion with the first two being involved in the selective paracellular 
diffusion of molecules. Intracellularly, TJs are connected to a protein complex 
that consists of membrane-associated guanylate cyclases (MAGUK) and 
proteins containing PDZ domains (PSD-95, Discs large A, ZO-1 homology). 
A vast network of other regulators mediates junctional-nuclear 
communication to regulate expression of genes involved in proliferation, cell 
cycle and cell density [248]. 
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Zonula occludens-1 (ZO-1) is a major TJ component and has SH3 (Src 
homology 3) and PDZ domains for protein-protein interactions. ZO-1 has 
been shown to interact with various signalling molecules that regulate G1/S 
phase transition, cellular stress responses and permeability through its SH3 
domain [248]. One of its partner molecules is the ZO-1 associated nucleic-
acid binding (ZONAB) protein. ZONAB is a Y-box transcription factor that 
recognises promoter sequences containing an inverted CCAAT box [249]. 
ZONAB regulates Erb-2 expression in a cell-density dependent way [250]. In 
low cell density conditions ZONAB localises in the nucleus where it activates 
Erb-2 transcription, leading to cell division. When cellular density increases, 
ZO-1 sequesters ZONAB as TJ assembly is increased resulting in a 
downregulation of Erb-2 and a subsequent slowing of cell proliferation. 
ZONAB is also regulated by other NACos in TJ specific transcriptional 
signalling. APG-2, a heat-shock protein encoded by an oncogene, competes 
with ZONAB for the SH3 domain of ZO-1 in a stress dependent manner 
thereby promoting proliferation by impeding ZO-1/ZONAB interactions, and 
hence ZONAB’s cytoplasmic sequestration [251]. TJ paracellular permeability 
is also regulated by Rho family GTPases which are involved in cytoskeletal 
rearrangements. Guanine nucleotide exchange factor (GEF), a proto-
oncogene, has been shown to activate Rho and directly associate with TJs 
increasing paracellular permeability [252]. Although the mechanism through 
which Rho GTPases rearrange cytoskeletal filaments to increase diffusion is 
not clear, the TJ “gate and fence” function does not get compromised in the 
process meaning that the epithelial monolayer integrity is retained. 
 
 
4.1.2    The RPE and tight junctions 
 
RPE cells not only support the function of photoreceptors, they also form the 
outer BRB that prevents fluid from choroidal vessels from entering the retina 
[253,254]. Breakdown of the BRB can lead to visual loss in a number of 
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homeostasis are not completely understood.   
 
Binding of ZONAB to ZO-1 results in cytoplasmic sequestration and, hence, 
inhibition of its transcriptional activity [248,255]. ZONAB interacts with the cell 
cycle kinase cdk4 and regulates the transcription of cell cycle genes such as 
cyclin D1 and PCNA, providing a molecular explanation for its role in the 
proliferation of epithelia cells in culture [249,250,256]. Little is known about 
the role of ZONAB in vivo and although TJ-associated knockout mouse 
models targeting ZO-2, ZO-3 and ZONAB have demonstrated the 
developmental importance of ZO-2 and the redundancy of ZO-3, lack of 
ZONAB expression was found to severely hinder embryonic development 
only when combined with depletion of YB-1, a cold shock domain protein 
[257,258]. Mice deficient only in ZONAB exhibited increased spermatocyte 
apoptosis leading to 50 % male infertility but otherwise no defective epithelial 
phenotype was observed. When combined with lack of YB-1, lack of ZONAB 
caused severe mid-to-late embryo development (E11.5) leading to lethality. 
The double YB-1 and ZONAB knockout phenotype was much more severe 
than the YB-1 knockout indicating that ZONAB interactions with other cold 
shock domain proteins are essential for embryo development.  In addition, 
nuclear translocation of ZONAB correlates with increased proliferation in the 
colonic epithelium of ethanol-fed mice and in adenomas of chronic alcoholics, 
suggesting a possible involvement in alcohol-induced gastrointestinal 
transformation [259].  
 
 
 
 
 
 
 
 
 
  1304.2     In vitro shRNA evaluation 
 
 
4.2.1    mu6pro & pHR’SIN hairpin expression vectors 
 
The targeting sequences for ZO-1 and ZONAB downregulation were kindly 
provided by Maria Balda and Karl Matter (Department of Cell Biology, 
Institute of Ophthalmology, UCL). They had previously tested their efficiency 
in downregulating ZO-1 or ZONAB synthetically in vitro by transfecting 
siRNAs against ZO-1 and ZONAB into MDCK cells (see section 2.2.5; Table 
1 for sequences). 
 
Oligonucleotides with the targeting sequences for each gene were 
subsequently cloned into the mU6pro hairpin expression vector downstream 
of the U6 polymerase III promoter and the integrity of the ZO-1 and ZONAB 
hairpin cassettes was established by enzyme digestion of the whole cassette, 
as described in section 3.2.1. The RNAi cassettes were further subcloned 
into the pHR’SIN backbone (see section 3.2.2). Prior to the production of 
recombinant lentiviruses using these two vector plasmids, we employed 
pHR’SIN.shGFP (see Chapter 3) as an RNAi non-targeting control for our 
experiments. Because of the interactions between ZO-1 and ZONAB in TJ 
regulation (see section 3.1), we also generated a lentiviral vector 
overexpressing ZONAB using an SFFV promoter (see section 2.5.2). This 
would allow us to assess the physiological effect of ZONAB upregulation on 
TJ regulation in contrast to downregulation of ZONAB. Thus, we produced 
four recombinant lentiviruses that we used to elucidate the ZO-1/ZONAB 
pathway: LNT.shZO-1, LNT.shZONAB, LNT.shGFP and LNT.ZONAB. The 
integrity of the RNAi cassettes in all the corresponding plasmids, 
pHR’SIN.shZO-1, pHR’SIN.shZONAB, pHR’SIN.shGFP and 
pHR’SIN.ZONAB, was confirmed by sequencing (MWG Biotech, UK, see 
Chapter 2.2.3). 
 
 
  1314.2.2    In vitro evaluation of lentiviral efficiency 
 
The four lentiviral vectors were produced using the same production protocol 
and were titre-matched for all subsequent in vitro and in vivo experiments. 
Initially, we wanted to confirm the silencing potential of LNT.shZO-1 and 
LNT.shZONAB (and lack thereof for LNT.shGFP) as well the overexpression 
levels of ZONAB after LNT.ZONAB transduction in different epithelial cell 
lines. A canine kidney cell line (MDCK) and a human breast epithelial cell line 
(MCF10A) were used for the testing of the lentiviral preparations as they form 
TJs in culture. A murine embryonic stem cell (ES) line was also used to test 
the efficiency of LNT.shZO-1 since it expresses ZO-1. LNT.shZO-1 silenced 
endogenous ZO-1 levels to undetectable levels by Western blotting in both 
MDCK and MCF10A cells as well as significantly reduced the endogenous 
levels in ES cells (Figure 4.2A) in comparison with that in LNT.shGFP 
transduced cells. The target sequences for both ZO-1 and ZONAB were 
selected from regions of the respective genes that are highly conserved 
between human, murine and canine orthologues. ZONAB was both 
overexpressed and downregulated in MDCK cells. After transduction with 
LNT.ZONAB, intracellular levels of ZONAB were considerably raised as 
visualised by Western blotting (Figure 4.2B), whereas transfection with 
LNT.shZONAB reduced endogenous expression to undetectable levels 
(Figure 4.2C). All western blot experiments were repeated twice. 
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Figure 4.2: Western blots of cell lines transduced with lentiviral vectors. Three cell 
lines were transduced with either the control LNT.shGFP or LNT.shZO-1 lentiviruses. ZO-1 
silencing was observed in all three cell lines in comparison to control (A). Overexpression of 
ZONAB after transduction of MDCK cells with LNT.ZONAB compared to LNT.GFP 
transduced cells (B). Silencing of ZONAB in MDCK cells after transduction with 
LNT.shZONAB (C). All transductions were done at MOI=20. α-tubulin was used as a loading 
control. MDCK: Madin-Darby canine kidney cells. MCF10A: human mammary epithelial cells. 
ES: murine embryonic stem cells. 
 
 
The levels of ZO-1 and ZONAB had been successfully reduced as indicated 
by Western blotting, but further experiments were needed to assess how 
their downregulation affected cellular morphology.  
 
 
 
  1334.2.3    Morphological impact of ZO-1 & ZONAB 
downregulation 
 
Since the tight junctions mediate cell-cell adhesion in epithelia, 
downregulation of junctional components should impede structural stability in 
monolayer formation (2-D culturing conditions) or cyst formation (3-D 
culturing conditions). In vitro experiments presented in this section were 
performed by Maria Balda and Karl Matter, Department of Cell Biology, IoO. 
 
Initially, MDCK cells were transduced with LNT.shZO-1 or LNT.shZONAB 
and their effect in 2-D cultures was assayed. Direct visualisation of ZO-1 
levels using immunocytochemistry on MDCK monolayers transduced with 
LNT.shZO-1 was carried out alongside cells transduced with LNT.shGFP as 
a control (Figure 4.3). In healthy confluent MDCK cells, ZO-1 was localised 
along the cellular membrane clearly indicating the intercellular contact points 
that form a tightly packed epithelial monolayer. In LNT.shZO-1 transduced 
MDCK cells the ZO-1 immunostaining of the cellular membranes was 
intermittent leading to the formation of a loosely packed monoloayer with a 
reduced cell density.  
 
 
 
Figure 4.3: ZO-1 immunocytochemistry on MDCK cells. ZO-1 immunofluorescence on 
confluent MDCK monolayers after transduction of LNT.shZO-1 and LNT.shGFP. A marked 
reduction in ZO-1 immunofluorescence was observed only following transduction with 
LNT.shZO-1. MOI=20. Magnification; x40. 
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on the 2D culturing platform because of inadequate immunostaining provided 
by the ZONAB antibody and also because of the low levels of ZONAB in 
MDCK cells. However, downregulation of ZONAB resulted in a marked 
decrease of MDCK cell proliferation in comparison to LNT.shGFP transduced 
cells (Figure 4.4). For quantification, 5,600 cells/cm
2 were plated in 24 well 
plates and after 2 days in culture BrdU was added for 2hrs. BrdU 
incorporation was assessed by counting 500 cells from 6 different areas 
using the same microscope objective (x20) and scoring for BrdU positive 
cells. The experiment was done in quadruplicates and the reduction in 
proliferation in LNT.shZONAB infected cells was found to be statistically 
highly significant using the student’s t-test (P<0.001, n=4). 
 
 
 
Figure 4.4: ZONAB regulates MDCK cell proliferation. Equal numbers of MDCK cells 
were transduced with LNT.shGFP or LNT.shZONAB and grown for 3 days. Phase-contrast 
images indicate a significant decrease in proliferation of MDCK cells transduced with 
LNT.shZONAB in comparison with LNT.shGFP transduced cells. MOI=20. Magnification: 
x10. 
 
 
To further assess the impact of ZO-1 or ZONAB downregulation in MDCK 
cells, we cultured transduced cell lines in a solid-phase Matrigel-collagen 
scaffold that allowed the MDCK cells to form cysts rather than monolayers. 
This approach enables the intercellular associations of MDCK cells to be 
assessed in a more relevant physiological environment than is possible when 
using two-dimensional culturing. This experiment also served as an 
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to the murine RPE in vivo.  
 
 
Figure 4.5: Manipulation of ZO-1 or ZONAB affects MDCK cyst formation in 3-D 
cultures. Matrigel-collagen solid culturing of MDCK cell lines 5 days following transduction 
with LNT.shGFP, LNT.ZONAB, LNT.shZONAB or LNT.shZO-1. Large field images (A, C, D, 
E, G) and larger magnifications of characteristic structures (B, F, H) were taken after 
immunolabelling with antibodies against β–catenin (red), phalloidin (green) and Hoescht 
33528 as nuclear counterstain (white). In MDCK cells transduced with LNT.shGFP normal 
cyst formation was observed. Irregular structures were found in MDCK cells transduced with 
LNT.shZO-1, LNT.shZONAB or LNT.ZONAB. They were categorised as spherical structures 
with no lumen (as in F), single lumen (as in B), multiple lumens (as in H) or other 
disorganised structure (as in C, D). For quantification of structures see figure 4.6. MOI=20. 
 
 
Healthy MDCK cells form single lumen cysts when cultured in solid-phase 
medium as depicted by combined immunostaining of β-catenin and phalloidin 
(Figure 4.5A,B). For this experiment, the vectors expressing the RNAi 
cassettes were used to transduce MDCK cells. After five days in culture, 
MDCK cells formed irregular structures that either lacked a lumen (Figure 
4.5F), had multiple irregular lumen (Figure 4.5H) or failed to form any kind of 
spherical structure (Figure 4.5D). For quantification, 10 pictures from different 
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independent experiments (Figure 4.6; see Chapter 2.3.8). Statistical analysis 
was performed for each observed structure type for each condition. After 
quantification of the observed structures in cells transduced with the RNAi-
expressing vectors as well as LNT.ZONAB, it is evident that manipulation of 
the ZO-1/ZONAB pathway greatly hinders polarity and intercellular 
organisation in epithelial cells. Furthermore, the similar distribution of cyst 
morphologies between LNT.ZONAB and LNT.shZO-1 transduced cells 
supports the proposed mechanism of ZO-1/ZONAB interactions in TJ-
regulated pathways for epithelial differentiation and proliferation, where 
raised intracellular concentration of one gene reduces the concentration of 
the other. Next we aimed to assess the impact of ZO-1/ZONAB manipulation 
in the murine RPE in vivo. 
 
 
 
Figure 4.6: Quantification of MDCK cyst morphology in 3-D cultures. Each type of cyst 
structure was counted from 10 different areas and the percentage occurrence was plotted. 
Apart from LNT.shGFP-transduced MDCK cysts, all other MDCK lines exhibited a reduced 
single lumen normal morphology and an increase in irregular structures with no spherical 
shape, multiple or absent lumen. For representative images of each structure see figure 4.5. 
Error bars show standard error of the mean. *P<0.05, n=10. 
  1374.3     ZO-1 & ZONAB silencing in the 
RPE in vivo 
 
 
4.3.1    Assessment of lentiviral transduction of the RPE 
 
We first aimed to titrate transduction levels in the RPE using serial dilutions 
of LNT.hrGFP. Wild-type (wt) mice (n=12) were subretinally injected and 
transgene expression within the treated area was analysed two weeks post 
injection (p.i.). Transduction of the entire RPE monolayer was observed 
following injection of a titre of 10
8 transducing units/ml (T.U./ml) (Fig. 4.7A, 
B). Injection of a titre of 10
7 T.U./ml resulted in discontinuous transduction of 
the RPE monolayer (Fig. 4.7C, D). At 10
6 T.U./ml, minimal RPE transduction 
was observed with expression of hrGFP by the occasional RPE cell (Fig. 
4.7E, F). No GFP expression was evident after injection of vector at a titre of 
10
5 T.U./ml. Even at the highest titre, GFP expression was only observed in 
RPE cells, supporting the specificity of the viral vector [122].  
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Figure 4.7: RPE transduction following subretinal delivery of LNT.hrGFP. Retinal 
cryosections were obtained from eyes 14 days after subretinal injection of LNT.hrGFP at 
titres of 10
8 T.U./ml (A, B), 10
7 T.U./ml (C, D) and 10
6 T.U./ml (E, F). Expression of GFP 
(green) was restricted to the RPE (left panel). Propidium iodide (red) was used as a nuclear 
counterstain (right panel, merged with GFP). White arrows, GFP-positive cells. GCL, 
ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform 
layer; ONL, outer nuclear layer; IS, inner segments; OS, outer segments; RPE, retinal 
pigment epithelium; Size bar, 20 μm. n=4 per treatment group. 
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lentiviral vectors expressing shRNAs (LNT.shZO-1, LNT.shZONAB and 
LNT.shGFP) at two titres. Since a pilot study using a high titre of 10
8 T.U./ml 
led to severe degeneration of the RPE and the neuroretina, a titre of 10
7 
T.U./ml was used in order to obtain discontinuous transduction of the RPE 
monolayer facilitating phenotypic characterisation. Where indicated, a titre of 
10
8 T.U./ml was also used in order to obtain transduction of the entire RPE 
monolayer and follow the progression of the phenotype observed using the 
10
7 T.U./ml titre. This approach enabled a more detailed analysis of the ZO-
1/ZONAB pathway and its impact on RPE homeostasis. 
 
 
4.3.2    ZO-1/ZONAB silencing and RPE proliferation 
 
We tested the ability of the lentiviral vectors to alter the levels of ZO-1 and 
ZONAB. Four eyes per virus group were injected subretinally in the superior 
and inferior hemispheres and the eyes were orientated prior to embedding. In 
this way, and due to the lack of a reporter gene, sections were taken at the 
centre of the injected hemispheres and close to the optic nerve head to 
ensure inclusion of the treated area. Ten sections from each treated 
hemisphere and for each of the four treated eyes were analysed per vector 
group. Following injection of the control LNT.shGFP virus in vivo, basal levels 
of ZONAB were observed in RPE cells (Fig. 4.8A). Increased levels of 
ZONAB were observed following subretinal injection of LNT.ZONAB (Fig. 
4.8C). Five days after subretinal injection of LNT.shZONAB, ZONAB 
immunostaining was abolished throughout the treated area (Fig. 4.8E), 
suggesting efficient silencing by the targeting vector. Following injection of 
the control LNT.shGFP virus, ZO-1 immunofluorescence in the RPE cells 
was observed at cell-cell junctions (Fig. 4.8B). No change in ZO-1 
immunostaining was observed after injection of LNT.ZONAB and 
LNT.shZONAB (Fig. 4.8B,D,F), whilst a marked reduction was observed 5 
days after subretinal injection of LNT.shZO-1 (Fig. 4.8H). Unexpectedly, 
increased expression of endogenous ZONAB expression was observed in 
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manipulation of ZONAB or ZO-1 levels in RPE cells in vivo can be obtained 
using HIV-1-based lentiviral vectors. 
 
 
 
Figure 4.8: Lentiviral-mediated silencing of ZO-1 and ZONAB. Retinal cryosections were 
obtained from eyes 5 days after the subretinal injections of LNT.shGFP (A,B), 
LNT.shZONAB  (C,D), LNT.ZONAB (E,F) or LNT.shZO-1 (G,H) at 10
7 T.U./ml. 
Immunostaining was performed using antibodies against ZONAB (left panel) and ZO-1 (right 
panel). Following injection of LNT.shGFP, ZONAB can only be detected at low levels in the 
RPE (A) and ZO-1 was observed in the RPE as well as along the outer limiting membrane 
(not shown) (B). Following subretinal injection of LNT.shZONAB, ZONAB was not detected 
within the transduced area (C) and no significant change in ZO-1 levels was observed (D). 
Subretinal injection of LNT.ZONAB resulted in an elevation of ZONAB levels in RPE cells (E) 
and did not affect ZO-1 levels (F). Subretinal injection of LNT.siZO-1 resulted in an increase 
in ZONAB expression (G) and a decrease of ZO-1 expression (H) compared with control 
eyes (B). Nuclei were counterstained with DAPI. White arrows, RPE monolayer. Size bar, 20 
μm. n=4 per treatment group. 
 
 
ZO-1/ZONAB signalling controls G1/S phase transition and differentiation of 
epithelial cells in culture [249,256]. We therefore analysed RPE differentiation 
by testing the expression of an RPE-specific marker, RPE65, five days after 
injection of LNT.shGFP, LNT.ZONAB or LNT.shZO-1 [13]. Four eyes per 
virus group were injected subretinally in the superior and inferior 
hemispheres and the eyes were orientated prior to embedding. In this way, 
and due to the lack of a reporter gene, sections were taken at the centre of 
the injected hemispheres and close to the optic nerve head to ensure 
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and for each of the four treated eyes were analysed per vector group. 
Immunostaining of RPE65 in the RPE following injection of LNT.shGFP, 
LNT.ZONAB or LNT.shZO-1 was not altered (Figure 4.9). However, 
downregulation of ZONAB following injection of LNT.shZONAB resulted in a 
reduction of RPE65 expression (Fig. 4.9C), suggesting that ZONAB 
downregulation results in a reduction of the cell density within the RPE 
monolayer.  
 
 
 
Figure 4.9: Manipulation of ZO-1 and ZONAB expression affects RPE65 expression 
and RPE proliferation. Retinal cryosections were obtained from eyes 5 days after the 
subretinal injections of LNT.shGFP (A,B), LNT.shZONAB (C,D), LNT.ZONAB (E,F) or 
LNT.shZO-1 (G,H) at 10
7 T.U./ml. BrdU was injected intraperitoneally following the subretinal 
vector administration. Immunostaining was performed using antibodies against RPE65 (left 
panel) and BrdU (right panel). In eyes injected with LNT.shGFP, high levels of RPE65 were 
evident in RPE cells (A) and there was no evidence of proliferation judged by the absence of 
BrdU staining (B). Depletion of ZONAB led to a significant reduction in RPE65 within the 
targeted area (C) and no BrdU positive cells could be found (D). Overexpression of ZONAB 
did not change RPE65 levels (E) but increased the number of BrdU positive cells, indicative 
of proliferation (F, white arrowhead. Inset shows x63 magnification). Delivery of LNT.shZO-1 
did not increase RPE65 expression (G) but increased BrdU positive cells suggesting RPE 
proliferation (H, white arrowhead). Nuclei were counterstained with DAPI. White arrows, RPE 
monolayer. Size bar, 20 μm. n=4 per treatment group. 
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phase progression. The postnatal RPE is not normally proliferative [260]. We 
therefore tested whether manipulation of ZONAB and ZO-1 expression in 
RPE in vivo affects cell cycle entry using BrdU incorporation. Whilst injection 
of control virus and downregulation of ZONAB following injection of 
LNT.shZONAB did not induce proliferation (Fig. 4.9B,D), proliferating cells 
were detected in eyes following injection of either LNT.ZONAB (Fig. 4.9F) or 
LNT.shZO-1 (Fig. 4.9H). We also quantified the number of BrdU-positive 
cells following injection of the lentiviral vectors (Fig. 4.10), confirming the 
induction of proliferation by downregulation of ZO-1 and overexpression of 
ZONAB. Thus, treatments that result in increased ZONAB activity also 
stimulate proliferation in RPE cells in vivo. 
 
 
 
Figure 4.10: Quantification of BrdU positive RPE cells. BrdU positive RPE cells and total 
RPE cell numbers were counted in the middle of the treated area of retinal cryosections 
obtained from subretinally injected mice 5 days after vector administration at a titre of 10
7 
T.U./ml. Following injection of LNT.shZO-1 or LNT.ZONAB BrdU positive cells increased to 
2.4 % and 2.0 % of total RPE cell number, respectively, whereas very few BrdU positive cells 
were identified in LNT.shGFP (0.05 %) or LNT.shZONAB (0.05 %) treated eyes. (*P<0.001 
compared with LNT.shGFP control. Student’s t-test. n=4 [20 measurements from 4 eyes per 
treatment group]). 
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As manipulation of ZONAB affects the expression of the RPE-specific 
marker, RPE65, and RPE proliferation, we next analysed changes in RPE 
morphology and retinal integrity after manipulation of ZONAB or ZO-1 
following injection of vectors at titres of 10
7 and 10
8 T.U./ml (Fig. 4.11). 
Semithin sections of treated eyes were analysed to determine morphological 
changes. Injection of control virus did not affect the morphology of the RPE 
and the neuroretina (Fig. 4.11A,E). There were, however, mild phenotypical 
changes following injection of the other vectors at 5 days p.i. (Fig. 4.9) and 
more pronounced phenotypes after 10 days such as a disrupted RPE 
monolayer and altered photoreceptor morphology. In LNT.shZONAB treated 
eyes, the RPE was considerably thinner than normal with evident cell loss 
and discontinuities in the monolayer (Fig. 4.11B,F; for quantification, see Fig. 
4.12). Photoreceptor outer segments appeared disorganised and with 
extracellular gaps. Accumulation of debris in the inter-retinal space indicated 
that the phagocytotic function of the RPE was compromised. This, along with 
reduced levels of RPE65 (Fig. 4.9) suggests loss of normal RPE function. In 
some areas, the presence of macrophage-like pigmented cells on the apical 
surface of the RPE suggested the disruption of the posterior BRB and 
possible leukocyte infiltration. Thus, downregulation of ZONAB appears to 
cause RPE dysfunction that leads to widespread degeneration of the retina. 
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Figure 4.11: Retinal morphology 10 days 
after subretinal injection of vectors. 
Retinal semithin sections were obtained after 
10 days of subretinal injection of LNT.shGFP 
(A,E), LNT.shZONAB (B,F), LNT.ZONAB 
(C,G) or LNT.shZO-1 (D,H) at 10
7 T.U./ml 
(left panel, x40 magnification) and 10
8 
T.U./ml (right panel, x20 magnification). 
Areas in red rectangles are shown in higher 
magnification. The LNT.shGFP treated eyes 
(A,E) exhibit normal retinal architecture 
showing that there are no adverse effects 
induced either by the lentiviral vector itself or 
by the expression of shRNA. In 
LNT.shZONAB treated eyes (B,F), a thinner 
RPE  monolayer as well as disorganisation of 
photoreceptor outer segment with 
intercellular vacuoles (asterisks) were found 
throughout the treated area. Following 
injection of either LNT. shZO-1 (C,G) or LNT. 
ZONAB (D,H) signs of RPE multilayerisation 
(black arrows) as well as retinal folding and 
rosette formation in areas corresponding to 
those with severe RPE abnormalities (white 
arrows) were observed. GCL, ganglion cell 
layer. IPL, inner plexiform layer. INL, inner 
nuclear layer. OPL, outer plexiform layer. 
ONL, outer nuclear layer. IS, inner segments. 
OS, outer segments. RPE, retinal pigment 
epithelium. CH, choroid. Size bar, 20 μm. 
n=4 per treatment group. 
 Injection of LNT.ZONAB (Fig. 4.11C,G) and LNT.shZO-1 (Fig. 4.11D,H) also 
strongly affected RPE morphology and the two vectors gave similar 
phenotypes (see figure 4.12 for quantification). Morphological changes were 
observed after delivery of either vector titre (Fig. 4.11C,D; 10
7 T.U./ml). 
However, following injection of vector at the higher titre of 10
8 T.U./ml, retinal 
foldings and rosette formations were evident. These alterations were 
particularly evident in the outer nuclear layer (ONL), which consists of 
photoreceptor nuclei. In some areas the RPE lost its monolayer structure and 
highly pigmented cells could be seen piling up and invading the inner 
photoreceptor matrix (IPM) (Fig. 4.11G,H). We observed three characteristic 
structural changes of the RPE monolayers, such as pyknosis, flattening and 
breaks. Pyknosis was identified as hyperpigmented RPE cells that do not 
adhere to the monolayer conformation. Figure 4.12 shows the quantification 
of such phenotypes. Downregulation of ZO-1 or overexpression of ZONAB 
induced predominantly pyknotic cells, whereas RPE flattening was observed 
by downregulation of ZONAB. RPE breaks occurred in all three treatment 
groups adjacent to either pyknotic or flat RPE areas. Thus, the levels of ZO-1 
and ZONAB expression are important determinants of RPE cell morphology 
and differentiation in vivo, indicating that the ZO-1/ZONAB pathway is critical 
for RPE cells to maintain their differentiated phenotype and to fulfil their 
support function for the neural retina. 
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Figure 4.12: RPE features after 10 days of subretinal injection of vectors at 10
8 T.U./ml. 
Three features were assessed: RPE pyknosis, RPE flattening and RPE breaks. Pyknotic 
RPE cells were defined as hyperpigmented cells that were not within a continuous 
monolayer. Percentage of retinal sections in which RPE pyknosis, flattening and breaks were 
observed is plotted. LNT.shZO-1 and LNT.ZONAB treated eyes contained many pyknotic 
RPE cells whereas RPE flattening was found consistently in LNT.shZONAB treated eyes. 
RPE breaks or cell loss occurred adjacent to either pyknotic or flat RPE areas of LNT.shZO-
1 and LNT.ZONAB or LNT.shZONAB treated eyes, respectively. (n=4, 20 measurements 
from 4 eyes per treatment group). 
 
 
We used transmission electron microscopy (TEM) to assess the 
ultrastructural changes of the RPE in more detail. Normal RPE consists of a 
monolayer of tightly packed cells that exhibit a highly polarised epithelial 
phenotype. They are separated from the choroid by Bruch’s membrane (BM) 
(Fig. 4.13A). Adjacent RPE cells are interconnected via a network of cell-cell 
intercellular junctions with tight junctions located towards the apical surface 
of the lateral membrane (Fig. 4.13A,B). The apical membranes of RPE cells 
are covered with finger-like microvilli that surround the photoreceptor outer 
segments. RPE cells with reduced expression of ZO-1 or increased 
expression of ZONAB were flatter and more elongated in comparison with 
the cuboidal architecture of normal RPE cells suggesting that they had lost 
polarisation (Fig. 4.13C, D). Basal infoldings were absent or highly 
disorganised and many cells did not adhere closely to the BM. Apical 
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multilayerisation were observed. The cells were often surrounded by cell 
debris or extracellular matrix components (Fig. 4.13C). Thus, downregulation 
of ZO-1 and overexpression of ZONAB in RPE cells in vivo appears to not 
only increase proliferation but also results in dedifferentiation. In contrast, 
RPE with reduced ZONAB expression retained some of the normal 
morphological characteristics of RPE cells but microvilli on the apical 
membrane and the basal infoldings appeared disorganised. Whereas only 
mature melanin vesicles could be observed in control eyes, different stages 
of melanin vesicle maturation were observed upon depletion of ZONAB 
expression (Fig. 4.13E). Microvilli, although reduced in number and size, 
were present and they surrounded the photoreceptor outer segments at the 
apical membrane (Fig. 4.13E). Even though the epithelial phenotype was 
often retained after ZONAB downregulation, these areas appeared thinner 
due to reduced  cell density.  Manipulation of ZO-1 or ZONAB expression 
thus affects RPE differentiation at the ultrastructural level. Moreover, 
downregulation of ZO-1 or overexpression of ZONAB promotes a 
mesenchymal-like phenotype similar to cases of epithelial-mesenchymal 
transition (EMT) [261-263].  
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Figure 4.13: Ultrastructure of the RPE after 10 days following subretinal injection of 
vectors at 10
8 T.U./ml. In LNT.shGFP treated eyes (A), the RPE monolayer lies on Bruch’s 
membrane, has apical microvilli towards the photoreceptor outer segments the cells are 
interconnected by tight junctions (A, black arrow. B, white arrows). In eyes either with 
depleted levels of ZO-1 (C) or overexpressing ZONAB (D), the RPE monolayer was highly 
disorganised with a marked loss of the epithelial monolayer characteristics, areas of RPE 
cells located on top of each other (see Figure 4.12: RPE pyknosis) and accumulation of 
extracellular debris was seen (C, asterisk). RPE cells appeared flattened and elongated with 
absent microvilli (black arrows), reduced basal infoldings, and mesenchymal-like 
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eyes injected with LNT.shZONAB (E), the RPE retained some of its epithelial characteristics, 
such as, microvilli present on the apical membrane and intracellular basal infoldings. 
However, melanin vesicle maturation was defective (asterisks). RPE cell size and the overall 
thickness of the monolayer were reduced (see Figure 6: RPE flattening). R, RPE cell nuclei. 
OS, photoreceptor outer segments. Mv, microvilli. BM, Bruch’s membrane. BI, basal 
infoldings. Ph, phagosome. Size bar, 1 μm (except in B, 200 nm) (n=4 per treatment group). 
 
 
During mesenchymal transition, epithelial cells start to express specific 
markers such as vimentin and glial fibrillary acidic protein (GFAP) [261,264]. 
We therefore analysed expression of these two markers by 
immunohistochemistry five days after injection. We did not observe vimentin 
or GFAP immunostaining in RPE from either LNT.shGFP or LNT.shZONAB 
injected eyes (Fig. X14A,B). Both markers were evident in the RPE following 
injection of either LNT.shZO-1 or LNT.ZONAB (Fig. 4.14C,D). Increased 
retinal GFAP staining of Müller cells was also observed in LNT.shZO-1, 
LNT.ZONAB and LNT.shZONAB injected eyes but not in the LNT.shGFP 
injected eyes, indicating increased levels of retinal stress caused by the RPE 
dysfunction (data not shown). 
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Figure 4.14: Vimentin and GFAP expression in the RPE 5 days following subretinal 
injection of vectors at 10
7 T.U./ml. Immunostaining on retinal cryosections obtained from 
treated eyes was performed using antibodies against vimentin and GFAP, two mesenchymal 
markers that are not expressed in the RPE. In LNT.shGFP (A) and in LNT.shZONAB (B) 
treated eyes no staining was observed, whereas vimentin and GFAP (white arrows) were 
upregulated in RPE cells following injection of LNT.ZONAB (C) and LNT.sh.ZO-1 (D). Onset 
of expression of these mesenchymal markers was different between transduced RPE cells 
with some cells exhibiting only faint co-expression (C, white arrowhead). The LNT.shZONAB 
Nomarski channel is shown to indicate how the RPE monolayer can be distinguished from 
the choroid (E). Split-channel image of a positive cell (F). Size bar, 20μm. For panels E and 
F a x40 magnification objective was used for imaging. n=4 per treatment group. 
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Cell-cell adhesion  is essential for the morphological integrity as well as the 
control of proliferation and differentiation of epithelial cells. Here, we 
demonstrate that alteration of the levels of the TJ components ZO-1 and 
ZONAB leads to changes in RPE cell proliferation, differentiation and 
function. Downregulation of ZO-1, or the overexpression of ZONAB, led to 
the induction of proliferation as well as altered morphology and expression of 
two epithelial-mesenchymal transition markers, vimentin and GFAP. These 
changes correlated with areas of RPE cell loss evident on fluorescein 
angiography. This study describes a novel approach to study the role of TJ 
proteins in RPE function in vivo and demonstrates that the ZO-1/ZONAB 
signalling pathway plays a critical role in RPE homeostasis.   
 
ZO-1 was the first TJ component to be identified [265]. It was shown to have 
a regulatory role in epithelial cell proliferation and gene expression in cells in 
culture [248] and its deficiency in mice causes an embryonic lethal phenotype 
associated with defected yolk sac angiogenesis and apoptosis of embryonic 
cells [266]. ZO-1 has multiple protein-protein interaction domains [267]. The 
SH3 domain is necessary and sufficient to regulate cell proliferation and 
interacts with the Y-box transcription factor ZONAB [249]. ZONAB was 
recently identified as a ZO-1–binding NACo protein that acts as a 
transcriptional activator of genes that regulate epithelial proliferation and 
differentiation. The cytoplasmic sequestration of ZONAB by ZO-1 regulates 
its nuclear localisation and, hence, its effect on gene expression. The ZO-
1/ZONAB pathway regulates cell cycle progression and epithelial 
morphogenesis in cells in culture [249,256]. In this study we have 
demonstrated that downregulation of ZO-1 induced RPE proliferation and 
dedifferentiation that eventually resulted in cell loss and retinal degeneration. 
Overexpression of ZONAB resulted in a very similar phenotype, suggesting 
that ZONAB activation is the main reason for the observed effects in 
response to depletion of ZO-1 expression in RPE cells. Downregulation of 
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transcriptional activity of ZONAB in epithelial cells in culture as ZO-1 
functions as an inhibitor of ZONAB [249,256]. In this study, reduced ZO-1 
expression in RPE cells using the same vector also resulted in an increase in 
ZONAB staining. A possible explanation for this might be that depletion of 
ZO-1 led to activation of ZONAB, which might in turn have caused a positive 
feedback loop on its expression as ZONAB is known to be upregulated 
during proliferation [249,259]. The similarities of the phenotypes observed 
following manipulation of ZO-1 or ZONAB levels together with their known 
biochemical and functional interactions suggest that ZO-1 and ZONAB exert 
their effects on the RPE by, at least in part, a common molecular pathway. 
This pathway is likely to involve transcriptional activation of ZONAB. 
However, it might involve alternative mechanisms. For example, ZONAB is a 
Y-box factor which are also known to participate in cytoplasmic processes 
such as mRNA translation [268]. Such a possibility is further supported by the 
strong cytoplasmic staining of ZONAB in RPE cells. In contrast, the complete 
absence of ZONAB immunostaining following injection of LNT.shZONAB at a 
titre of 10
7 T.U./ml could be explained by intercellular signalling along the 
RPE monolayer mediated by TJs. Silencing of ZONAB in transduced RPE 
cells could possibly trigger endogenous ZONAB inactivation through the ZO-
1/ZONAB pathway in adjacent untransduced cells that diminish the basal 
expression levels of ZONAB. 
  
Certain features of the induced phenotype are common to disorders of the 
human RPE. Increase in ZONAB activity and ZO-1 downregulation resulted 
in an RPE cell phenotype that resembled EMT. RPE cells not only started to 
express the mesenchymal markers vimentin and GFAP, their cuboidal 
morphology changed to a flattened structure lacking the clear morphological 
hallmarks of RPE cells such as clear cell junctions, apical microvilli and basal 
infoldings. Together with the induction of cell proliferation, EMT and co-
expression of glial markers like vimentin and GFAP are all features of 
proliferative vitreoretinopathy (PVR) [261], a condition of exaggerated peri-
retinal gliois induced by retinal detachment that is believed to be caused by 
proliferation and transdifferentiation of RPE cells. Furthermore, aberrant or 
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breakdown in diabetic retinopathy [262,269]. 
 
The molecular function of ZONAB in healthy RPE is currently not known. In 
this study we have observed that an increase in ZONAB activity results in 
increased RPE cell proliferation. As the postnatal RPE is no longer 
proliferative [270], the observed phenotype suggests that postnatal defects in 
RPE proliferation lead to RPE dysfunction. ZONAB activation has also 
previously been linked to the cellular stress response [251]. It is therefore 
possible that the phenotype we observed might also result from a cellular 
stress response in the RPE.  It will thus be interesting to test if Apg-2, which 
is responsible for ZONAB activation in response to heat shock, is also 
important for RPE homeostasis and, if so, what types of retinal stress 
conditions stimulate Apg-2 to activate ZONAB in the RPE. 
 
In this study, we demonstrated efficient lentiviral-mediated RNA interference 
and expression of junctional proteins in RPE cells in vivo that can be used to 
study the role of cell-cell adhesion-associated signalling mechanisms in a 
mature epithelial tissue. The induced phenotypes highlight the importance of 
ZONAB and ZO-1 in RPE homeostasis in vivo. However, additional 
characterisation of the expression profiles of dedifferentiated RPE cells are 
required to define the underlying molecular mechanism more clearly. Firstly, 
even though the reduction in ZO-1 and ZONAB protein levels was 
demonstrated using immunohistochemistry and, it would have also been 
useful to confirm gene suppression in mRNA levels by quantitative PCR. 
Although mRNA silencing can be suggested through the reduction in protein 
levels, it cannot be confirmed. In addition, comparison of mRNA and protein 
levels after suppression would provide a correlation between mRNA 
molecules and protein translation for the ZO-1/ZONAB pathway. In addition, 
we followed the phenotypes after subretinal delivery of vectors by tissue 
orientation and identification of phenotypical changes. The use of a reporter 
gene expression cassette would have made the process easier, but when 
designing the experiment this option was omitted as we have observed in 
vitro that high expression of reporter genes like eGFP can interfere with the 
   154junctional machinery Furthermore, since immunohistochemistry provides a 
semi-quantitative approach in demonstrating alterations in gene expression, 
RNA-based data should also be generated to confirm not only the extent of 
ZO-1 and ZONAB downregulaiton, but also overexpression of EMT markers 
like GFAP and vimentin. Future work will include laser capture 
microdissection (LCM) of RPE cells and subsequent analysis of EMT marker 
expression by RT-PCR. Further analysis of ZO-1 and ZONAB in human 
tissues derived from patients with different retinopathies will help to elucidate 
the functional contributions of this TJ-associated signalling pathway in retinal 
physiology and pathology. Finally, we demonstrated how shRNA-mediated 
silencing in a potent viral context provides a very efficient way to study 
complex mechanisms and disease processes by selectively downregulating 
key components of a pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   1555 AAV-mediated RNAi targeting 
of Prph2 
 
 
5.1     Introduction 
 
 
Peripherin-2 (Prph2, also known as peripherin-rds or rds) is an essential 
component of the photoreceptor outer segment (OS). It is required for 
morphogenesis of the OS discs that are produced everyday to replenish the 
OS tips that are being phagocytosed by the RPE. Mutations in PRPH2 
account for approximately 10 % of adRP cases. The aim of the work 
described in this chapter is to silence Prph2 using AAV-mediated RNAi and 
to establish a robust vector platform for the treatment of patients with gain of 
function mutations in PRPH2. 
 
 
5.1.1    Photoreceptor disc structure 
 
A unique property of the OS is the presence of an elaborate intracellular 
membrane system that holds the phototransduction proteins and provides the 
requisite lipid environment. The maintenance of normal physiological function 
requires that these post-mitotic cells retain the unique structure of the outer 
segment regions; stacks of membrane discs in the case of rods and a 
continuous infolding of membrane in the case of cones. As shedding of older 
membranous material occurs, new material is synthesised, transported, and 
incorporated into newly forming OS membranes thereby maintaining the 
segment at a constant length. These processes are collectively referred to as 
rod outer segment or cone outer segment renewal.  
 
Prph2 is localised in the periphery of OS rims which provide the structural 
substrate for the phototransduction cascade to take place. It is 32 kDa and 
   156346 amino acid long tetraspanin-family protein with four transmembrane 
segments and a large intradiscal (EC-2) domain between the third and fourth 
membrane-spanning segments [271,272]. There is an N-glycosylation site at 
asparagine on residue 230 and an O-glycosylation site at serine on 263 
(Figure 5.1). 
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Figure 5.1: Structure of Prph2.  Amino acid sequence of the human Prph2 protein. 
Insertions, deletions and amino acid changes involved in disease are annotated in colour. 
Murine Prph2 shares 92 % homology with its human orthologue (316 of 346 aa are 
identical). Glyc, glycosylation site. del, deletion. (Retina International Scientific Newsletter, 
http://www.retina-international.org)   
 
   158Prph2 forms homodimers through the formation of disulphide bonds. The 
polymerisation of Prph2 into higher order oligomers is essential for OS 
stability. For the formation of these oligomers in rods Prph2 associates with a 
homologous protein, rod outer segment protein 1 (ROM-1), with which it can 
form non-covalently bound tetramers [273]. The function of these hetero-
tetramers, as opposed to the essential Prph2 homo-tetramers, is not fully 
understood since absence of ROM-1 has an impact on rod OS ultrastructure 
but not on OS assembly [274]. It seems that ROM-1 is a non-essential 
accessory to rod OS morphogenesis catalysing Prph2 polymerisation. 
However, mutations in ROM-1 are known to cause digenic retinitis 
pigmentosa when occurring with Prph2 mutations as compound 
heterozygotes (see section 1.2.1).  
 
Another vital step in OS morphogenesis is membrane fusion that gives rise to 
the highly organised structure of OS. There are around one thousand discs 
per rod OS and their formation is facilitated by the vesicular flattening 
properties of Prph2 and the enhancing effect on membrane fusion that ROM-
1 has on the oligomer [275,276]. ROM-1 potentiates the fusogenic activity of 
the C-terminal domain (residues 311-325) of Prph2.  
 
Prph2 maintains the cohesion of the OS discs and its function is essential for 
photoreceptor cell viability. In the absence of Prph2, OS discs that are being 
phogocytosed by the RPE layer do not reform. This leads to the degeneration 
of both rods and cones, although the latter have been shown to compensate 
for lack of Prph2 by forming open membranous structures that do not align 
with the RPE [277]. In effect, a diminished matrix area for the 
phototransduction cascade to take place causes photoreceptor cell 
dysfunction and death. Most of the information on the function of Prph2 and 
its essential role on photoreceptor viability has been acquired by studying the 
Prph2
Rd2/Rd2  or  rds (retinal degeneration slow) mouse model, a naturally 
occurring model in which a 9.2 kb viral insertion in exon 2 of the gene 
abolishes its expression [278]. Recessive in nature, the null mutation of the 
rds mouse causes absence of OS, hence phototransduction events per 
photoreceptor cell are greatly reduced [271]. This process finally leads to 
   159photoreceptor death probably through a programmed cell death pathway that 
is not clearly understood [279]. After two months of age, the rds mouse loses 
around 50 % of the photoreceptors. 
 
 
5.1.2    Peripherin-2 dominant mutations and disease 
 
Patients with missense PRPH2 mutations develop adRP with late-onset 
retinal degeneration and signs of night blindness and tunnel vision by 50 
years of age [19]. After screening 200 families and 2000 individuals, 67 
mutations in PRPH2 have been identified to date which constitute 8-9 % of 
adRP in patients [280,281] (Figure 5.1). PRPH2 adRP can be monogenic in 
nature or digenic in conjunction with ROM-1 mutations. In its digenic form, 
adRP rises from the failure of PRPH2  and ROM-1 to form hetero-tetramers 
and stabilise the oligomeric transmembrane protein complex that anchors rod 
OS [282]. Classical RP symptoms like diminished scotopic vision with 
delayed cone involvement are observed in the patients but sustained visual 
acuity and visual fields persist through middle age [283]. 
 
In order to study the disease processes underlying dominantly inherited 
Prph2 mutations, animal models engineered to express these mutations have 
been produced. Dominant gain-of-function mutations in Prph2 cause slower 
degeneration in mouse and Xenopus models [284,285] with the exception of 
the Δ307 (deletion at codon 307) mutation that causes faster photoreceptor 
degeneration than the rds null mutation [286]. The P216L mutation is an 
amino-acid changing point mutation that affects the stability of the protein 
tetramers. P216L Prph2 is delivered to the OS where its accumulation has a 
dominant negative effect on OS formation (similar to the effect of the Δ307 
mutation). Once in the OS, the mutated Prph2 affects OS structure by either 
competing with the wild-type (wt) protein (C150S, L185P), or by incorporating 
and destabilising the structure (P216L) [285]. Other malformed proteins (e.g. 
C214S) fail to pass an inner segment checkpoint before OS incorporation. 
The different levels of severity in retinal degeneration observed in these 
   160models reflect the phenotypical heterogeneity of Prph2 gain-of-function 
mutations in patients This indicates their relevance in studying Prph2-
associated dominant retinopathies. 
 
 
5.2     In vitro siRNA evaluation 
 
When undertaking RNAi experiments it is essential to select an siRNA target 
area that provides a high level of mRNA silencing and although most 
sequences will provide a certain degree of silencing, their efficiency may vary 
considerably [173,180,233,234,287]. A number of criteria for target selection 
been proposed (see section 1.5.2) and web-based siRNA design 
programmes take these into account when designing siRNAs. However, the 
only way to ensure selection of efficient molecules is to test the selected 
siRNAs in an in vitro cell-based platform that allows mRNA and/or protein 
level measurements.  
 
 
5.2.1    Stable cell line generation & siRNA silencing 
 
Human embryonic kidney fibroblasts (293T) were used to generate a cell line 
that stably expresses the murine Prph2 cDNA. The Prph2 cDNA was cloned 
into a lentiviral HIV-1 based backbone driven by an SFFV promoter (see 
section 2.5.2) and recombinant vectors were prepared. In order to ensure 
that there was only one integrated Prph2 expression cassette, 293T cells 
were transduced at a limiting MOI (i.e. <1) and allowed to grow for a few 
days. In order to create a homogenous Prph2-expressing 293T cell line, 
clonal populations of positive cells were propagated from single cells. 
Although separation of cells expressing a target gene from untransduced 
cells is easily done using antibody staining and flow cytometry, in the case of 
Prph2 this was not possible. The only antibodies available for Prph2 are 
raised against the C-terminus of the protein. Prph2 is a membrane-bound 
   161protein and the C-terminus is cytoplasmic. Therefore, flow cytometric 
separation of viable Prph2-expressing cells was impossible. In order to 
overcome this limitation, the transduced 293T cells were plated in a 96-well 
plate at limiting dilutions and the single cells were propagated. A few cell 
clones were collected and total protein was extracted. The levels of 
endogenous Prph2 were assessed using Western blotting and the clonal 
populations of interest (293T/RDS
+) were selected and propagated further 
(Figure 5.2A). We selected a cell clone that expressed Prph2 at intermediate 
levels (Clone #8) for two reasons. Firstly, low Prph2 levels would not enable 
thorough silencing titration of selected siRNAs.  Different siRNAs with varying 
efficiency could reduce the levels below detection leading to false 
conclusions about their potency. Secondly, too high levels of Prph2 affect 
293T viability as it is an exogenous protein not naturally present in human 
embryonic kidney fibroblasts and its association with cell membranes affects 
culturing efficiency and cell confluency. 
 
Three siRNA sequences targeting Prph2 and a non-targeting control were 
selected using an online siRNA design application and named siRDS4, 
siRDS5, siRDS6 and siCON, respectively (see section 2.2.5; Table 1). Each 
of the three siRNAs target different areas of the murine Prph2 mRNA. More 
specifically, all three target murine Prph2 within the open reading frame with 
siRDS4 binding at nucleotide positions 674-692, siRDS5 at 365-384 and 
siRDS6 at 906-925. None of the three selected sequences share 100 % 
homology with the human orthologue. Murine and human Prph2 genes share 
81 % homology and no target areas that have 100 % complementarity with 
both genes while fulfulling the sequence design parameters could be found. 
For future applications in patients with dominant Prph2 mutations, new 
siRNAs specifically targeting the human gene would have to be designed. 
The siCON target sequence was scanned for homology with murine and 
human genome databases using the BLAST alignment algorithm 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and no positive hits were returned. 
However, the siCON molecule was not assessed in vitro to investigate 
whether it incorporates into RISC or whether it elicits any innate immune 
responses via the TLR3 pathway. The siRNAs were used to transfect the 
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+ cell line at a concentration of 20 μM. Duplicate samples for each 
siRNA transfection were collected and total protein lysates were analysed 
using Western blotting for Prph2 (Figure 5.2B). Of the three siRNAs, only 
siRDS6 transfection resulted in significant silencing of Prph2 at the protein 
level. Although the experiment should have been repeated to correct for the 
ambiguity observed in siRDS6 duplicate transfections, it was not repeated 
and the siRDS6 was selected as the target sequence of choice for the 
subsequent vector-based experiments. 
 
 
 
Figure 5.2: Generation of stable Prph2-expressing cell line and siRNA knockdown. (A) 
Western blot for Prph2 on 10 different clonal populations propagated from single 293T cells 
transduced with the LNT.RDS virus. Clones 2, 3, 4, 5, 8 and 10 expressed Prph2. Clone #8 
expressed Prph2 at approximately 5-fold β-actin levels and was selected for subsequent 
experiments. (B) Three siRNAs targeting Prph2 at different regions (siRDS4,5,6) and a non-
targeting control (siCON) were transfected into 293T/RDS
+ #8 at 20 μM. Only siRDS6 
conferred significant silencing. 
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experiments we constructed an additional Prph2-expressing 293T cell line 
that expressed an altered Prph2 cDNA mutated at the target area of siRDS6. 
This was done in order to be able to test evasion of silencing by siRDS6 
using the degeneracy of the code. The rationale lies in the “suppression-and-
replacement” concept (see section 1.5.2) where an altered cDNA could be 
used for gene supplementation to counter effects of haploinsufficiency 
following downregulation of the mutated allele.  
 
We mutated the cDNA of Prph2 at the target area of siRDS6 (Figure 5.3). We 
selected the first three codons (9 nucleotides) in the targeted area for our 
mutation strategy for two reasons. Firstly, they included the “seed area” of 
the siRNA and their mismatch would not allow for siRNA:mRNA duplex 
formation. Secondly, they were in the centre of the siRNA target area which 
is essential for mRNA cleavage impeding its function, if the siRNA manages 
to attach itself to the mRNA “seed area”. 
 
 
 
Figure 5.3: Nucleotide alterations between wtRDS and 
mutRDS. Site-directed PCR mutagenesis in mutRDS to alter 
nucleotides within the region targeted by siRDS6. Three 
nucleotides (in red) were altered (at 907-917 bp of Prph2 ) 
using the degeneracy of the genetic code to retain codon 
characteristics. Both nineplets encode for Tyrosine–Serine–
Tyrosine (amino acids 234-236, see Figure 5.1). The relative 
abundances of tRNAs for each codon in mice are indicated. 
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new altered Prph2 cDNA was named mutRDS (see section 2.2.6). The 
mutRDS cDNA was used to construct a stable expressing cell line 
(293T/mutRDS
+) in the same way as for 293T/RDS
+ (see section 2.5.2). Both 
cell lines expressed either the wtRDS or mutRDS cDNA from a single 
integrated copy of an SFFV-based expression cassette. The 293T/mutRDS
+ 
cell line was used later in order to test whether it could evade the silencing 
effect of the Prph2-targeting hairpin (see section 5.3). 
 
 
5.2.2    shRDS expression vector 
 
The siRDS6 sequence was cloned downstream of the U6 promoter using the 
mu6pro vector and the resulting plasmid was named mu6.shRDS6. Correct 
processing of the shRNA and levels of expression were assessed by plasmid 
transfection into the 293T/RDS
+ cell line (see section 2.3.5 for transfection 
method). Significant Prph2 silencing was observed and with increasing 
efficiency that correlated with the increase in the amount of mu6.shRDS6 
(Figure 5.4). A drawback of this experiment is the lack of RNA suppression 
data to couple the gradual decrease in protein levels following transfection of 
increasing amounts of mu6.shRDS6. Although the experiment should have 
been repeated to obtain a western blot of higher quality, it was not repeated 
and the mu6.shRDS6 plasmid was used to sub-clone the shRDS6 cassette 
for the subsequent vector-based experiments. 
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Figure 5.4: Silencing of Prph2 after transfection of hairpin expression cassettes. The 
stable cell line 293T/RDS
+ was transfected with 0.5 μg or 1 μg of mu6.shRDS6 or 1 μg of 
mu6.shCON. No silencing of Prph2 was observed after shCON hairpin expression, whereas 
a dose-dependent silencing was observed after transfecting 0.5 μg and 1 μg of 
mu6.shRDS6, respectively. β-actin levels are displayed as a loading control. — = 
untransfected. 
 
 
Next, we wanted to address the issue of alternative hairpin design using a 
miRNA template and whether it would increase the efficiency of the 
knockdown provided by the shRDS6 hairpin. Therefore, the miR-30 template 
(see section 1.5.2) was used to construct another hairpin targeting Prph2. 
The resulting hairpin retains the same target area as in shRDS6 and was 
named miRDS6 (see section 2.2.5; Table 1 for sequence). The same 
rationale was used to adapt the shCON sequence and the resulting hairpin 
was named miRCON. 
 
The shRDS6, miRDS6 and miRCON hairpin expression cassettes were 
cloned into the pD10.RFP.poly backbone (as in section 5.2.3) and the 
plasmids were named pD10.RFP.shRDS6, pD10.RFP.miRDS6 and 
pD10.RFP.miRCON, respectively. 
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Although the silencing capacity of the selected siRDS6 sequence was tested 
in vitro synthetically, the hairpin expression levels of the pD10.RFP.shRDS6 
and pD10.RFP.miRDS6 plasmids had to be tested prior to the production of 
rAAV because of the plasmid backbone’s viral nature. We had already 
determined that the pD10 AAV backbone is prone to intramolecular 
recombinations because of the presence of ITRs, jeopardising the function of 
the expression cassettes as well as the ability of the plasmid to generate 
rAAV particles. 
 
All the pD10-based constructs also contained an RFP expression cassette 
that could be used to correct for variability in transfection efficiency. Hence, 
after transfection of pD10.RFP.shRDS6, pD10.RFP.miRDS6 and 
pD10.RFP.miRCON into 293T/RDS
+ or 293T/mutRDS
+, the RFP
+ cells 
(Figure 5.5) were selected for using FACS flow cytometry. The representative 
plots for the 293T/RDS+ cell line are presented in Figure 5.6. The 
transfections were performed in quadruplicates (n=4) for each plasmid but 
were not repeated. 
 
 
Figure 5.5: Indicative image of 
293T/RDS
+ cells expressing 
RFP. Twenty-four hours after 
transfection of 50,000 cells with 
1 μg of pD10.RFP.miRCON, cell 
populations were assessed for 
RFP expression to confirm 
transfection efficiency. RFP 
expression is driven by a CBA 
promoter. 
 
 
 
 
   167When sorting for cells, it is important to adjust the collection gate so that only 
viable cells are retrieved from the total sample population. This preset is 
important especially if further analysis on the sorted population is to be 
carried out (e.g. DNA/RNA/protein extractions). In our experiments, a 
negative control of untransfected 293T/RDS
+ cells was used to determine 
both the gate for RFP detection as well as cell viability based on forward and 
side scatter characteristics (Figure 5.6; top panel). The middle panel 
indicates the total transfection efficiency of each sample according to the 
selected gate. Although in theory the sorter is able to select a near 100% 
pure population positive for the marker of interest, in reality the end 
population purity may vary. For this reason, it is sensible to re-count a 
fraction of the sorted cells to get an estimate of the sorting efficiency. The 
bottom panel in figure 5.6 indicates the end purity of each sample which can 
be used for post-analysis adjustments in order to correct for the dilution effect 
of the untransfected cells. 
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Figure 5.6: FACS plots of RFP
+ 293T/RDS
+ cells after transfection of RNAi cassettes. 
Untransfected 293T cells were used as a negative control to set the gate for the collection of 
healthy cells based on forward and side scatter characteristics. Representative transfection 
efficiency plots for each of the plasmids (miRCON, miRDS6 and shRDS6) are indicated 
together with the population purity plots after cell sorting for RFP
+ cells (72.7 %, 74.4 % and 
71.9 %, respectively). For each sample 10,000 live events were counted.  
 
 
The purified RFP+ cell populations were used to extract total RNA and 
generate total cDNA for real-time relative quantification (see section 2.6). 
Real-time PCR was performed on the cDNA samples using probe-based 
assays to trace the expression levels of Prph2 and β-actin as a loading 
control (Figure 5.7). 
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Figure 5.7: Silencing of Prph2 in vitro after transfection of RNAi cassettes. Relative 
expression of wtRDS and mutRDS in 293T/RDS
+ and 293T/mutRDS
+ cells, respectively 
(adjusted to β–actin levels) after transfection of pD10-based plasmids expressing miRCON, 
shRDS6 and miRDS6 hairpin cassettes. No silencing was observed for mutRDS in any of 
the transfections whereas wtRDS was only silenced by shRDS6 and miRDS6 constructs at 
46 % and 83 % of the untransfected levels, respectively. All sample values were corrected 
for sorting efficiency. *P<0.05. **P<0.001 (Student’s t-test; n=4, where 4 is the number of 
transfections performed per plasmid type). 
 
 
The relative expression levels of the wild-type and mutated Prph2 in 
comparison to the endogenous β-actin levels were measured for each 
sample. An untransfected sample for both tested cell lines was used to set 
the 100 % mark for the Prph2/β-actin ratio. After transfection of 
pD10.RFP.miRCON, no silencing of either wtRDS or mutRDS was observed 
as expected since the target sequence of this hairpin does not bind any 
murine mRNA sequences. Neither the shRDS6 or miRDS6 RNAi cassettes 
silenced the mutRDS cDNA indicating that the 3 inserted point mutations in 
the seed area of the target region abolished any siRNA:mRNA interactions. 
The wtRDS levels were reduced in both plasmid transfections. The shRDS6 
cassette silenced Prph2 at 46 % of the untransfected endogenous levels, 
whereas the miRDS6 cassette delivered a silencing of 83 % – an almost 2-
fold increase in comparison with the shRDS6-mediated silencing. 
   170The quantification of relative silencing suggested that hairpin design might 
have an impact on the final silencing capacity presumably because of the 
efficiency of hairpin processing. The shRDS6 and miRDS6 hairpin share 
exactly the same targeting sequence and differ only in the design of the 
hairpin loop, 5’ and 3’ flanking sequences. However, the alteration in design 
was able to increase the silencing potential of the same target area by 
approximately 90 %. Moreover, the control non-targeting miRCON hairpin did 
not exert any silencing on Prph2 and the levels were comparable to the 
untransfected control. Finally, the potency of the RNAi cassettes indicated 
the integrity of the bicistronic system (RFP & RNAi) in the pD10-based 
plasmids suggesting that no recombination effects had taken place within the 
vector backbone and allowed their subsequent use in the preparation of 
rAAV for in vivo administration.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   1715.4  Efficiency of AAV-mediated silencing 
of Prph2 in vivo 
 
 
After ensuring the integrity of the AAV vector plasmids that encode the RNAi 
cassettes, rAAV preparations were produced for each of the three RNAi 
expression vectors (pD10.RFP.shRDS6/miRDS6/miRCON). The provirus 
structure that would persist episomally in the transduced retinal cells after 
viral transduction is depicted in Figure 5.8. 
 
 
 
Figure 5.8: Schematic diagram of AAV vectors. Vector expressing a hairpin cassette 
targeting  Prph2 through an RNA polymerase III U6 promoter. Downstream of the RNAi 
cassette there is a chicken β–actin promoter (CBA) driving the expression of red fluorescent 
protein (RFP). ITR; inverted tandem repeats. 
 
 
Although rAAV2/2 is the most widely used serotype to date in photoreceptor 
transduction studies, we considered employing rAAV2/8 due to the 
advantages it confers with regard to transgene expression levels [93,99]. 
Apart from the fact that the use of such a potent vector would reduce the 
timeframe for our experiments, it may be useful for treating mouse models 
with rapid degenerations. 
 
After producing rAAV2/8 preparations for each of the RNAi cassettes, the 
titre of each preparation was determined so that equivalent numbers of viral 
particles could be administered.  
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Figure 5.9: Autoradiogram of a dot-blot. The serial dilution of a plasmid DNA 
of known concentration served as a standard ladder. 1 µl and 5 µl of the virus 
suspension were loaded and the concentration was estimated by comparing the 
sample to the dilution series. In this case, it was estimated that the virus 
suspension had a concentration of 2x10
11 particles/ml. 
 
 
We delivered 2 μl of each of each vector subretinally at a concentration of 
2x10
11 v.g./ml (i.e. 4x10
8 v.g. in 2 μl) into wt young adult mice (n=4 per 
constuct) (Figure 5.9). 
 
At three weeks p.i., treated retinae (n=4 per treatment group) were dissected 
out and cells dissociated by treating with trypsin. RFP
+ photoreceptors were 
selected from each retina after FACS sorting and the collected transduced 
photoreceptors were lysed in a manner appropriate for nucleic acid 
extraction. After total RNA extraction and cDNA generation, real-time PCR 
was performed on the samples to assess the endogenous Prph2 levels in 
comparison with endogenous β-actin levels. The relative Prph2 levels in the 
AAV2/8.RFP.miRCON control were set as 100 % against which the levels of 
Prph2 from the cells transduced with the two targeting AAV2/8 viruses were 
compared (Figure 5.10). AAV2/8.RFP.shRDS6 transduced photoreceptors 
exhibited a 19.6 % silencing of Prph2 in vivo – considerably lower than the 
equivalent silencing levels in the in vitro platform. The AAV2/8.RFP.miRDS6 
   173virus showed a robust silencing of 82.6 % that not only surpassed the degree 
of silencing achieved by the shRDS6 cassette but also correlated with the in 
vitro silencing efficacy. Although the differences between the in vitro and in 
vivo sets of data could be explained by the difference in the host cell 
(immortalised human embryonic kidney fibroblasts versus murine 
photoreceptors) or the Prph2 expression levels, they could also be explained 
by the difference in the RNAi design. The fact that the miRDS6 virus resulted 
in consistent and robust Prph2 silencing might be explained by the nuclear 
processing advantage over the shRDS6 design based on “miRNA mimetics”. 
 
 
 
Figure 5.10: Silencing of Prph2 in vivo following subretinal injections of AAV2/8-RFP-
RNAi viruses. For each treatment group, RFP
+ photoreceptors were collected by FACS 
sorting from dissociated retinae and Prph2 expression levels were measured (adjusted to β–
actin levels). In comparison to AAV2/8.RFP.miRCON injected eyes, Prph2 levels were 
silenced 19.6 % and 82.6 % in eyes injected with AAV2/8.RFP.shRDS6 and 
AAV2/8.RFP.miRDS6, respectively. *P<0.001 (Student’s t-test; n=4). 
 
 
The morphological impact of Prph2 knockdown in the retina and the 
downstream impact on photoreceptor survival was assessed using 
   174immunohistological and ultrastructural analysis at 3 and 5 weeks p.i., 
respectively. 
 
 
 
Figure 5.11: Fluorescent fundoscopy imaging of an AAV2/8.RFP.miRCON injected eye 
3 weeks p.i. A single 2 μl subretinal injection was performed in the superior hemisphere. 
AAV2/8 viruses transduce photoreceptor and RPE cells. The RFP fluorescence in the fundus 
indicates strong expression of the provirus in transduced cells within the treated area. 
Representative picture shown for all titre-matched injected eyes. ONH, optic nerved head. 
RFP, red fluorescent protein. 
 
 
Prior to the collection of treated eyes (n=4 per treatment group) for 
histological analysis, fluorescent fundoscopy was performed to image RFP 
expression  in vivo. All treated eyes exhibited high levels of retinal RFP 
expression that correlated with the injected hemisphere. A representative 
fundus picture is shown in Figure 5.11. After collection, the eyes were 
carefully orientated in a way that the injection area would be included in 
sections taken around the optic nerve head. Immunohistochemistry for Prph2 
was performed on cryosections taken from each eye and they were 
examined using confocal microscopy (Figure 5.12). At 3 weeks p.i. eyes 
   175treated with the control AAV2/8.RFP.miRCON virus exhibited strong Prph2 
staining within the treated area and in RFP
+ photoreceptors that correlated 
with the natural levels found in unprocedured animals indicating that no 
silencing of Prph2 occurred in the transduced photoreceptors. 
AAV2/8.RFP.shRDS6 administration resulted in some decrease in Prph2 
staining within the treated area that still allowed the maintenance of the outer 
segment layer. AAV2/8.RFP.miRDS6 treated eyes, in contrast, exhibited 
robust Prph2 silencing that resulted in extensive decrease in Prph2 staining 
as well as extensive thinning of the outer segment layer within treated areas. 
Furthermore, it was also evident that the knockdown in Prph2 expression had 
an impact on photoreceptor survival as the thickness of the ONL was slightly 
reduced. In order to quantify the photoreceptor loss and visualise the outer 
segment disorganisation, a second set of eyes was prepared for semithin 
sectioning 5 weeks p.i.  
 
 
 
 
 
 
 
   176 
Figure 5.12: Immunohistological analysis of Prph2 silencing in vivo 3 weeks p.i. (A) 
Each treated eye received a single 2 μl subretinal injection in the superior hemisphere that 
led to very high transduction levels of the ONL within the treated area. (B) In the 
AAV2/8.RFP.miRCON treated eyes strong Prph2 straining was observed throughout the 
treated area confirming that the control RNAi cassette does not lead to Prph2 silencing. (C) 
In the AAV2/8.RFP.shRDS6 treated eyes some Prph2 silencing was observed leading to 
vacuole formation within a loosely-packed outer segment layer. (D) In the 
AAV2/8.RFP.miRDS6 treated eyes low levels of Prph2 immunoreactivity were detected 
within the treated area confirming the levels of silencing observed in figure 5.10. Size bar, 20 
μm (except in A; 10 μm). INL, inner nuclear layer. ONL, outer nuclear layer. IS/OS, inner 
segments/outer segments. RPE, retinal pigment epithelium. n=4 eyes per treatment group. 
 
 
Low (x20) and high (x40) magnification pictures of representative areas from 
semithin sections are depicted in Figure 5.13 together with their 
   177corresponding electron micrographs. The retinal architecture in control 
AAV2/8.RFP.miRCON injected eyes was normal with well organised outer 
segments and unaffected ONL. In AAV2/8.RFP.shRDS6 treated mice, 
although the ONL thickness appeared equal to that in the control, the outer 
segment layer was highly disorganised and reduced in size. Note the 
fragmented stacks of discs that piled up in the IPM indicating inefficient outer 
segment regeneration. The reason for outer segment disorganisation lies 
presumably in the reduced rate of Prph2 assembly at the connecting cilium 
where normally tightly packed stacks of discs are added to compensate for 
those lost by RPE phagocytosis. In AAV2/8.RFP.miRDS6 treated eyes the 
outer segment layer was almost absent with certain areas presenting a thin 
layer of highly disorganised discs. Such a dramatic loss of outer segments 
was expected in light of the highly reduced Prph2 immunostaining 3 weeks 
p.i. In addition, the impact of Prph2 loss on photoreceptor survival was 
evident by the thinning of the ONL which appeared dramatically reduced in 
comparison to control eyes. Quantitative measurements of photoreceptor cell 
numbers from 32 sections (n=4) for each treatment group are presented in 
Figure 5.14. From these measurements, it is evident that the loss in Prph2 
caused rapid photoreceptor degeneration within 5 weeks of treatment in the 
AAV2/8.RFP.miRDS6 injected eyes leading to a reduction of photoreceptor 
nuclei to 54 % of the number found in the AAV2/8.RFP.miRCON treated 
eyes. The rate of Prph2 silencing by the shRDS6 RNAi cassette did hinder 
outer segment organisation but was not potent enough to reduce intracellular 
levels to such an extent that would trigger extensive photoreceptor cell death 
(95 % of AAV2/8.RFP.miRCON numbers).  
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Figure 5.13: Morphological and ultrastructural analysis of Prph2 silencing in vivo 5 
weeks p.i. Semithin (left panel) and EM (right panel) pictures of AAV2/8.RFP.miRCON 
(A,B,C), AAV2/8.RFP.shRDS6 (D,E,F) and AAV2/8.RFP.miRDS6 (G,H,I) injected eyes. (C) 
AAV2/8.RFP.miRCON treated eyes showed normal retinal ultrastructure with healthy outer 
segment morphology. (F) AAV2/8.RFP.shRDS6 treated eyes showed highly fragmented 
outer segments throughout the treated area that accumulated in the IPM. (I) 
AAV2/8.RFP.miRDS6 treated eyes had lost most of the outer segment layer with highly 
disorganised disc structures accumulating between the inner segments and the RPE. OS, 
outer segments. Mv, microvilli. RPE, retinal pigment epithelium. Size bar, 20 μm (semithin 
panel), 2 μm (ultrathin panel). INL, inner nuclear layer. ONL, outer nuclear layer. IS, inner 
segments. OS, outer segments. RPE, retinal pigment epithelium. n=4 eyes per treatment 
group. 
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Figure 5.14: Photoreceptor nuclei quantification in AAV.RFP.RNAi treated eyes 5 
weeks p.i. The photoreceptor nuclei from pictures of semithin sections for each treated eye 
were counted and plotted. There was no significant difference between the number of nuclei 
in uninjected and AAV2/8.RFP.miRCON injected eyes. However, a significant reduction in 
photoreceptor nuclei numbers was observed for both AAV2/8.RFP.shRDS6 and 
AAV2/8.RFP.miRDS6 treated eyes showing a 5 % and 46 % reduction in numbers, 
respectively, in comparison to AAV2/8.RFP.miRCON injected eyes. Nuclei counts from 32 
pictures of semithin sections taken around the optic nerve head for each treatment group. 
*P<0.05. **P<0.001 (Student’s t-test; n=4 per treatment group). 
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In this study, the direct comparison of the shRDS6 and miRDS6 hairpins 
enables us to assess how the difference in RNAi design can affect the 
silencing of the same targeting sequence in vitro and in vivo. The standard 6 
nt loop-design of shRDS6 silenced endogenous Prph2 levels by 46 % in vitro 
and 20 % in vivo. The miR30-adapted miRDS6, however, silenced 
endogenous Prph2 levels by 83 % in vitro and in vivo. Whereas shRDS6 lost 
half of its potency across experimental platforms, miRDS6 was highly 
consistent in silencing Prph2. Of course, the difference in shRDS6 
downregulation could be accounted for by the difference in initial Prph2 
expression levels that differ between the stable-expressing cell line used in 
the in vitro experiments from the endogenous levels in a wt murine retina. 
However, both design strategies were tested and the miR-based strategy 
appears to consistently and efficiently silence Prph2 in both in vitro and in 
vivo experimental platforms. 
 
Not only was miRDS6-mediated silencing consistent between in vitro and in 
vivo sets of data, it also delivered a significant morphological effect in the 
treated retinae in comparison to shRDS6. Silencing of Prph2 did not only 
occur at the mRNA level but also at the protein level as demonstrated by a 
reduction in Prph2 immunohistochemistry levels and reduced numbers of 
photoreceptorss caused by lack of Prph2 after 5 weeks of treatment. The use 
of rAAV2/8 provided high levels of hairpin expression and led to a 46 % 
reduction in photoreceptor cell numbers. Such a reduction in photoreceptor 
cell numbers is bound to have an impact on visual function, however it would 
have been useful to quantify the visual loss using ERGs. Although previous 
studies in animal models have demonstrated knockdown of mutations in 
photoreceptor-specific genes, this is the first study to demonstrate a 
significant morphological impact on photoreceptors following silencing of a 
highly expressed gene.  
 
   181The adaptability of miRDS6 in different experimental contexts (human cells 
and mouse retinae) lies in its miR30-based design. The two main enzymes in 
miRNA processing are Drosha and Dicer. In miRNA mimetics, the sequences 
are altered so that the molecule has restriction sites compatible with those 
recognised by Drosha and Dicer. Correct Drosha processing together with 
the natural loop sequence increases the levels of nuclear export, possibly by 
Exportin 5. Correct Dicer processing increases RISC incorporation and, 
hence, silencing effect. The role of the hairpin’s secondary structure is very 
important in the RNAi pathway and miRNA-based design has been shown to 
mitigate shRNA-induced toxicity in murine brain [194,288]. McBride and 
colleagues noted that the brain was very sensitive in shRNA-related toxicity 
even by a non-targeting hairpin. A miR30-based design abolished the toxicity 
caused by the shRNA indicating that cellular processing of the hairpin plays a 
role in off-targeting or pathway saturation. In an elaboration of that study, 
Boudreau and colleagues showed that shRNAs disrupt miRNA biogenesis 
causing neurotoxicity in mouse cerebella [288]. The concept of minimising 
toxicity by entering the natural pathway of RNAi at an earlier point is of 
considerable interest for potential clinical application, and considering their 
increased potency [193], miRNA approaches are likely to attract increasing 
attention. 
 
The use of the miRNA-based design is not a necessity and to date numerous 
studies have efficiently downregulated genes in vitro and in vivo using 
shRNAs. However, each tissue has different sensitivity to toxicity and each 
target may trigger different stress pathways. Adapting the design to utilise a 
more natural template could minimise unwanted secondary effects as well as 
delivering higher levels of silencing when required. Although this study did 
not focus on testing various miRNA sequence templates, there is an 
important experiment missing from the comparison studies between miR30-
based and standard design hairpins. RNase protection assays for the in vivo 
part of this study would have provided useful information on the amount of 
mature siRNAs generated from each cassette (miRDS6 vs. shRDS6). Such 
work will be carried out in the future to determine whether it is the amount of 
siRNAs that it is increased or their ability to enter RISC more efficiently. 
   182Further work should be carried out to evaluate hairpin expression in relation 
to endogenous miRNA levels. The expression of the hairpin depends on the 
promoter used and the copy number of the RNAi cassette. Silencing should 
be achieved with the lowest possible hairpin expression levels in order to 
avoid saturating the endogenous miRNA pathway [289]. Optimised 
promoters and the comparison of their expression levels with those provided 
by endogenous miRNA promoters using real-time PCR, could optimise 
dosage in order to avoid side-effects associated with intracellular toxicity and 
activation of the host immune system.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   1836 Discussion 
 
6.1  Therapeutic gene silencing 
 
 
Whereas gene replacement approaches have been used successfully for 
treating animal models of recessive disorders, the treatment of dominant 
retinopathies is often more complicated. In dominant disease, the mutated 
allele may exert a toxic effect on the cell and in these cases gene 
supplementation on its own may not suffice. The requirement for an inhibiting 
agent that abolishes the expression of the mutant gene has led to the 
development of gene silencing techniques such as ribozyme and antisense 
RNA technologies. Whilst ribozyme and antisense RNA intervention have 
been used in animal models of retinal degeneration to ablate mutant 
rhodopsin alleles and downregulate caspase-3, the levels of inhibition did not 
lead to significant amelioration of the phenotype [136-140].  
 
Around ten years ago, the development of RNAi paved the way for the 
development of much more effective methods for ablating gene expression. 
The recent success of RNAi is very promising as the technique is still 
developing and RNAi vectors are constantly being optimised in order to 
deliver stable gene silencing over longer periods of time and with minimal 
adverse effects. 
 
There have been several studies to date that have employed RNAi for the 
treatment of animal models of adRP [232-236,290]. All of the published 
studies used standard shRNA design for their expression vectors and AAV-
mediated delivery to the retina. The two most promising have emerged 
during the last couple of years from Jane Farrar’s group in Ireland [235,236]. 
O’Reilly and colleagues used a “suppression and replacement” approach in 
order to rescue a transgenic mouse expressing the rhodopsin P23H mutation 
using AAV2/5-mediated delivery [235]. The “suppression and replacement” 
   184approach aims to downregulate all endogenous mRNAs of the gene of 
interest, irrespective of allelic origin, prior to gene supplementation with a 
codon-modified cDNA. Due to the stringency of the RNAi mechanism, a few 
point mutations in the cDNA can abolish shRNA silencing while retaining the 
wt amino acid sequence of the protein. In their study, a potent shRNA 
targeting rhodopsin was used to efficiently silence all endogenous transcripts 
(<10 % of control levels) while the codon-modified cDNA (8 nt mismatches 
with the shRNA) evaded silencing. Although there was a significant 
photoreceptor rescue after 10 days of treatment, no later timepoints were 
assessed to follow the persistence of the rhodopsin knockdown. Earlier this 
year, Chadderton and colleagues demonstrated the most promising and 
persistent amelioration of phenotype in the transgenic mouse expressing the 
human Pro347Ser mutation [236]. The group used the same AAV2/5-based 
RNAi vector as in the study by O’Reilly and colleagues to silence the human 
mutation but with a reporter gene in place of the codon-modified cDNA. The 
reason for this was that their model was heterozygous for the dominant 
human mutation that was bred on a wt background (Pro347Ser
+/-Rho
+/+) and 
hence no further supplementation was required. By silencing the Pro347Ser 
toxic allele, they observed a 2-fold increase in ERG amplitudes in treated 
eyes in comparison to control eyes ten weeks after subretinal delivery [236]. 
Although this study successfully demonstrated in vivo silencing of a mutated 
allele that directly contributed to functional rescue of the model, the 
amelioration in visual function was brought about by the wt background 
haplotype for rhodopsin and not by supplementation with an engineered 
cDNA as would probably be required for clinical applications. It will be 
interesting to see future results in which the silencing of a dominant allele is 
coupled with supplementation to treat any underlying genetic 
haploinsufficiency. 
 
Treating patients with dominant retinopathies in the future will mainly depend 
on the efficiency and safety of vectors delivering hairpin expression cassettes 
in the affected retinal cells or on more potent neurotrophic agents. However, 
dominant retinal disorders are not the only ocular conditions amenable to 
treatment by RNAi. A number of other applications are currently advancing 
   185towards the clinic. These focus on focusing on angiogenesis and especially 
the delivery of anti-angiogenic agents such as siRNAs targeting VEGF [225-
229], a key regulator of neovascularisation. It has been shown to be 
downregulated following delivery of siRNAs or virus-mediated delivery of 
shRNAs in models of CNV [227-229]. It is likely that the first clinical trials 
using RNAi in the eye will involve intravitreal injection of siRNAs targeting 
VEGF in AMD patients to halt CNV, the hallmark of “wet” AMD. To date, 
there are two promising siRNA molecules targeting VEGF, bevasiranib and 
AGN211745, and both are currently in pre-clinical development [291,292].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   1866.2 miRNA  mimetics 
 
 
RNA interference involves a complex pathway that takes place in both the 
cell nucleus and the cytoplasm (see Chapter 1.4) and its components are still 
being characterised. During the last five years, the discovery of endogenous 
miRNA molecules that regulate gene expression has led to an alternative 
shRNA design that results in more potent and stringent silencing. In order to  
optimise siRNA design and reduce adverse toxic effects while maintaining 
silencing capacity, non-standard designs, such as asymmetric siRNAs or 
miRNA-based hairpins, have been devised [293]. A number of studies on 
hairpin design have shown that target sequences incorporated in a miRNA-
based design can deliver more potent silencing in comparison with the 
standard design, while reducing toxic side-effects [193,194,288,289]. The 
reasons why miRNA-based hairpins may confer more efficient silencing or 
reduce shRNA-related toxicity are not yet known. It is possible that the 3’- 
and 5’- sequences as well as miRNA-based loops facilitate Drosha digestion 
or nuclear export by Exportin5, respectively, thereby increasing the 
cytoplasmic concentration of the mature hairpin. It has been suggested that 
mimicking the endogenous miRNA pathway might reduce saturation-
dependent toxicity [194]. 
 
AAV vectors have been used extensively to transduce photoreceptors and in 
this study we selected AAV2/8 particles to deliver RNAi expression cassettes 
to the murine retina to silence Prph2 which is the second most highly 
expressed gene in the retina (after rhodopsin) and hence a useful candidate 
gene to test the efficacy of hairpin-mediated silencing in vivo. We constructed 
an AAV vector with two separate expression cassettes: a reporter gene 
(RFP) expression cassette to follow transduction efficiency and onset of 
expression within the treated areas, and an RNAi cassette to silence Prph2. 
The selected RNAi target sequence that was validated in vitro (RDS6) was 
placed in the AAV hairpin expression cassette using two design strategies: 
One in which the hairpin is formed using the standard short hairpin design 
(sense–6nt-loop–antisense; shRDS6), and another in which the hairpin 
   187design was based on the sequence of the endogenous miR30a (miRDS6). 
Both vector plasmids were used to generate AAV2/8 particles and the 
preparations that were titre matched and subsequently delivered in the 
subretinal space of wt mice. In this way, we aimed to compare the design 
strategies (sh vs. miR) and their effect on the efficacy of our Prph2 target 
sequence (RDS6). Although both shRDS6 and miRDS6 hairpins silenced 
Prph2 in vitro and in vivo, we found that the miR30-based design significantly 
increased the potency of suppression achieved. The severity of outer 
segment malformation caused by Prph2 knockdown also had an impact on 
photoreceptor viability with the miRDS6-treated eyes showing almost a 50 % 
reduction in nuclei counts compared to controls. Although loss of visual 
function was not assessed using ERGs since this study concentrated on 
proof of concept rather than rescuing a model of disease, it would have been 
useful to follow outer segment degeneration due to lack of Prph2 in 
association with a decrease in visual responses. That way, comparisons 
between the treated mice and the rds mouse model could have been drawn. 
 
These results demonstrate miRNA-based silencing of a retinal gene in vivo 
for the first time as well as the use of AAV2/8 particles for the delivery of an 
RNAi cassette in the neuroretina. Although the miR30-based design 
significantly increased the silencing potential of our Prph2 target area, we 
cannot conclude that every RNAi application will benefit from a miRNA-based 
design. An experiment omitted from this study that would have provided a 
preliminary answer to this question was RNase protection assays. Had 
RNase protection assays been performed for both the miRDS6 and shRDS6 
hairpins, it would have been possible to identify whether the miR30-based 
design resulted in higher amounts of mature siRDS6 being produced or 
whether the miR30-based design increases processing efficiency without 
necessarily increasing the final output of mature siRNAs. However, this study 
adds weight to the rationale that miRNA-based silencing might enhance the 
efficiency of RNAi, especially in cases where target selection is very limited. 
For example, in allelic-dependent silencing of a point mutation the target area 
cannot be altered as the mutation has to be placed in the middle of the 
hairpin. Alternative miRNA-based design would be one way to enhance the 
   188knockdown effect of the hairpin if the levels achieved by conventional hairpin 
design are not high enough.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   1896.3  Using RNAi to study pathophysiology 
 
 
Stable genetic silencing can be used not only for therapeutic interventions to 
treat dominant disorders, but also in studies to elucidate molecular pathways 
and disease processes. As with therapeutic approaches, an RNAi cassette 
has to be delivered efficiently into the target tissue using an appropriate 
vector. Lentiviruses have been used extensively for the transduction of the 
RPE and one recent study successfully used a lentiviral vector to deliver an 
RNAi cassette targeting FGF-2 [239]. The potential advantages of using 
RNAi to study gene function and molecular pathways is the reduced cost and 
shorter time required in comparison to more conventional methods, such as 
generation of transgenic animal models using homologous DNA 
recombination.  
 
We employed lentiviruses to deliver RNAi cassettes targeting ZO-1 and 
ZONAB into the RPE of wild-type (wt) mice in an effort to shed light on the 
complex TJ signalling pathways that regulate proliferation and differentiation 
of the monolayer. Using a combination of downregulating and upregulating 
transgene cassettes, we observed the effect of the transcription factor 
ZONAB on RPE cell proliferation, density and polarity. Studies on molecular 
signalling pathways involving transcription factors, like ZONAB, are not 
feasible using conventional transgenic lines as they are essential during 
development. Complex inducible systems would be required in order to study 
the effects of tissue-specific downregulation. Using RNAi, we studied the 
function of ZONAB in mature RPE cells in vivo and its potential role in 
disease processes.  
 
Given the known associations of ZONAB and ZO-1 in regulating epithelial 
cell density, we studied their role in vivo in the RPE of wt mice by 
downregulating both genes independently and following the impact of 
downregulation on retinal integrity and RPE monolayer stability. We also 
overexpressed ZONAB in a separate cohort of mice in order to compare its 
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ratio” connection for the action of ZO-1 and ZONAB that had only been 
previously shown in vitro [248-251,256]. Whereas downregulation of ZONAB 
reduced the RPE cell density and overall thickness leading to breaks in the 
posterior blood-retina-barrier (BRB), downregulation of ZO-1 or 
overexpression of ZONAB triggered RPE proliferation and at later stages 
induced EMT. The results suggested that TJ regulation in the RPE plays a 
major role in RPE proliferation, cell density and overall homeostasis 
elucidating the mechanisms that can cause RPE loss or posterior 
proliferative vitroretinopathy (PVR). The ZO-1/ZONAB pathway provides the 
RPE with a regulatory pathway linking cell density (sensed by TJ component 
recruitment in the cell membrane) and proliferation (initiated by transcriptional 
activation of proliferation markers in the nucleus). The intracellular trafficking 
of the transcription factor ZONAB tightly regulates the pathway in two ways: 
either by being localised in the nucleus when cell density is low triggering 
RPE proliferation, or by being sequestered in the cytoplasm to bind ZO-1 
when cell density is high. RPE homeostasis is highly dependent on cell cycle 
regulation as reduced cell density may lead to breaks in the BRB and an 
immunological insult on the retina, whereas increased proliferation may lead 
to retinal gliotic scars affecting retinal function. Altough the experiments 
performed provide evidence of the essential role of ZO-1/ZONAB pathway in 
RPE homeostasis qualitatively, there was a lack of quantitative data to further 
dissect the dynamics between ZO-1 and ZONAB and the relative 
concentrations required for RPE monolayer integrity. Immunohistochemistry 
does not provide a quantitative method for gene expression and this is the 
reason why no statistical interpretation was performed in Figures 4.8 and 4.9. 
Although the lack of a reporter gene in our vectors (as used in Chapter 5) is 
debatable due to possible interference with the signalling pathway (see 
section 4.4), RNA suppression data would have been invaluable as an 
additional demonstration of gene knockdown and further proof that all the 
analyses were performed within the treated area. These points will be taken 
into account for future work on this project where laser captured RPE cells 
will be analysed more closely for induction of EMT marker expression using 
RT-PCR. The lack of RNA suppression data is a drawback not only for this 
   191project but also for experiments presented in Chapter 3. Hence, all future 
work on data presented in this thesis will aim to correct that. 
 
In addition to new conclusions drawn on monolayer integrity from our RNAi-
mediated results on either RPE proliferation or topical RPE atrophy, this is 
the first experimental model that displays RPE dedifferentiation and retinal 
degeneration as a direct result of EMT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   1926.4 Future  directions 
 
 
Many current studies are trying to optimise the efficiency and stringency of 
RNAi. However, since the therapeutic applications of RNAi may require the 
delivery of targeting cassettes as part of a vector rather than as naked 
nucleic acids, the impact of the hairpin sequence on vector integrity should 
also be examined. In this study during preliminary reporter gene silencing 
experiments, we encountered obstacles in the generation of a particular AAV 
vector plasmid targeting eGFP. Upon inspection, it became evident that the 
selected target sequence was highly recombinogenic at the specific sense-
loop junction area. Although it is known that viral vectors are prone to 
recombination due to the presence of palindromic sequences such as LTRs 
or ITRs, in this case no tandem repeat sequences were involved in the 
recombination events. In addition, even though the recombination junction 
was identical in all three tested clones, the resultant aberrant sequence 
varied. This might indicate that the recombinogenic effect depended mostly 
on the hairpin sequence rather than the vector plasmid backbone. Since we 
encountered no problems in incorporating any other hairpins into the AAV 
vector backbone, neither did we observe any such obstacles in the 
generation of lentiviral vectors, these results suggest that selected target 
RNAi sequences should also be tested in their destination vectors and not 
only in synthetic (i.e. siRNA) form prior to selection. 
 
The importance of RNAi in gene characterisation and especially therapeutic 
intervention has been extensively studied in various research fields apart 
from ophthalmology. The design of the shRNA molecule can vary as well as 
the delivery method of choice depending on the target tissue. However, there 
are still issues to be addressed regarding the molecular kinetics of the RNAi 
pathway, hairpin expression levels and off-targeting. Studies on the 
endogenous miRNA transcripts and their respective targets have shed light 
on the enzymatic complexes that catalyse basic steps in the pathway 
(Drosha, Exportin5, Dicer and RISC) [146,147,152,154,157]. Studies on 
RNA-protein interactions between shRNA and RNAi enzymes can reveal the 
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same time testing the redundancy of the passenger strand (sense). In other 
words, each nucleotide of the guide strand plays a role in guiding the RISC 
complex to recognise and bind to the target mRNA while the passenger 
strand has not functional role apart from its requirement in hairpin formation. 
An example of a study contributing to siRNA optimisation is the development 
of asymmetric siRNAs (asiRNAs) that retain their silencing capacity even 
though the sense strand is considerably smaller than the antisense [293]. 
Chang and colleagues demonstrated that while retaining the 19+2 nucleotide 
format for the antisense strand, they were able to construct efficient asiRNAs 
with a sense strand of 13 nucleotides. The advantage was that the asiRNAs 
did not lose any of their silencing capacity in comparison to their symmetrical 
counterparts, while the off-targeting and pathway saturation caused by the 
sense strand was reduced to a minimum.  
 
One of the main concerns with RNAi technology is the level of off-targeting 
that can be triggered by any given siRNA/shRNA molecule. The “seed 
region” of an siRNA molecule (2-8 nt positions) is part of the molecule 
associated with off-targeting especially when it shares complementarity with 
the 3’ UTR region of a gene (other than the gene of interest) [184,185]. The 
reason for this was found to be the non-perfect complementarity between 
either strand of a hairpin with a gene’s 3’UTR. These associations mimic the 
endogenous miRNA-mediated silencing that is brought about by translational 
repression rather than mRNA degradation. Nowadays, algorithms for siRNA 
design exclude candidates with partial complementarity within the first 8 
nucleotides in order to address this issue. A few studies have demonstrated 
alarming levels of off-targeting and systemic toxicity after delivery of siRNAs 
[207,209,211-214] and more recently one reason for siRNA-induced toxicity 
was found to be the activation of the Toll-like receptor 3 (TLR3) [210]. TLR3 
is a cell surface double-stranded viral RNA sensor that protects the cell from 
viral infections. Naked siRNAs are able to activate the extracellular part of 
TLR3 causing non-specific mRNA degradation and eventually leading to cell 
death. This process is initiated by TLR3 and propagated through the 
interferon response system for the protection of the host. Kleinman et al. also 
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was 21 nt of conventional design [210]. Smaller siRNAs did not activate the 
receptor. Although the authors clearly demonstrated TLR3 activation by 
naked RNA, they did not test corresponding shRNAs or siRNAs delivered 
using transfection reagents. Some of the problems underlined here can be 
circumvented by adapting to a miRNA-based design [288] or simply by 
selecting a different target area. It is highly probable that there are still more 
components of the RNAi pathway to be discovered and until their functions 
are also incorporated in algorithm-based bioinformatics tools to ensure safer 
siRNA design, target area selection for RNAi experiments will depend on a 
“hit-and-miss” approach.  
 
 
 
In the future, inclusion of miRNA target sequences in transgene constructs 
may target expression to specific cell types depending on their miRNA 
expression profile. This approach may result in finely tuned transgene 
expression beyond the targeting capabilities of the delivery vector. This 
technique has been recently demonstrated in haematopoietic lineages and its 
efficiency indicates the feasibility of miRNA-based transgene regulation 
depending on the type and developmental stage of the host cell [294,295]. 
miRNA profiling has shown that there is varying miRNA expression between 
RPE, peripheral, central neuroretina and the macula (Shunbin Xu; 
unpublished data). Since the miRNA transcriptome of the retina has been 
mapped [150,296], it would be possible in the future to deliver a transgene or 
shRNA expression cassette to the retina and based on the miRNA adaptor 
sequence inserted in the expression cassette, so that the transgene is 
silenced in different parts of the retina. In effect, after viral delivery of the 
transgene in all parts of the retina, transgene expression could be further 
regulated not based on transduced cell type or promoter of choice, but 
instead based on the miRNA sequence attached to it. 
 
RNAi is a promising technique for therapeutic intervention for the treatment of 
gain of function retinal disorders. The results presented in this study suggest 
   195further optimisation studies to be conducted on target area selection 
parameters, nucleotide positioning, siRNA:mRNA associations, dosage and 
evasion of off-targeting. With the experience gained from the RPE65 clinical 
trials concerning vector delivery and safety and the promising results 
obtained from RNAi-mediated knockdown in animal models, it is likely that 
the first RNAi-based clinical trials to treat adRP patients will take place within 
the next decade. 
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   218Abbreviations 
 
 
aa   amino acid 
AAV adeno-associated  virus 
ABCR  ATP-binding cassette transporter 
Ad adenovirus 
ADA adenosine  deaminase 
ADP adenosine-5'-diphosphate 
adRP  autosomal dominant retinitis pigmentosa 
Ago argonaute 
AJ adherens  junction 
AMD  age related macular degeneration 
AMD  age-related macular degeneration 
Arr arrestin 
arRP autosomal  recessive retinitis pigmentosa 
ATP adenosine-5'-triphosphate 
Aub aubergine 
BDNF brain-derived  neurotrophic factor 
bFGF  basic fibroblast growth factor 
BHK  baby hamster kidney cells 
Bmp bone  morphogenetic  protein 
BNB blood-neural  barrier 
bp base  pair 
BRB brain-retina  barrier 
BrdU 5-bromo-2-deoxyuridine solution 
cAMP cyclic  AMP 
cDNA complementary  DNA 
CFH  complement factor H 
CGD  chronic granulomatous disease 
cGMP  cyclic GMP 
CMV cytomegalovirus 
CMZ  ciliary margin zone 
CNS  central nervous system 
CNTF  ciliary neurotrophic factor 
CNV choroidal  neovascularisation 
CORD   cone-rod dystrophy 
CRALBP cellular  retinaldehyde binding protein 
CRBP  cellular retinol-binding protein 
CRX cone-rod  otx-like homeobox 
Cx connexin 
DMEM  Dulbecco’s Modified Eagle’s Medium 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic  acid 
ds   double stranded 
EAM  encapsidated adenoviral mini-chromosome 
EAU experimental  autoimmune uveoretinitis 
eGFP  enhanced green fluorescent protein 
   219EIAV  equine infectious anaemia virus 
ERG electroretinogram 
ES  embryonic stem cell 
Exp exportin 
FACS  fluorescence-activated cell sorter 
FBS  fetal bovine serum 
Fgf  fibroblast growth factor 
FITC fluorescein  isothiocyanate 
FIV  feline immunodeficiency virus 
GC ganglion  cell 
GCAP  guanylate cyclase activator protein 
GDNF  glial-cell line derived neurotrophic factor 
GDP guanosine-  5'-diphosphate 
GJ gap  junction 
GMP guanosine  5'-monophosphate 
GTP guanosine-5'-triphosphate 
HEK  human embryonic kidney cells 
HIV  human immunodeficiency virus 
hr   hour 
hrGFP  human recombinised green fluorescent protein 
HRP horseradish  peroxidase 
HSV  herpes simplex virus 
IL interleukin 
ILM  inner limiting membrane 
IMPDH1  inosine monophosphate dehydrogenase 1 
INL  inner nuclear layer 
IPL  inner plexiform layer 
IPM  inter photoreceptor matrix 
IRBP interphotoreceptor  retinoid-binding protein 
IS inner  segments 
ITR  inverted terminal repeats 
JAM  junction adhesion molecule 
kb   kilobase 
kDa kilodalton 
l litre     
LCM  laser capture microdissection 
LRAT lecithin-retinol  acyltransferase 
LTR  long tandem repeats 
m   meter 
m- milli 
μ- micro- 
MAGUK membrane-associated  guanylate  cyclase 
MD macular  degeneration 
MDCK  Madin-Darby canine kidney cells 
Mertk mer-receptor  tyrosine  kinase 
min   minute 
miRNA   micro RNA 
miRNP miRNA  ribonucleoprotein 
MOI  multiplicity of infection 
mRNA messenger  RNA 
   220mut    mutant 
Mv microvilli 
n- nano- 
NACos  nucleus and adhesion complexes 
ncRNA   non-coding RNA 
NF nerve  fibre  layer 
NRL  neural retina leucine zipper transcription factor   
nt   nucleotide 
OIR oxygen-induced  retinopathy   
OLM  outer limiting membrane 
ONL  outer nuclear layer 
OPL  outer plexiform layer 
OS outer  segments 
P postnatal  day 
PAZ  Piwi Argonaute and Zwille 
PCR  polymerase chain reaction 
PDE phosphodiesterase 
PEDF  pigment epithelium derived factor 
PEG Polyethylene  glycol 
Ph   phagosome 
pi post  injection 
piRNA   Piwi-interacting RNA 
Prph2 peripherin2 
PTGS  post transcriptional gene silencing 
R* metarhodopsin 
rAAV recombinant  AAV 
rasiRNA repeat-associated  siRNA 
RCS  royal college of surgeons 
rd   retinal degeneration 
RDH retinol  dehydrogenase 
RDS  retinal degeneration slow 
Rec recoverin 
retGC  retinal guanylate cyclase 
RFP  red fluorescent protein 
RGC  retinal ganglion cells 
RGR  retinal G-protein-coupled receptor 
Rho rhodopsin 
RISC  RNA induced silencing complex 
RK rhodopsin  kinase   
RNA ribonucleic  acid 
RNAi RNA  interference 
ROM-1  retinal outer segment membrane protein-1 
RP retinitis  pigmentosa 
RPC  retinal progenitor cell 
RPE  retinal pigment epithelium 
RPGR  retinitis pigmentosa GTPase regulator 
RPGRIP RPGR-interacting  protein 
rRNA ribosomal  RNA 
RT reverse  transcriptase 
RVE  retinal vascular endothelium 
   221scAAV self-complementary  AAV 
SCID  severe combined immunodeficiency   
SFFV  spleen focus-forming virus 
sFLT  soluble fms-like tyrosine kinase 1 
Shh sonic  hedgehog 
shRNA  short hairpin RNA 
SIN self  inactivating 
siRNA  short interfering RNA 
ss  single strand    
TEM  transmission electron microscopy 
TIMP3 tissue  inhibitor  of metalloproteinase 3 
TJ tight  junction 
TNF-α  tumor necrosis factor alpha 
tRNA   transfer RNA 
UCOE  ubiquitously-acting chromatin opening element 
UTR untranslated  regions 
VEGF  vascular endothelial growth factor 
vp viral  particles 
VSV-G  vesicular-stomatitis virus G-protein 
w/v weight/volume 
WPRE  Woodchuck hepatitis virus post-transcriptional 
 element 
wt wild-type 
xl   X-linked 
ZO-1 zonula  occludens-1 
ZONAB  ZO-1 associated nucleic-acid binding 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   222Publications arising from this 
project 
 
 
 
 
Regulation of PCNA and cyclin D1 expression and epithelial 
morphogenesis by the ZO-1-regulated transcription factor 
ZONAB/DbpA. Tony Sourisseau, Anastasios Georgiadis, Anna Tsapara, 
Robin R. Ali, Richard Pestell, Karl Matter, Maria S. Balda. Molecular and 
Cellular Biology. 2006. 26(6):2387-98 
 
AAV-mediated knockdown of Peripherin-2 in vivo using miRNA-based 
hairpin design. Anastasios Georgiadis, Marion Tschernutter, James W. B. 
Bainbridge, Scott J. Robbie, Adrian J. Thrasher, Alexander J. Smith, Robin 
R. Ali. Gene Therapy. 2009. In Press. 
 
The tight junction-regulated ZO-1/ZONAB pathway regulates retinal 
pigment epithelium homeostasis in mice. Anastasios Georgiadis, Marion 
Tschernutter, James W. B. Bainbridge, Kamaljit S. Balaggan, Freya Mowat, 
Peter M.G. Munro, Adrian J. Thrasher, Karl Matter, Maria S. Balda, Robin R. 
Ali. 2009. Manuscript in preparation for Molecular and Cellular Biology. 
 
 
 
 
 
 
 
 
 
   223Appendix 
 
Plasmids used in viral-mediated RNA interference: 
 
RNAi expression plasmids – mu6pro 
 
mU6pro vector
4143 bp
GFP (spacer)
f1F primer
f1 origin
SV40 polyA
M13R primer
U6 promoter
SnaBI (777)
XbaI (766)
BbsI (4141)
AscI (3803)
 
 
mu6RNAi2
3448 bp
f1F primer
f1 origin
SV40 polyA
M13R primer
U6 promoter
Hairpin
SnaBI (85)
XbaI (74)
AscI (3111)
 
 
 
   224AAV backbone plasmids – pD10 
pD10CBARFPpoly 2
6532 bp
RFP
ITR
ITR
CBA
AscI (133)
BstZ17I (142)
BsrGI (152)
EcoRV (160)
PmeI (181)
NsiI (130)
 
 
SmaI (6807)
pD10CBARFPRNAi
6927 bp
RFP
ITR
ITR
U6 promoter
CBA
Hairpin
AscI (1)
SmaI (6796)
XbaI (6105)
XbaI (412)
XbaI (2111)
SmaI (2286)
SmaI (3339)
XbaI (2992)
SmaI (3350)
  XbaI (3447)
 
   225Lentivirus backbone plasmids – pHR’SIN 
 
 
 
pHR'SIN-cPPT-SFFV-ZONAB
10214 bp
ampicillin resistance gene
gpt (OFR-frame shift)
gag (ORF-disrupted)
LTR HIV-1
LTR-HIVdelU3
3' LTR SFFV
RRE-Rev responsive element
3'-splice site
5'-splice site
cPPT
WPRE
SV40 promoter-enhancer
ZONAB-B
rep ori
XbaI (432) XbaI (9534)
EcoRI (7850)
EcoRI (8378)
 
   226pHR'SINcPPT-RNAi
8191 bp
ampicillin resistance gene
gpt (OFR-frame shift)
gag (ORF-disrupted)
LTR HIV-1
LTR-HIVdelU3
RRE-Rev responsive element
3'-splice site
5'-splice site
cPPT
SV40 promoter-enhancer
U6 promoter
rep ori
Hairpin
AscI (1)
SnaBI (423)
XbaI (412)
XbaI (731)
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